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An SOS-inducible DNA repair system has been linked to transient hyper-
mutation and the development of drug resistance in Mycobacterium tuberculosis. 
Previous work has established that this “mycobacterial mutasome” comprises 
the specialist DNA polymerase, DnaE2, and accessory factors of unknown 
function, ImuA′ and ImuB. However, the molecular interactions and sub-
cellular recruitment dynamics enabling mutasome function remain poorly 
understood. Here, a panel of fluorescent strains of M. smegmatis was developed 
to investigate expression and subcellular localization of ImuA′ and ImuB in live 
mycobacteria exposed to genotoxic agents. Using fluorescence microscopy, it 
was observed that, during prolonged genotoxic stress, single M. smegmatis cells 
exhibited an elongated cell phenotype and apparent aneuploidy – potentially 
providing an environment for recombination between differentially mutated 
chromosomes. Furthermore, ImuB was seen to associate with the dnaN-
encoded β clamp in discrete foci during mutagenic DNA repair. In contrast, 
ImuA′ did not exhibit similar localization and instead appeared to diffuse 
throughout the bacillus. A mutant ImuB protein deficient in the β clamp-
binding motif failed to co-localize with the β clamp, reinforcing the inferred 
essentiality of the ImuB-β clamp protein-protein interaction for mutasome 
recruitment and induced mutagenesis. Additionally, exposure of M. smegmatis 
to griselimycin, a novel β clamp-targeting natural product antibiotic, prevented 
ImuB-β clamp co-localization during SOS induced mutagenesis, an observation 
confirmed by superresolution, three-dimensional interferometric photo-
activated light microscopy. These results establish the capacity of griselimycin 
to inhibit DNA replication as well as prevent DNA damage-induced 
mutagenesis by disrupting mutasome assembly and activity. Notably, this 
 iii 
differentiates griselimycin from other inhibitors of DNA metabolic function 
which carry the often-unavoidable liability of accelerating drug-resistance by 
inducing mutagenic DNA repair. In turn, it suggests the potential application 
of griselimycin as an anti-evolution agent in novel therapeutic regimens 
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Chapter I 3 
1. Introduction 
Mycobacterium tuberculosis (Mtb) is the etiological agent of tuberculosis (TB), a 
disease which is prevalent in 1 % of the global population and caused the death 
of 1.67 million people in 2016 (WHO, 2017). Moreover, it is estimated that 
between one third and one quarter of the global population is infected with 
latent Mtb (Dye, et al., 2002; Houben and Dodd, 2016). In alignment with the 
global occurrence of latent Mtb infection, active TB disease presents a large 
healthcare problem in southern Africa and, together with Human 
Immunodeficiency Virus (HIV) infections, continues to exact a massive toll on 
public health programs in the region (Gandhi, et al., 2006; Dheda, et al., 2014, 
2017). This co-morbidity is contributed to by a multitude of socioeconomic and 
biological factors including the dysregulation of the anti-TB immune response 
caused by the depletion of immune cells, in particular CD4+ T-cells, as a result 
of infection with HIV (Miedema, et al., 1988; Brenchley, et al., 2004; Dheda, et 
al., 2017); treatment with corticosteroids; diabetes mellitus (Dheda, et al., 2017); 
vitamin D deficiency; poor nutrition; smoking; over-crowding; and alcohol or 
drug abuse. As such, TB is considered one of the largest global health issues 
together with other infectious diseases such as malaria and HIV. As a result, TB 
continues to affect a large number of people both within South Africa and 
throughout the world. 
 
The reasons for the continued impact of Mtb infection are multiple and complex 
and include environmental as well as biological factors. Among the latter is the 
genetic malleability of the microorganism, which is epitomized by the rapid 
development of drug resistance globally (Dheda, et al., 2017). The micro-
evolution and adaptation of Mtb against chemotherapy illustrates a core 
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property responsible for the success of this pathogenic organism which 
seemingly transcends the ability of modern medicine to restrict it – thereby 
threatening the major pillar of TB control efforts globally (Andrei and Platon, 
2017). As a result, patients infected with multi-drug resistant (MDR) or 
extensively drug resistant (XDR) strains of Mtb are often unable to be 
effectively cured of TB (Dheda, et al., 2017). The increasing proportion of MDR 
– rifampicin (RIF) and isoniazid (INH) resistance – and XDR – resistance to RIF, 
INH, any fluoroquinolone (FLQ), as well as an injectable aminoglycoside (AMI) 
– cases of TB underscores the need to develop new and effective anti-TB drugs. 
Furthermore, anti-TB drugs are often highly toxic to patients (Zheng and Av-
Gay, 2016; Yee, et al., 2003; Forget and Menzies, 2006; Yew and Leung, 2006; 
Bloss, et al., 2010; Falzon, et al., 2012), particularly in combination (WHO, 2013), 
further justifying the need for new anti-TB drugs. However, drug discovery 
and development are expensive, time-consuming, and often fail to yield 
suitable drug options that translate into clinical use (reviewed by Ma, et al., 
2010; Koul, et al., 2011; Mikušová and Ekins, 2017; Zheng and Av-Gay, 2016; 
Butler, et al., 2016).  
 
Drug resistance occurs in Mtb through the random acquisition of nucleotide 
sequence changes within the gene encoding the protein target of the antibiotic 
(or proteins involved in the uptake or activation of the compound). Such 
mutations can result in the loss of susceptibility to a compound at 
concentrations that would normally result in the cessation of growth 
(bacteriostatic) or bacillary death (bactericidal) (Kaur, et al., 2015). In the 
majority of cases, microbes develop drug resistance through the acquisition of 
drug-resistance cassettes via horizontal gene transfer (HGT) mechanisms 
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(Ochman, et al., 2000; Gogarten, et al., 2002) such as plasmid acquisition, 
insertion sequences, or phage infection, which allows the distribution of drug-
resistance genes throughout a microbial population. Such gene transfers often 
result in the recombination, deletion, or duplication of operons, genes, or gene 
segments that consequently confer drug resistance by a number of mechanisms 
(review by Munita and Arias, 2016; and Blair, et al., 2015). However, drug 
resistance mutations can also occur through the de novo acquisition of single 
nucleotide polymorphisms (SNPs) (discussed in detail in subsequent sections), 
insertions and deletions (indels), and gene duplication by recombination 
(Zhang, 2003; Gevers, et al., 2004; Serres, et al., 2009). However, unlike other 
bacteria, intra- and inter-species HGT is uncommon in members of the Mtb 
complex, with the exception of Mycobacterium canettii (Boritsch, et al., 2016; 
Eldholm and Balloux, 2016). This fact is exemplified by the closed genome of 
Mtb which does not include significantly large pangenomic regions that vary 
between different strains (Cole, et al., 1998; Ochman, et al., 2000; Borrell and 
Gagneux, 2011). This is likely associated with the significant physical barrier of 
entry to environmental DNA molecules caused by the complex and highly 
specialized mycobacterial cell wall – the same factor that renders Mtb 
intrinsically tolerant to many compounds that exhibit in vitro target efficacy 
(reviewed by Jarlier and Nikaido, 1994; Jankute, et al., 2015). This is potentially 
further confounded by the ‘genetic isolation’ associated with pulmonary 
alveoli, granulomas, and phagosomes where Mtb naturally occurs during 
infection resulting in very limited opportunity to interact and transfer DNA 
with other bacteria within the relatively sterile environments. However, it 
should be noted here that conjugation has been identified to be dependent on 
functional ESAT6-protein family secretion system (ESX)-1- and ESX-4-
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mediated pathways in Mycobacterium smegmatis (Msm) (Parsons, et al., 1998; 
Coros, et al., 2008; Gray, et al., 2016) and in Mycobacterium canettii but is absent 
in other strains of the Mtb complex (Boritsch, et al., 2016). Regardless, drug 
resistance appears to occur exclusively as a result of de novo mutation in clonal 
Mtb (Dos Vultos, et al., 2008). These resistance-conferring mutations consist 
predominantly of SNPs within specific genes and have been linked to the 
resistance of almost all anti-TB drugs (as discussed in subsequent sections). In 
addition, the development of MDR strains has been observed to occur by the 
step-wise acquisition of mutations (Manson, et al., 2016; Borrell, et al., 2013; 
Saunders, et al., 2011; Merker, et al., 2013; Trindade, et al., 2009; Bergval, et al., 
2012) – both in terms of resistance-associated and compensatory mutations 
(Comas, et al., 2012; de Vos, et al., 2013; Casali, et al., 2014; Brandis and Hughes, 
2013). This information highlights the requirement for endogenous mutations 
for the success of Mtb and suggests a potential weak link due to the complete 
dependence on mutation for adaptive evolution.  
 
Within mycobacteria and Mtb in particular, de novo mutations can occur by a 
number of processes. However, the focus of this thesis is on the mechanism 
known as inducible mutagenesis, which is characterized by the increase in 
mutation rate following DNA damage. A mutagenic DNA repair pathway has 
been identified to be responsible for this phenomenon in Mtb and Msm 
(Boshoff, et al., 2003) and consists of a C family polymerase, encoded by the 
gene dnaE2, capable of synthesizing new DNA across lesions induced by 
ultraviolet (UV) irradiation, such as cyclobutane pyrimidine dimers and 6-4 
pyrimidine-pyrimidone adducts (Beggs, 2002), or mitomycin C (MMC), which 
results in inter- and intra-strand DNA cross-linking (Tomasz, et al., 1988). 
 
Chapter I 7 
Repair of such lesions occurs through the process known as translesion DNA 
synthesis (TLS), which is a phenomenon that has been identified in eukaryotes 
as well as prokaryotes (reviewed by Goodman and Woodgate, 2013). Although 
some TLS polymerases are able to repair DNA lesions in a non-mutagenic 
fashion (i.e., Takeiri, et al., 2014; and reviewed by McCulloch and Kunkel, 2008), 
in the case of DnaE2, DNA synthesis is associated with the generation of 
mutations (Boshoff, et al., 2003).  
 
In a later development, the accessory factors ImuA′ and ImuB were determined 
to be essential to the function of DnaE2 (Warner, et al., 2010). Together, the 
three-component, SOS-dependent mechanism, known as the ‘mycobacterial 
mutasome’, contributes to the in vitro (and potentially in vivo) tolerance of DNA 
damage as well as DNA damage-inducible mutagenesis (Boshoff, et al., 2003; 
Warner, et al., 2010). The term ‘mutasome’ refers to the complex of proteins 
associated with a stalled replication fork during mutagenic TLS (Echols and 
Goodman, 1990). Importantly, this mycobacterial mutasome is the only 
inducible mutagenesis pathway identified in Mtb and is highly conserved in 
the model organism, Msm (Warner, et al., 2010).  
 
Despite the significant contribution of the mycobacterial mutasome to the 
mutagenic capacity and micro-evolution of Mtb, the precise molecular 
mechanisms enabling mutasome function remain largely unknown. To this 
end, this literature review will explore associated literature and knowledge 
surrounding bacterial inducible mutagenesis, drug resistance in Mtb, as well as 
the knowledge of the mycobacterial mutasome and similar mutagenic 
pathways in other bacteria. The aim is to synthesize all available evidence into 
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a composite review that details DNA replication dynamics; the utility of the 
mycobacterial mutasome during infection of Mtb; and explores the potential 
for targeting the mycobacterial mutasome to reduce the micro-evolution of 
drug resistance. 
 
1.1. Host Responses and Conditions Associated with Genotoxic 
Stresses in Mtb 
TB is an airborne disease and is transmitted by aerosol via the respiratory tract. 
Here, Mtb bacilli are inhaled deep into lung alveoli where they are taken up by 
pulmonary macrophages that initiate a series of immunological events 
resulting in the formation of a granuloma, consisting of macrophages, foamy 
macrophages, Langerhans cells, antibody-producing B-cells, dendritic cells, 
natural killer (NK) cells, epithelioid cells, fibroblasts, and T-lymphocytes 
(reviewed by Russell, 2007; Ramakrishnan, 2012; and Cadena, et al., 2017). One 
of the responses of mononucleated phagocytes following uptake of Mtb is an 
oxidative burst. Here, macrophages generate reactive oxygen species (ROS) 
such as hydrogen peroxide and superoxide (Adams, et al., 1997). In parallel, 
reactive nitrogen intermediates (RNI), such as nitric oxide, nitroxyl, nitrogen 
dioxide, and nitrate, are generated by nitric oxide synthase as a result of 
interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α) produced 
by associated Th1 lymphocytes (Adams, et al., 1997). However, a recent study 
from the Sassetti laboratory has suggested that nitric oxide plays a subtler role 
during Mtb infection by regulating anti-inflammatory responses (specifically of 
neutrophils) rather than by direct antibacterial activity (Mishra, et al., 2017). 
Regardless of the role of nitric oxide, it is theorized that the resulting oxidative 
conditions mediated by ROS within the site of infection represent one of the 
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main innate immune responses to Mtb infection in an attempt to clear 
intracellular bacterial infection. These oxidizing agents are able to damage 
macromolecules such as proteins, lipids, and the genetic material of the 
intracellular Mtb, ultimately leading to bacterial death (Nathan and Shiloh, 
2000; Burney, et al., 1999). It is important to reiterate that DNA damage may 
therefore occur as a result of infection and the host immune response. 
Correspondingly, it has been long thought that the generation of oxidative 
stress plays an important role in the bactericidal effect of antibiotics (see Zhao, 
et al., 2014a; and Kohanski, et al., 2007). However, this idea is highly disputed 
(Liu and Imlay, 2013; Keren, et al., 2013) and fails to provide a functional 
mechanism of antibiotic killing during anaerobic conditions, although 
oxidation of dCTP has been linked to antibiotic killing of stationary phase Mtb 
(Fan, et al., 2018). Regardless, it is evident that both exogenously- and 
endogenously-derived DNA-damaging oxidative stress is present within Mtb 
during infection.  
 
1.2. Antitubercular Drug Therapy 
In addition to the host-derived defences, Mtb encounters other factors that 
influence not only the propagation of the pathogen but the integrity of the 
genome as well. Following diagnosis of active Mtb infection, standard 
combination therapy is administered and consists of treatment with INH, RIF, 
ethambutol (EMB), and pyrazinamide (PZA) for two months followed by a 
further four months of treatment with only INH and RIF. Previously treated 
(and unresponsive) cases of TB are treated for three months with INH, RIF, 
EMB and PZA, followed by a further five months of INH, RIF, and EMB 
chemotherapy. Cases suspected of drug resistance are treated for a total of 18 
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months with a combination of PZA or EMB, an injectable AMI, and a FLQ 
(Reviewed by Müller, et al., 2013). However, treatment courses for MDR-TB in 
some countries last in excess of 20 months and require daily administration of 
drugs which are generally less effective and often cause side-effects (Shehzad, 
et al., 2013; WHO, 2017). Such scenarios may contribute to patient non-
adherence which is commonly associated with treatment failure (Frieden and 
Sbarbaro, 2007; Volmink and Garner, 2007; Hirpa, et al., 2013; Ormerod, 2005; 
Moonan, et al., 2011). In addition, the exposure of anti-TB compounds to 
mycobacteria has numerous effects on bacilli physiology that may or may not 
result in the clearance of the pathogen. Recent studies have reported that 
Escherichia coli (E. coli) developed antibiotic tolerance during intermittent 
ampicillin exposure in vitro (Fridman, et al., 2014; van den Bergh, et al., 2016) 
which was eventually followed by the development of drug resistance (Levin-
Reisman, et al., 2017). The formation of drug-tolerant persister (or slow 
growing) Mtb bacilli has previously been observed in vitro (Deb, et al., 2009; 
Torrey, et al., 2016), therefore it is possible this also plays a role in the 
development of drug resistant TB during drug therapy (see review: Fisher, et 
al., 2017). This further reinforces the need to discover novel anti-TB compounds 
capable of shortening treatment and effectively sterilizing infection. 
 
1.3. The Mycobacterial Replication Machinery 
A very promising category of novel therapeutics against TB includes those that 
target DNA replication and synthesis in Mtb (as reviewed by Reiche, et al., 
2017). However, it is necessary to discuss the mechanism of genome replication 
in mycobacteria, in particular the dnaN-encoded β sliding clamp, which links 
DNA replication with DNA repair. 
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The mechanism of DNA replication is well understood in model organisms 
such as E. coli, Caulobacter crescentus (C. crescentus), as well as Bacillus subtilis. 
The orthologous systems in other bacteria such as mycobacteria are also 
understood, albeit to a lesser extent. The multi-protein complex involved in 
DNA synthesis and replication fork progression consists of a variety of 
proteins. The constituents of the holoenzyme include DNA polymerase – 
consisting of an α subunit (PolC or DnaE), ε subunit (DnaQ), and θ subunit 
(HolE); the β sliding clamp processivity factor (DnaN); the clamp loading units 
– consisting of τ subunit (DnaX) and δ and δ′ (HolA and HolC, respectively); a 
helicase (DnaB); a primase (DnaG); and a topoisomerase (TopA) or DNA 
gyrase (GyrAB) in addition to other proteins such as χ (HolB) (Beattie, et al., 
2017; Reyes-Lamothe, et al., 2010; reviewed in van Oijen and Loparo, 2010; 
reviewed by Pomerantz and O’Donnell, 2007). In addition, these processes 
must be finely controlled and orchestrated both spatially and temporally in 
order to prevent lethal events such as improper chromosomal segregation or 
chromosome cleavage.  
 
In this vein, the replisome is thought to be largely stationary within E. coli 
during DNA replication and functions like a ‘factory’ whereby the DNA is 
pulled through the holoenzyme as DNA synthesis occurs (Lemon and 
Grossman, 1998). However, this observation was contradicted by Reyes-
Lamothe and colleagues who showed that independent replication fork 
progression is dictated by chromosomal DNA only and that the position of the 
replisome is only dependent on the dynamics of the chromosome itself (Reyes-
Lamothe, et al., 2008). Additionally, replication of the chromosome in C. 
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crescentus occurs by the movement of the replisome along the chromosome 
(Jensen, et al., 2001). Irrespective, the β sliding clamp is essential to mediate 
polymerase access to the replication fork during DNA synthesis (Burgers, et al., 
1981). Furthermore, it was recently suggested that β promotes the stability of 
the replication fork and maintains a longer association to the replication fork in 
E. coli than other replisome components (Beattie, et al., 2017). As a result, it is 
thought that this allows the β clamp to act as a base to which different 
polymerases can rapidly associate and dissociate (Beattie, et al., 2017), 
indicating that β serves a critically important, multi-faceted function in DNA 
replication. 
 
1.3.1. The β Sliding Clamp 
Studies in Msm have elucidated the dynamics of β in live cells, indicating the 
highly dynamic nature of the replication fork through observations of DnaN 
(Santi, et al., 2013, Santi and McKinney, 2015; Trojanowski, et al., 2015, 2017). 
Using fluorescent microscopy to study live bacilli, the formation of foci of 
constitutively expressed, fluorescently labelled DnaN proteins is thought to 
correlate with the formation of the replication fork and initiation of the 140 
minute long C-phase (DNA synthesis) of the Msm cell cycle. This phase 
accounted for 77.78 % of the total cell replication time (Santi, et al., 2013). In 
addition, chromosome replication occurred immediately after cell division of 
the parental cell into two daughter cells where the B-phase (from the end of cell 
division to the initiation of DNA replication) was largely absent (Santi, et al., 
2013). Therefore it can be deduced that DNA replication contributed to a large 
portion of the time between cell division events. Trojanowski and colleagues 
further showed that mycobacteria are capable of multi-fork chromosome 
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replication, indicating heterogeneity in whether successive rounds of DNA 
replication occur before or after termination of the previous round 
(Trojanowski, et al., 2017). This implied that in instances where cell division is 
slowed down or inhibited, resultant daughter cells can inherit partially 
duplicated chromosomes. 
 
Indeed, the replisome is highly dynamic within mycobacteria as multiple 
replication forks can be observed within single Msm cells, where it was 
reported that 35.5 % of exponentially growing cells exhibit two DnaN foci 
(Trojanowski, et al., 2015). In the same study, it was observed that the replisome 
does not assemble and that DNA replication does not occur during stationary 
phase (Trojanowski, et al., 2015). Similarly, Santi et al. observed that 13 % of all 
cells contained no DnaN foci and attributed this to cell division corresponding 
to the B-phase in short cells and D-phase (from the end of DNA replication to 
cell division) in long cells (Santi, et al., 2015). However, the location of DnaN 
did not exclusively indicate the location of the replication fork, as previous 
studies have suggested multiple roles played by β during DNA repair (de Saro 
and O’Donnell, 2001; Simmons, et al., 2008a; Pillon, et al., 2015; Grompone, et 
al., 2002). It is therefore possible that, in addition to the one or two ‘replicative’ 
foci observed in Msm, the non-replicative foci (‘denoted as minor foci in 
Trojanowski, et al., 2015, and observed as ‘dim’ foci in Santi, et al., 2015) may 
indicate locations of non-replicative DNA processing such as DNA repair. 
 
The precise dynamics and localization of DnaN during cell growth were 
assessed by Santi and colleagues, where DnaN foci were observed to form at 
the midcell during the initiation of the C-phase, during which the majority of 
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DnaN foci remained as a single focus (Santi, et al., 2015). However, the foci were 
observed to be highly dynamic and underwent multiple splitting and re-joining 
events with time. As these experiments were not conducted in three-
dimensions (3D), it is unclear if the dynamic foci represented completely 
separate replisome complexes that stochastically occupy the same lateral 
position within the cell or complexes that actively merge and split from one 
another. Regardless, it remains unclear how these processes relate to DNA 
damage repair, highlighting the gap in knowledge that exists regarding the 
dynamics of DnaN and the contribution of this protein to DNA repair. 
 
1.4. Understudied Anti-TB Drugs 
The development of drug resistance in Mtb is of particular relevance to the 
global TB control programme and thus is of special interest to TB drug 
discovery and development research. Recently, a number of unapproved, 
novel, and promising antitubercular compounds have been identified which 
target bacillary processes involved in genome replication and DNA synthesis 
(Reiche, et al., 2017), namely griselimycin (GRS) (Kling, et al., 2015), nargenicin 
(NRG) (International Patent Number: WO 2016 064982 A1; Young, et al., 2016), 
and moxifloxacin (MOX) (Xu, et al., 2017). The implications of these drugs on 
the mutagenic capacity of mycobacteria and their potential contribution to the 
development of drug resistance is under-explored. In the past, other drugs that 
have been shown to induce the SOS response in other organisms have also 
shown a resulting increase in mutagenesis and genetic diversity (reviewed by 
Galhardo, et al., 2007; Couce and Blázquez, 2009; Blázquez, et al., 2012). For 
example, ciprofloxacin (CIP), which induces the SOS response in Staphylococcus 
aureus (S. aureus) (Cirz, et al., 2007), has been shown to increase the mutation 
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rate of Mycobacterium fortuitum (Gillespie, et al., 2005) as well as induce the SOS 
response in Mtb (O'Sullivan, et al., 2008) and Msm (Fan, et al., 2018). 
Importantly, the use of FLQs was shown to induce the development of drug 
resistance in Msm and Mtb (Malik, et al., 2012). Indeed, earlier it was shown that 
the development of E. coli drug resistance in vivo and in vitro was dependent on 
the induction of the SOS response (Cirz, et al., 2005). Therefore, if any of the 
novel compounds that target DNA replication result in DNA lesions that 
induce expression of the mutagenic DNA repair mechanism, there may be an 
associated increase in inducible mutagenesis associated with therapeutic 
treatment comprising MOX, GRS, or NRG. Such an implication is of significant 
concern and warrants investigation in the early stages of drug development. 
 
1.4.1. Nargenicin 
NRG is a natural product antibiotic that has efficacy against E. coli as well as S. 
aureus and was determined to have a novel mode of action in the latter that 
involves the specific inhibition of DnaE (Painter, et al., 2015). Such a compound 
would hold potential promise for the treatment of TB if it were to act via the 
same mechanism as dnaE1 is essential within Mtb and is also a previously un-
explored drug target (Reiche, et al., 2017). Although no report in the scientific 
literature has confirmed the efficacy of NRG as a sterilizing agent against Mtb, 
a patent published in 2016 has signposted the potential use of NRG as a novel 
antitubercular (Young, et al., 2016). However, it must be noted here that the 
compound may not be suitable as an anti-TB therapeutic as exposure of this 
compound to E. coli resulted in the induction of the SOS response and caused 
cell elongation (Painter, et al., 2015). As a potential consequence of the 
activation of the SOS response, it is possible that the mutasome is induced 
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during NRG-exposure of Mtb, which could ultimately contribute to increased 
levels of mutagenesis and the development of drug resistance. However, there 
exists an intriguing possibility that NRG may simultaneously inhibit DnaE2 in 
addition to the replicative DnaE1 subunit based on the shared homology 
between the two proteins (Boshoff, et al., 2003), which could limit DnaE2-
mediated mutagenesis. The potential impact of NRG on mutagenesis in 
mycobacteria is unknown and warrants investigation.  
 
1.4.2. Moxifloxacin 
MOX is a fourth-generation FLQ that shows increased antibacterial activity and 
serum half-life and decreased toxicity when compared to earlier generation 
FLQs (Stass, et al., 1998). This antimicrobial agent shows promise in treating TB 
disease as it inhibits DNA gyrase (GyrA2B2), a topoisomerase critically 
involved in the structural maintenance of the mycobacterial chromosome by 
controlling negative supercoiling ahead of the replication fork (Reece and 
Maxwell, 1991; Ashley, et al., 2017). Considerable effort has been made to 
determine the efficacy of MOX in both reducing treatment duration 
(Nuermberger, et al., 2004a,b; Burman, et al., 2006; Conde, et al., 2009, 2016; 
Dorman, et al., 2009; Gillespie, et al., 2014; Li, et al., 2017; Moodley and Godec, 
2016) and treating resistant cases of TB (Murray, et al., 2016; Kang, et al., 2016), 
making MOX a drug of high interest. Of further interest within the scope of this 
work, inhibition of DNA gyrase results in the development of double-stranded 
DNA breaks which contributes to the lethality of FLQs in Mtb (Mduli and Ma, 
2007), which may imply the potential for mutagenic DNA repair as a direct 
result of MOX exposure. This possibility is supported by the observation that 
MOX induced the SOS response and expression of the UmuD2C’ mutasome in 
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S. aureus at sub-inhibitory concentrations (Mesak, et al., 2008). Therefore, it is 
imperative to investigate the concern regarding the mutagenicity of MOX if it 
is to be used as a successful anti-TB drug in the future.  
 
1.4.3. Griselimycin 
The natural product, GRS, is a cyclic peptide antibiotic isolated from 
Streptomyces spp. (Terlain and Thomas, 1971) which was found to have potent 
activity against mycobacteria (Kling, et al., 2015). The target of this drug was 
recently elucidated to be the dnaN-encoded β clamp, which, as previously 
indicated, is an essential component of the DNA replication machinery (Kling, 
et al., 2015; Reiche, et al., 2017). Furthermore, GRS was shown to have a high 
binding affinity to, and low dissociation constant for, the β clamp to which it 
binds via the hydrophobic cleft of domains II and III known to be required for 
polymerase binding (Bunting, et al., 2003; Burnouf, et al., 2004). Additionally, 
an Ames test conducted with GRS on Salmonella enterica serovar Typhimurium 
(S. typhimurium) indicated no mutagenicity (Kling, et al., 2015); however, 
induction of the SOS response by GRS may potentially indicate activity of the 
mutagenic DNA repair pathway in mycobacteria, although there is no 
evidence, as yet, to support this. Given the inhibition of DnaN by the 
compound, specifically the interruption of replicative and repair processes, it 
remains possible though that, at inhibitory concentrations, the mutasome is 
unable to function despite formation of the complex at the replication fork. 
Thus, the effect of DnaN inhibition by GRS on inducible mutagenesis remains 
unknown. This represents a knowledge gap that must be addressed to 
determine whether this represents a positive feature or drawback of this drug 
candidate. 
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2. Drug Resistance and Mutations in Mycobacteria 
In 2014, the World Health Organization (WHO) reported that 3.6 % of new and 
20.2 % of recurring TB patients were estimated to have MDR-TB (WHO, 2014). 
Furthermore, in 2016, 8.1 % of global TB cases were reported as MDR/RIF-
resistant (WHO, 2017). With regard to mortality, 170,000 deaths resulted from 
the 350,000 reported cases of MDR-TB in 2014 (WHO, 2014). Subsequent 
acquisition of resistance to a FLQ and an AMI in MDR-TB leads to XDR-TB, a 
highly-resistant form of TB that has a very poor treatment success rate of only 
28-30 % versus 52-54 % and 83 % in MDR-TB and drug-susceptible TB, 
respectively (WHO, 2014, 2016, 2017). XDR-TB has been reported in 117 
countries world-wide (WHO, 2016), indicating that this is an issue of global 
concern.  
 
Drug-resistance mutations include SNPs that occur within specific regions of a 
target (or antibiotic processing- or uptake-related) gene, thereby affecting the 
molecular affinity of the compound to the corresponding binding site within 
the target protein. As an example, RIF, discovered in 1959, is a highly utilized, 
first-line anti-TB drug and, together with the resistance mechanisms against it 
(Wehrli, 1983), represents one of the best studied anti-TB drugs (Koch, et al., 
2014). Resistance to RIF is conferred by SNPs that occur within the rifampicin-
resistance determining region (RRDR) of rpoB, the gene that encodes the target 
of RIF, DNA-dependent RNA polymerase subunit β (Ramaswamy and Musser, 
1998).  
 
In addition to the list of mutations that directly influence the efficacy of drugs 
against Mtb, the acquisition of SNPs within mycobacteria also poses a 
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significant threat to global health through the function of indirect, 
compensatory mutations. Mutations that confer a high level of drug resistance 
usually incur a significant fitness cost associated with the altered gene 
expression or altered amino acid sequence of the protein (Gagneux, et al., 2006; 
Heym, et al., 1995). The downstream effect a SNP has is not exclusively 
restricted to the antibiotic efficacy and can affect a variety of additional protein 
and physiological properties (reviewed by Hershberg, 2017). Although the 
mutation confers resistance to the drug (and therefore circumvents the large 
selective pressure of chemotherapy), it can also significantly reduce the overall, 
relative fitness of the bacterium – potentially reducing virulence or leading to 
a loss of the mutation within a population in the absence of the selective 
antibiotic (Andersson and Hughes, 2010; Koch, et al., 2014). In some cases, the 
(beneficial) drug resistance conferred by a mutation may be overshadowed by 
the detrimental effects of that mutation, compromising the “success” of any 
strain containing the drug-resistance-conferring mutation and thus, preventing 
its fixation within a population (Levin, et al., 2000). Despite the 
disadvantageous effects of most mutations, other genetic changes can result in 
the compensation of the detrimental effect associated with resistance mutations 
and render the resistant bacterium equally, or more, fit than the original, drug-
sensitive strain – effectively ensuring the success of the otherwise deleterious 
resistance mutation through genetic linkage (Comas, et al., 2012; Sherman, et 
al., 1996; Heym, et al., 1995; Koch, et al., 2014; Durão, et al., 2018). This renders 
the antibiotic unable to suppress antibacterial growth or impose a highly 
selective force. In such cases, mutations that occur at unrelated loci within the 
genome can alleviate the detrimental characteristic associated with previously 
fixed, resistance-conferring mutations and may even be a necessary precursor 
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before severely detrimental resistance mutations can be tolerated by the 
bacteria (e.g., rpoC and ahpC mutations, as outlined in more detail below) 
(Trindade, et al., 2009). Compensatory mutations are often an overlooked 
consequence of mutagenesis and mutation acquisition in mycobacteria despite 
being frequently linked to the development and success of MDR and XDR 
strains of Mtb (Trindade, et al., 2009). Overall, the generation and acquisition of 
mutations in mycobacteria lead to the development of drug resistance as well 
as the accumulation of compensatory mutations that help propagate other 
drug-resistance mutations. 
 
2.1. Drug Resistance-Conferring Mutations 
Despite the dependence on chemotherapy to cure TB, subsequent to the 
development of RIF in 1967, bedaquiline (BDQ) (2012) is the only new anti-TB 
drug to be widely used against (MDR-)TB (Mahajan, 2013; Jain, et al., 2008; 
Long, 1991; Wolfson, et al., 2015; Udwadia, et al., 2014). As a consequence of the 
considerable lack of new drugs in recent decades, a large proportion of the 
drugs available for use are ineffective due to the dramatic and sharp rise of 
MDR and XDR strains of Mtb that have accumulated in recent years (Yanling, 
et al., 2006; WHO, 2017; Tessema, et al., 2017; Dheda, et al., 2017), culminating 
in a scenario where drug resistance occurs against almost all drugs (Gygli, et 
al., 2017). A non-exhaustive list of drug resistance-conferring SNPs and indels 
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Rv3547 
        
+ 
   
Rv3792    +         
Rv3806c    +         
srmR 
      
+ 
     
thyA 
       
+ 
    
tlyA + 
           
Based off information from citations in text. 
AMI, Aminoglycosides; BDQ, Bedaqualine; CFZ, Clofazamine; EMB, Ethambutol; ETH, Ethionamide; FLQ, Fluoroquinolones; INH, Isoniazid; PAS, Para-aminosalisylic Acid; PZA, Pyrazinamide; RIF, 
Rifampicin; SM, Streptomycin. 
First-line, combination TB drugs are indicated in red. 
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Mtb becomes refractory to standard RIF treatment following the acquisition of 
mutations (usually SNPs) in rpoB that result in amino acid changes within the 
RRDR of the translated protein – thereby reducing the binding affinity of the 
compound to the essential target RNA polymerase (Campbell, et al., 2001; 
Feklistov, et al., 2008). The two most frequent SNPs that confer RIF-resistance 
to Mtb in vitro and in vivo are substitutions that cause amino acid changes either 
from a serine to a leucine at the 450th position of RpoB (S450L) or a TCGTTG 
transition mutation that changes the serine to a leucine at position 531 (S531L) 
(Morlock, et al., 2000). Mutations such as those that occur in the RRDR result in 
conformational changes of RpoB that reduce the binding affinity of RIF, thereby 
preventing the inhibitory effect on the protein (Telenti, et al., 1993; Campbell, et 
al., 2001). In addition to this, many other SNPs outside of the RRDR contribute 
to RIF-resistance (Siu, et al., 2011). These include mutations in rpoA as well as 
rpoC; however, these mutations do not contribute directly to the mechanism of 
resistance and rather are associated with the restoration of fitness in strains of 
Mtb that contain RIF-resistance-conferring mutations in rpoB, allowing for 
greater success of the pathogen (Comas, et al., 2011; de Vos, et al., 2013; Brandis 
and Hughes, 2013; Koch, et al., 2014).  
 
In the case of PZA, resistant strains are usually associated with SNPs in a single 
gene, pncA, which encodes the pyrazinamidase enzyme responsible for 
converting the prodrug into the active form, pyrazinoic acid (Scorpio and 
Zhang, 1996; Juréen, et al., 2008). PZA resistance-associated SNPs are abundant 
throughout the pncA gene and all result in either the loss of protein function or 
a decrease in expression levels (Yadon, et al., 2017). Similarly, INH-resistance 
occurs mainly as a result of resistance-conferring non-synonymous SNPs in a 
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number of genes (Zhang, et al., 1992; Ramaswamy, et al., 2003; Seifert, et al., 
2015). However, in a similar fashion to that of RIF, fitness compensation 
mutations are also found in INH-resistant strains. Here, mutations in the 
promoter of the ahpC gene in strains resistant to INH allow for greater survival 
and transmission of the bacillus (Sherman, et al., 1996; Heym, et al., 1997). A 
similar change of ahpC regulation is associated with a silent, compensatory-
conferring SNP within mabA (Ando, et al., 2014). In a similar example, 89 % of 
EMB-resistant Mtb strains are associated with SNPs that replace the canonical 
methionine residue at position 306 of the translated EmbB protein, which is 
thought to prevent drug-protein binding (Sreevatsan, et al., 1997; Telenti, et al., 
1997). Adding complexity to this example and further highlighting the role of 
mutations in drug resistance, the level of resistance conferred in EMB-resistant 
strains is dependent on the number and type of mutations present in other 
genes involved in arabinogalactan production (Safi, et al., 2008). In the last 
example, high-level SM-resistance is mediated by SNPs in rpsL (K43R and 
K88Q) and rrs (nucleotide position 530 and 915), while low level resistance is 
associated with mutations in gidB (Sreevatsan, et al., 1996; Okamoto, et al., 2007). 
 
In addition to contributing to first-line drug resistance, mutations are also 
linked to resistance against second-line drugs. FLQ-resistance is associated 
with SNPs in gyrA and gyrB (Takiff, et al., 1997); AMI-resistance is associated 
with mutations in rrs (Alangaden, et al., 1998; Suzuki, et al., 1998; Stanley, et al., 
2010), eis (Zaunbrecher, et al., 2009), and tlyA (Johansen, et al., 2006). ETH-
resistance occurs as a result of mutations in inhA, ethA, ethR, and mshA 
(Brossier, et al., 2011; Vilchèze, et al., 2008). Mutations in thyA and folC cause 
PAS-resistance (Rengarajan, et al., 2004; Zhao, et al., 2014b). While other 
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mutatable resistance-associated genes include Rv0678 (CFZ and BDQ); rplC 
(linezolid); atpE (BDQ); fdg1 (PA-824); as well as others (as reviewed by 
Palomino and Martin, 2014; Da Silva and Palomino, 2011; Sandgren, et al., 2009; 
and Müller, et al., 2013).  
 
2.2. Acquisition of Mutations and the SOS Response 
In addition to the presence of antibiotics during infection, pathogenic 
mycobacteria experience harsh physiochemical conditions due to hypoxia, the 
scarcity of nutrients, and the natural immune response of the host to clear the 
infection (Russell, 2001; Moore, et al., 2017). Not only do these conditions select 
for more fit (or drug resistant) strains from the ever-diversifying population, 
but they also directly contribute to this genetic diversity through the induction 
and subsequent activity of the DNA damage-inducible mutagenic DNA repair 
pathway (Warner, et al., 2010), which will be discussed below. 
 
Bacteria have evolved a multitude of responses to stressful or suboptimal 
conditions (Storz, et al., 2011). Environmental stresses that cause DNA damage 
(genotoxic stress), which include exogenous sources such as macrophage-
generated ROS and chemotherapy, as well as endogenous production such as 
by-products of respiration and metabolism, are usually lethal to bacteria if left 
unrepaired. Bacteria have evolved a variety of mechanisms to deal with the 
DNA damage encountered during these conditions – one of which, the SOS 
response, is the primary response to DNA damage (Little and Mount, 1982). 
This response is a mechanism that tightly regulates the expression of a wide 
variety of genes (Table 1-2) in an attempt to ensure cell survival and viability 
when genome integrity is lost. Throughout the entire bacterial domain, genome 
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robustness is maintained during genotoxic stress through the function of a 
highly conserved array of pathways that act to limit and repair DNA damage 
(reviewed by Erill, et al., 2007). Transcription of the DNA damage-responsive 
genes is often (but not exclusively) mediated by specific transcription operator 
elements known as SOS boxes that allow for highly dynamic regulation of 
multiple genes throughout the genome. The SOS box sequences are located 
directly upstream of the regulated genes to which a dimer of the LexA 
regulatory protein binds under normal cellular conditions (Davis, et al., 2002a; 
Little, et al., 1981; Brent and Ptashne, 1981). Binding of the LexA repressor 
prevents transcription initiation of the downstream gene by DNA-dependent 
RNA polymerases (Little, et al., 1981; Brent and Ptashne, 1981; Durbach, et al., 
1997). 
 
During genotoxic stress, single-stranded DNA (ssDNA) accumulates in the cell 
as a consequence of stalled replication forks caused by DNA damage lesions 
and a loss of chromosomal integrity (Moore, et al., 1981; Sogo, et al., 2002). A 
second regulatory protein, RecA, subsequently binds cytosolic ssDNA (in an 
ATP-dependent fashion) to form activated, multimeric, helical nucleoprotein 
filaments referred to as RecA* (Miura and Tomizawa, 1968; Friedberg, et al., 
1995). These RecA* filaments interact with LexA, causing the repressor to 
undergo proteolytic autocleavage (Little, 1984, 1993). Once LexA is cleaved and 
rendered non-functional, the repressor protein is no longer able to bind the SOS 
box and the down-stream SOS gene is de-repressed, allowing transcriptional 
initiatiation (Papavinasasundaram, et al., 2001). The order of expression of the 
SOS genes corresponds with the level of DNA damage present in the cell and  
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Table 1-2 | DNA damage inducible (potential SOS) genes of Mtb 
H37Rv 
gene 












Smollett, et al., 
(2012) ChIP-seq 
LexA binding site 
Other experimental DNA damage 
references 
Rv0054 ssb - Yes Yes -  
Rv0055 rpsR - Yes - -  
Rv0056 rplI - Yes - -  
Rv0058 dnaB Yes Yes Yes -  
Rv0071  Yes Yes - Yes  
Rv0094c  - Yes - -  
Rv0095c  - Yes Yes Yes  
Rv0181c  - Yes - -  
Rv0182c sigG - Yes Yes -  
Rv0184  - Yes Yes -  
Rv0185  - Yes - -  
Rv0186 bglS - Yes - -  
Rv0335c pe6 Yes - - -  
Rv0336  Yes Yes - Yes  
Rv0427c xthA - Yes Yes -  
Rv0515  Yes Yes - Yes  
Rv0516c  - Yes - -  
Rv0605  - Yes Yes -  
Rv0606  - Yes - -  
Rv0607  - Yes - -  
Rv0829  - Yes - -  





Rv0921  - Yes - -  
Rv0922  - Yes - -  
Rv0991c  - Yes - -  
Rv1000c  Yes Yes - Yes  
Rv1001 arcA Yes - - -  
Rv1057  - - - Yes  
Rv1128c  - Yes Yes -  
Rv1148c  - Yes Yes -  
Rv1169c lipX - Yes - -  
Rv1277  - Yes Yes -  
Rv1278  - Yes - -  
Rv1317c alkA - - Yes -  
Rv1376  - Yes - -  
Rv1377c  Yes Yes - -  
Rv1378c  Yes Yes - Yes  
Rv1379 pyrR Yes - - -  
Rv1406 fmt - Yes Yes -  
Rv1407 fmu - Yes - -  
Rv1547 dnaE1 - - Yes - Boshoff, et al., 2003 
Rv1587c  - Yes - -  
Rv1588c  - Yes Yes Yes  
Rv1633 uvrB - Yes Yes -  
Rv1638 uvrA - Yes Yes -  
Rv1702c  Yes Yes - Yes  
Rv1765c  - Yes Yes -  





Rv1907c  - - Yes -  
Rv1945  - Yes Yes -  
Rv1948c  - Yes - -  
Rv1955 higB - - Yes -  
Rv1961  - Yes - -  
Rv2014  - Yes - -  
Rv2015c  - Yes Yes -  
Rv2016  - - Yes -  
Rv2017  - Yes - -  
Rv2018  Yes - - -  
Rv2024c  - Yes Yes -  
Rv2099c pe21 Yes - - -  
Rv2100   Yes Yes Yes Yes  
Rv2119  - - Yes -  
Rv2191   - Yes - -  
Rv2428 ahpC - - Yes -  
Rv2517c  - - - Yes  
Rv2578c   Yes Yes - Yes  
Rv2579 linB Yes Yes - -  
Rv2592c ruvB Yes Yes - -  
Rv2593c ruvA Yes Yes - Yes  
Rv2594c ruvC Yes Yes Yes Yes Dawson, et al., 2010 
Rv2595 vapB40 Yes -  -  
Rv2660c   - Yes - -  
Rv2717c   Yes Yes - -  





Rv2719c   Yes Yes Yes Yes  
Rv2720 lexA Yes Yes - Yes  
Rv2721c   - - - - Brooks, et al., 2006 
Rv2734  - - Yes -  
Rv2735c   - Yes - -  
Rv2737c recA Yes Yes Yes Yes  
Rv2790c ltp1 - Yes - -  
Rv2791c   - Yes - -  
Rv2792c   - Yes Yes -  
Rv2884   - Yes - -  
Rv2885c   - Yes - -  
Rv2975c   - Yes Yes -  
Rv2976c ung - Yes - -  
Rv2977c thiL - Yes - -  
Rv2978c   - Yes - -  
Rv2979c   - Yes Yes -  
Rv3048c nrdG/nrdF2 - Yes Yes -  
Rv3073c  Yes - - -  
Rv3074   Yes Yes - Yes  
Rv3164c moxR3 Yes - - -  
Rv3191c   - Yes - -  
Rv3198c uvrD2 - Yes Yes -  
Rv3201c   - Yes - -  
Rv3202c   - Yes - -  
Rv3223c sigH - - Yes -  





Rv3260c whiB2 Yes - - Yes  
Rv3261 fbiA Yes - - -  
Rv3263  - - Yes -  
Rv3296 lhr - Yes Yes -  
Rv3297 nei - Yes - -  
Rv3370c dnaE2 Yes Yes - Yes Boshoff, et al., 2003; 
Rv3371  Yes - - -  
Rv3393 iunH - Yes - -  
Rv3394c imuB Yes Yes - - Warner, et al., 2010 
Rv3395c imuAʹ Yes Yes - Yes Warner, et al., 2010; 
Rv3466   - Yes Yes -  
Rv3467   - Yes  -  
Rv3517   - Yes Yes -  
Rv3534c hsaF Yes - - -  
Rv3554 fdxB - Yes - -  
Rv3555c   - Yes Yes -  
Rv3585 radA - Yes Yes -  
Rv3644c   - Yes Yes -  
Rv3714c   - Yes Yes -  
Rv3776   Yes Yes - Yes  
Rv3777   Yes Yes - -  
Rv3827c   - Yes - -  
Rv3828c   - Yes Yes -  
Rv3914 trxC - Yes - -  
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is modulated by the differential binding affinity of LexA to variable SOS box 
sequences controlling transcription of each gene (Friedberg, et al., 1995; 
Friedman, et al., 2005). Operator-binding affinity confers the level of repression 
exerted on the corresponding gene by LexA, with genes that have less 
detrimental effects on the cell having a lower LexA-binding affinity, allowing 
expression of these genes at lower levels of DNA damage (Kamenšek, et al., 
2010; Schnarr, et al., 1991). The more severe and critical the damage 
encountered by the cell, the greater the extent that the SOS response is initiated 
and as a consequence, the more severe the secondary effects of the SOS 
response, such as mutagenesis (Schnarr, et al., 1991; Friedman, et al., 2005; 
reviewed by Simmons, et al., 2008b). This cascade of events ultimately 
contributes to the survival of the cell by rigorous control of DNA repair 
pathways and limiting expression to appropriate levels corresponding to the 
conditions of genotoxic stress. Following the successful expression of the SOS-
regulated genes, the resulting gene products function together, either 
dependently or independently of one another, to perform functions in an 
orchestrated and highly regulated manner to reduce the amount of genomic 
stress and allow the survival of the cell. Thereafter, in the absence of active 
RecA*, newly expressed LexA is free to bind to the SOS boxes and prevent 
further downstream transcription of the responding genes, thereby turning off 
the SOS response.  
 
The SOS response as a whole (RecA-dependent and -independent pathways) 
consists of multiple mechanisms, ranging from nucleotide excision repair 
(NER) to mutagenic DNA repair, non-homologous end-joining (NHEJ) to 
single-strand annealing (SSA), and cell division inhibition to recombination 
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(reviewed by Simmons, et al., 2008b). Error-free repair mechanisms such as 
NER are induced early during the response due to weak LexA-binding 
promoters (Schnarr, et al., 1991). If the level of DNA damage is too extensive to 
be repaired by NER alone, homologous recombination machinery is expressed 
to help repair damaged DNA (Hedge, et al., 1996). In addition, cell division 
inhibitors such as SulA and MinC in E. coli or YneA in B. subtilis remodel cell 
division timing to allow repair and segregation of the chromosome before cell 
division occurs (Bi and Lutkenhaus, 1993; Kawai, et al., 2003). Finally, if the 
DNA damage is too extensive to be repaired by non-mutagenic mechanisms, 
mutagenic polymerases (such as Pol V) are expressed in order to avoid lethal 
interruptions to DNA synthesis; however, expression of UmuDC (Pol V) in E. 
coli requires extensive post-translational regulation (Erdem, et al., 2014) in 
addition to a strong LexA-binding operator (Burckhardt, et al., 1988; 
Shinagawa, et al., 1988; Friedman, et al., 2005). It has also been shown more 
recently that UmuC activity is additionally regulated by spatial sequestration 
of the protein to the cell membrane in E. coli (Robinson, et al., 2015). 
 
In the specific example of the E. coli SOS response, varying strengths of the SOS 
promoters co-ordinates the induction of the different pathways (Kamenšek, et 
al., 2010; Schnarr, et al., 1991). Thus, following DNA damage, the weaker 
regulator sequences allow expression of the corresponding genes first, as low 
levels of non-cleaved LexA disassociate from the sequence more frequently 
(Kamenšek, et al., 2010; Schnarr, et al., 1991). Because highly pleiotropic effects 
such as the expression and engagement of mutagenic TLS polymerases need to 
be tightly regulated in order to prevent unnecessary mutations when cell 
viability is not jeopardized, the stronger promoters controlling these genes are 
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further repressed as more LexA is expressed as part of this SOS response 
(Tippin, et al., 2004). Repression of the tightly regulated genes is maintained 
until such time that the DNA damage is too extensive and the high 
concentration of ssDNA and newly synthesized RecA* results in the cleavage 
of the vast majority of LexA repressors within the cell. 
 
The mycobacterial SOS response shares many similarities with the SOS 
response regulons in other bacteria and is largely similar to that of the E. coli 
model organism, as described above. The SOS response of Mycobacterium spp. 
is only functional after induction of gene expression following DNA damage 
and thus does not function under normal growth conditions (Davis, et al., 
2002a; Boshoff, et al., 2003; Warner, et al., 2010; Durbach, et al., 1997; Brooks et 
al., 2001). In Mtb, genes of the SOS regulon are controlled by SOS boxes with 
the consensus sequence of 5′-TCGAACACATGTTCGA-3′, to which LexA is 
able to bind (Davis, et al., 2002a). However, there are also distinct differences 
between the model organism and the mycobacterial SOS response that need to 
be noted. In addition to the canonical SOS response, mycobacteria also contain 
a set of genes that are expressed during DNA damage but are not regulated by 
LexA. These so-called ‘RecA-nondependent’ genes are regulated by an 
unknown mechanism governed by a different promoter element (Gamulin, et 
al., 2004; Davis, et al., 2002b; Dawson, et al., 2010; Brooks, et al., 2001; 
Movahedzadeh, et al., 1997) that likely includes the function of the ClpR protein 
(Wang, et al., 2011), making it distinctly and differentially regulated in 
comparison to traditional RecA-LexA-regulated genes. Additionally, there are 
notable differences in the genes controlled by the SOS regulon between E. coli 
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and that of mycobacteria, which includes discrepancies in the presence of E. coli 
structural homologues such as UmuDC and MinBC (see Table 1-2).  
 
2.2.1. Inducible DNA Mutagenesis and TLS 
DNA-dependent DNA polymerase enzymes are required to copy and replicate 
the genome with a high degree of fidelity; however, the high degree of fidelity 
offered by replicative enzymes prevents the compact catalytic active site from 
accommodating DNA lesions often encountered on template strands during 
replication (Boudsocq, et al., 2004; Yang and Woodgate, 2007; Wang and Yang, 
2009; Wu, et al., 2017). These lesions can result in stalled replication forks that 
can be lethal to the cell, thus necessitating the evolution of TLS polymerases 
that have more ‘forgiving’ catalytic sites that allow incorporation of 
deoxyribonucleotides (dNTPs) necessary to facilitate DNA synthesis opposite 
the lesion, such as observed in the case of human DNA Polymerase ι (Donigan, 
et al., 2014), and allowing for the continuation of DNA replication. Polymerases 
that possess a less stringent active site allow for the polymerization of dNTPs 
in the presence of DNA lesions on the template strand by the process of TLS 
(Table 1-3), ultimately contributing to the continuation of chromosomal 
replication. 
 
The primary role of TLS is to facilitate the continuation of genome replication 
and thus ensure the survival of the cell following severe genotoxic stress. In the 
case of mutagenic TLS, cell survival usually occurs as a trade-off against an 
increased mutation rate as a result of the incorporation of incorrect nucleotides 
opposite the DNA lesion by specialist TLS polymerases in an attempt to  
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Table 1-3 | Summary of bacterial DNA polymerases 





E. coli PolA (Pol I)   
 PolB (Pol II) Yes  
 DnaE (Pol III)  Yes (non-mutagenic) 
 DinB (Pol IV) Yes Yes (Moore, et al., 2017) 
 UmuC (Pol V) Yes Yes 
Bacillus subtilis DnaE Yes Yes (Le Chatelier, et al., 2004) 
Streptococcus pyogenes DnaE  Yes (non-mutagenic; Bruck, et 
al., 2003) 
Msm DnaE1 Yes  
 DnaE2 Yes Yes (Boshoff, et al., 2003) 
 DinB   
 DinX   
 PolA No  
Mtb DnaE1 Yes  
 DnaE2 Yes Yes (Boshoff, et al., 2003) 
 DinB No  
 DinX No  
 PolA No  
C. crescentus DnaE1   
 ImuC Yes  
Pseudomonas spp. ImuC Yes Yes (Jatsenko, et al., 2017) 
 DinB  Yes (Jatsenko, et al., 2017) 
 
continue DNA replication (Moore, et al., 2017). This phenomenon of inducible 
mutagenesis (or adaptive mutagenesis) results in the generation of mutations 
within the region of repaired DNA (Tippin, et al., 2004) and, as a consequence, 
allows for variation of mutation rate through the function of stress-induced, 
SOS-regulated, low-fidelity polymerases (Bruck, et al., 2003). The ultimate 
evolutionary consequence of this mechanism is the generation of genomic 
heterogeneity during severely adverse environments, which may result in a 
subpopulation of cells enduring the stress (Radman, et al., 1999; Bruck, et al., 
2003). It is postulated that inducible mutagenesis evolved as a result of a 
combination of second-order selection for a variable mutation rate, genetic drift 
due to rare selection events, as well as the proximal consequence of surviving 
the associated stress (MacLean, et al., 2013). Regardless, the heterogeneity 
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generated as a result of inducible mutagenesis, although typically deleterious 
(Taddei, et al., 1997), can lead to enough diversity in key genes to allow survival 
and endurance of a bacterial population through the harsh selective pressure 
associated with nutrient deprivation, genotoxic stress, and antibiotic 
chemotherapy (Warner, et al., 2010; Moore, et al., 2017). Although low mutation 
rates are beneficial on long time-scales, temporary periods of increased 
mutation can be beneficial to the organism. The increased mutagenesis 
associated with lesion bypass by random nucleotide insertion is a potential 
contributor to the micro-evolution of the bacterium and, in cases where the 
mutation has a non-deleterious effect on immediate cell survival, the error may 
become fixed overtime resulting in genetic diversity. Fixation is more likely to 
take place during selective conditions such as occurs during antibiotic exposure 
(Baym, et al., 2016).  
 
Mutagenic TLS polymerases contain a promiscuous active site that can 
accommodate an array of DNA lesions and adducts to be replicated past 
(Boudsocq, et al., 2004; Goodman and Woodgate, 2013); however, due to the 
nature of the active site of these polymerases, nucleotide incorporation is not 
highly specific and accounts for the associated low fidelity and resultant highly 
error-prone DNA polymerization (Ling, et al., 2001; Boudsocq, et al., 2004). In 
organisms such as E. coli, the RecA-dependent, inducible mutagenic repair 
pathway consists of UmuD′2C (Pol V) (Tang, et al., 1998; Pham, et al., 2001). 
DNA Pol V is a Y family polymerase that requires the activity of RecA to 
function (Jiang, et al., 2009; Pham, et al., 2001). In contrast, other bacteria such 
as Mtb and C. crescentus have different DNA-damage induced mutagenic repair 
machinery (Table 1-4). In these cases, C family polymerases such as DnaE2 are 
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responsible for TLS and mutagenesis following DNA damage (Boshoff, et al., 
2003; Galhardo, et al., 2005) (Table 1-3). 
 
Table 1-4 | Summary of the genes consituting the mutagenic cassette in various bacterial species 






Msm MSMEG_16201* MSMEG_16222 MSMEG_1633 
Mtb Rv3395c1* Rv3394c2 Rv3370 
C. crescentus CC32131 CC32122 CC32113 
Pseudomonas aeruginosa PA06711 PA06702 PA06693 
Vibrio vulnificus VV12961 VV12952 VV12943 
Vibrio parahaemolyticus VP20341 VP20352 VP20363 
Ralstonia solanacaerum RSp07981X RSp07992 RSp08003 
Bordetella bronchisceptica BB30861 BB30872 BB30883 
Bordetella parapertussis BPP16421 BPP16412 BPP16403 
Pseudomonas putida PP31171  PP31182 PP31193 
Methylococcus capsulatus MCA21661  MCA21652 MCA21643 
Pseudomonas syringae PSPTO_27931 PSPTO_27942 PSPTO_27953 
Xanthomonas campestris XCC10991 XCC11002 XCC11013 
Xanthomonas axonopodis XAC11971  XAC11982 XAC11993 
Corynebacterium glutamicum NCgl05901 NCgl05912 NCgl0611 
Sinorhizobium meliloti SMc037901 SMc03789#2 SMc037882 
Nocardia farcinia Nfa90591  Nfa90602 Nfa9150 
Rhodopirellula baltica RB118941 RB118912 RB1262 
Streptomyces avermitilis - SAV6556#1 SAV65552 
Propionibacterium acnes PPA16521* PPA16512 PPA16503 
Mycobacterium bovis Mb3427c1* Mb3426c2 Mb3405c 
Agrobacterium tumefaciens AGR_L_31701  AGR_L_31711 AGR_L_31733 
Adapted from Galhardo, et al., 2005., Abella, et al., 2004, and Clark, et al., 2016. 
Numerical superscript indicates the putative position of the gene within the predicted operon. 
* RecA homologue 
# DinB homologue 
X Annotated as pseudogene 
 
Within E. coli, all three SOS-regulated DNA polymerases (Pol II, Pol IV, and Pol 
V) are required to bypass DNA lesions of different kinds (Napolatino, et al., 
2000), with Pol V being the largest factor contributing to survival following UV 
irradiation (Courcelle, et al., 2005). Maor-Shoshani and colleagues assessed the 
gap-filling replicative capacity of different combinations of proteins and 
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proposed that the in vitro activity of UmuC (Pol V) requires processed UmuD’, 
RecA, as well as single-stranded binding protein (SSB) and is responsible for 
SOS-mediated, non-specific mutagenesis by TLS (Maor-Shoshani, et al., 2000). 
Furthermore, multiple other interactions have been identified as being 
necessary for the complete function of this UmuD’2C pathway in E. coli, 
including interactions between UmuD’2C, the β clamp (Tang, et al., 2000), Pol 
II, the γ clamp loader (Pham, et al., 2001), as well as the co-factor ATP (Jiang, et 
al., 2009). Overall, Pol V is tightly regulated by multiple levels of control at both 
pre-transcriptional and post-translational levels (briefly reviewed by 
Goodman, et al., 2016). On the other-hand, the analogous ImuABC/DnaE2 
mutagenic repair mechanism found in mycobacteria and C. crescentus is 
considerably less well studied and the detailed structure, function, and 
regulation of this mutasome is not completely understood.  
 
2.2.1.1. E. coli UmuDC 
In E. coli, three DNA polymerases contribute to TLS, namely Pol II, Pol IV, and 
Pol V (Napolitano et al., 2000). In combination, these three polymerases are able 
to synthesize DNA while using a damaged DNA strand as a template for 
replication; however, it is Pol V that contributes the most to inducible 
mutagenesis (Courcelle, et al., 2005). UV irradiation and chemicals such as 4-
nitroquinoline 1-oxide (NQO) and methyl methanesulfonate (MMS) appear to 
cause mutagenesis as a result of TLS and requires DNA Pol III and the SOS-
regulated proteins DinB, UmuD, UmuC and RecA (Friedberg, et al., 1995). Kato 
and Shinoura screened E. coli mutants for a Umu-deficient, UV-nonmutatable 
phenotype and observed mutations in umuA, umuB and umuC (Kato and 
Shinoura, 1977). Although deficiencies in UmuA and UmuB resulted in slight 
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decreases in UV-inducible mutagenesis, UmuC was found to be more 
important to inducible mutagenesis as umuC-knockout strains were 
considerably more sensitive to UV irradiation and exhibited a considerable 
decrease in SOS induced mutagenesis (Kato and Shinoura, 1977). UmuC is a 
well conserved polymerase in prokaryotes, with a homologue in eukaryotes 
(Murakumo, et al., 2001; and reviewed by Lawrence and Maher, 2001). In 
addition to UmuC, a second component of the E. coli inducible mutagnesis 
pathway was found to be UmuD (Shinagawa, et al., 1983). Sequence data of 
UmuD allowed researchers to discover that the 45 kD protein shared homology 
with a region of LexA that is responsible for the autolytic cleavage of the 
repressor (Perry, et al., 1985). This subsequently lead to the discovery that 
UmuD also underwent autocatalytic cleavage in a similar but distinct fashion 
to that of LexA (Burckhardt, et al., 1988; Shinagawa, et al., 1988). Once more, it 
was determined that RecA* nucleofilaments were responsible for protein 
autolytic cleavage, in this instance, resulting in the cleavage of the first 24 
amino acid residues in UmuD to yield UmuD’. This processing was deemed 
essential to the function of the UmuDC pathway, as strains deficient in both 
LexA and RecA (UmuDC was still expressed but RecA was absent) failed to 
yield wild-type (WT) levels of induced mutagenesis following UV exposure 
(Nohmi, et al., 1988). Furthermore, a strain of E. coli with a mutated copy of recA 
such that the encoded protein could no longer form nucleoprotein filaments 
also failed to exhibit any degree of UV-induced mutagenesis despite the 
production of processed UmuD’ (Bailone, et al., 1991; Dutreix, et al., 1992). This 
further established an additional role of RecA in SOS-mediated DNA damage 
repair beyond the regulatory role of the protein. 
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Adding to the utility of RecA and the associated RecA* nucleoprotein filament, 
it was further determined that RecA* together with a bound ATP molecule is 
required to assemble with the rest of the Pol V complex for inducible 
mutagenesis to occur (Jiang, et al., 2009). It was found that the presence of this 
RecA*-ATP molecule is required for a biochemical reason: to remotely recycle 
the Pol V complex by activation to the Pol V Mut state prior to TLS (Jiang, et al., 
2009). Here, RecA* was able to activate Pol V prior to the polymerase being 
purified and subsequently used to synthesize DNA in the absence of RecA*. 
Activation of Pol V occurs when the 3’-end of RecA* donates a RecA-ATP 
complex to UmuD’2C to yield UmuD’2C-RecA-ATP (Jiang, et al., 2009). The 
UmuD’2C-RecA-ATP complex is active and performs TLS until which point it 
becomes inactive following single primer extension of a single DNA template. 
It is postulated that the conversion from active to inactive Pol V Mut is 
associated with a conformational change of the UmuD’2C complex and a 
repositioning of bound RecA-ATP from UmuD’2 to UmuC (Jiang, et al., 2009). 
This inactivation allows the bacterium to endure of the function of Pol V during 
the SOS response due to the decrease in mutational load associated with the 
rapid inactivation of Pol V (Jiang, et al., 2009). 
 
A further level of regulation and control of mutagenic polymerases exists 
beyond protein activity. Degradation of low-level Pol V expressed under 
conditions of minimal DNA damage (Frank, et al., 1996) and sequestration of 
mutagenic polymerases to the cell membrane (Robinson, et al., 2015) also 
contribute to the limited functionality of Pol V in E. coli. Therefore, error-prone 
DNA repair in E. coli is only fully functional if the DNA damage (and RecA*) 
persists beyond initial repair attempts by non-mutagenic pathways (Robinson, 
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et al., 2015). It is likely that this high level of regulation evolved to tightly control 
when the error-prone Pol V complex is functional, as evidenced by experiments 
by Caillet-Fauquet and colleagues in which E. coli cells containing the 
constitutively active recA730 allele exhibited higher levels of spontaneous 
mutations without conditions of genotoxic stress (Caillet-Fauquet and 
Maenhaut-Michel, 1988). This phenotype was reversed following disruption of 
the umuC gene (thus eliminating Pol V function), suggesting that that Pol V has 
the capacity to introduce mutations into non-damaged DNA (Caillet-Fauquet 
and Maenhaut-Michel, 1988). This observation is reinforced by similar accounts 
of over-expressed SOS-dependent polymerases, such as DinB, resulting in 
increased mutational load in the absence of DNA damage (Kim, et al., 1997). 
 
2.2.1.2. C. crescentus ImuA, ImuB, and ImuC 
Although E. coli is historically considered the ‘gold standard’ bacterial model, 
it differs significantly from other bacterial species, including, but not limited to, 
Mtb and Msm, in terms of metabolism and physiology. This generalization also 
applies to mutagenic repair and the error-prone polymerases, whereby, as 
discussed earlier, E. coli contains genes encoding the Pol V mutasome system. 
To this end, it is worthwhile to review another model organism, C. crescentus, 
which employs the more relevant imuA-imuB-dnaE2 cassette-based 
mutagenesis mechanism (Galhardo, et al., 2005). C. crescentus is UV-mutable but 
contains no homologues of the E. coli UmuD’2C polymerase complex. Rather, 
C. crescentus contains genes encoding ImuA, ImuB, and ImuC (Galhardo, et al., 
2005). Here, DnaE2 is referred to as ImuC and completes the full array of the 
ImuABC cassette genes in the organism (Galhardo, et al., 2005). The ImuABC 
proteins share no homology with components of UmuD’2C pathways but are 
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thought to perform an analogous function. Furthermore, imuC (CC3211) is part 
of an SOS-regulated tricistronic operon within C. crescentus including imuA 
(CC3213), a homologue of sulA, as well as imuB (CC3212), a distant homologue 
of dinB (Galhardo, et al., 2005). The regulation of the ImuABC system in C. 
crescentus has been shown to be mediated by a single GTTCN7GTTC SOS box 
located 66 bp upstream of imuA (Galhardo, et al., 2005). The resultant mRNA 
molecule is present during normal cell growth but is strongly upregulated 
following UV irradiation and induction of RecA expression as part of the SOS 
response (Galhardo, et al., 2005). 
 
Homologues of C. crescentus ImuA in other bacteria, such as Pseudomonas 
putida, share sequence conservation with the corresponding SulA protein in 
that species; however genetic knockouts of CC3213 did not indicate 
involvement in the SOS-dependent suppression of cell division during MMC 
exposure (Galhardo, et al., 2005), indicating that ImuA does not contribute to 
the inhibition of cell division. The CC3212 gene (imuB) shares homology with 
other DinB proteins and it is intriguing to note that all bacteria that encode 
ImuB also possess one or more genes encoding a DinB polymerase (Galhardo, 
et al., 2005). However, phylogenetic analysis of ImuB and DinB proteins from a 
variety of organisms indicate highly divergent evolution – with the exception 
of Streptomyces avermitilis, which is also the only bacterium that encodes ImuB 
but lacks an imuA homologue (see Table 1-4) – suggesting that ImuB belongs 
to the UmuC superfamily (Galhardo, et al., 2005). Similarly, what is evident 
from the strong co-evolution of the system is that DnaE2 polymerases from all 
bacterial backgrounds exhibit considerable divergent evolution from 
corresponding replicative DnaE(1) proteins (Galhardo, et al., 2005). A large 
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proportion of α-proteobacteria (as well as other lineages such as 
Actinomycetales) exhibit marked divergence in sequence of the two dnaE-type 
genes, suggesting a gene duplication event in an extremely distant common 
ancestor (Galhado, et al., 2005; Timinskas, et al., 2013) (Figure 1-1). It is evident 
from this that DnaE2 performs a non-analogous and specialized function 
distinct from that of the distantly related replicative enzyme, DnaE1. 
 
 
Figure 1-1 | Representative phylogenetic tree of the evolutionary relationship between DnaE2 and other 
polymerases from other model organisms 
 
Single gene knockouts in imuABC showed a mild increase of UV sensitivity in 
C. crescentus, but double knockouts had no additive effect confirming that these 
proteins are involved in the same, non-redundant pathway (Galhardo, et al., 
2005). In the same vein, MMC and UV irradiation resistance as well as 
mutagenesis were negatively affected by the absence of any single imuABC 
open reading frame (ORF) – a phenotype that is recapitulated by double 
knockouts of the same genes (Galhardo, et al., 2005). In addition to this, 
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mutagenic DNA repair that is underrepresented in pathway-deficient strains. 
When assessing RIF-selected, UV-induced RIF-resistance mutations within the 
rpoB gene of C. crescentus, Galhardo and colleagues identified that G:CC:G 
transversion mutations were only present in WT strains and accounted for 
28.5 % of SNPs present in these cases (Galhardo, et al., 2005). Conversely, these 
transversions were completely absent in ∆imuB and ∆imuC strains. In the latter 
case, G:C→A:T transitions were much more abundant, contributing 
approximately 90 % of the SNPs in the knockout strain, but only accounting for 
42.9 % of SNPs in WT (Galhardo, et al., 2005). The preference for the G:C→C:G 
transversions by ImuABC differentiates the role of this mutagenic repair 
system from UmuD’2C, which instead favours TC mutations from T(6-4)T 
photodimers following DNA damage by UV irradiation, and likely indicates a 
nucleotide preference during TLS as well as mechanistic differences between 
the two pathways (LeClerc, et al., 1991; Napolitano et al., 2000; Galhardo, et al., 
2005). 
 
It is thought that following the formation of a DNA lesion which prevents the 
progression of the replicative DnaE polymerase, the resulting stalled 
replication fork induces expression of SOS-controlled genes. Thereafter, 
expressed ImuABC displaces the replicative polymerase and performs TLS for 
a limited number of bases (Galhardo, et al., 2005; Moore, et al., 2017). Beattie and 
colleagues have recently indicated that this ‘polymerase swapping’ occurs 
frequently, at a rate of turnover in the region of 10 s (Beattie, et al., 2017). 
Furthermore, the swapping is predicted to be mediated by the more stable 
DNA-β clamp interaction and perhaps the dnaB-encoded helicase subunit 
(Galhardo, et al., 2005; Beattie, et al., 2017). Under this model, the mutagenic 
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repair polymerase is able to outcompete the replicative polymerase – 
particularly at stalled replication forks – and perform mutagenic TLS. 
However, the complete regulatory mechanism of TLS activation has not been 
elucidated in C. crescentus and it is likely that other factors influence the activity 
of ImuABC following expression. This is evidenced by the observation that 
SOS-level expression of ImuABC in the absence of genotoxic stress does not 
yield an increase in spontaneous or induced mutagenesis in C. crescentus 
(Alves, et al., 2017). It is therefore possible that in the absence of lesion-specific 
factors (such as polymerase stalling), TLS cannot be successfully initiated by 
this pathway. This finding is in contrast to the observation that UmuD’2C 
mutagenesis is functional in the absence of DNA damage during over-
expression studies and highlights another key difference between the two 
mutagenic pathways (Caillet-Fauquet and Maenhaut-Michel, 1988; Tang, et al., 
2000). Additionally, Alves and colleagues provided evidence that RecA is not 
required for ImuABC function; therefore, it can be inferred that activated RecA* 
is not involved in ImuABC function (Alves, et al., 2017), further identifying 
another dissimilarity to UmuD’2C mutagenesis.  
 
2.2.2. The Mycobacterial Mutasome 
As with E. coli and C. crescentus, mycobacteria contain a complement of 
mutagenic DNA repair genes. The mutagenic DNA repair pathway in 
mycobacteria is encoded by the genes imuA′, imuB and dnaE2 in a homologous 
pathway to that of C. crescentus (Boshoff, et al., 2003; Warner, et al., 2010). In 
further contrast to E. coli, which expresses three polymerases as part of the 
RecA-dependent response, DnaE1 and DnaE2 are the only known SOS-
regulated polymerases identified in Msm and Mtb (Boshoff, et al., 2003; Warner, 
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et al., 2010). The mycobacterial mutasome functions in an analogous manner to 
the previously discussed systems, namely, to continue DNA strand synthesis 
across DNA damage lesions on the template strand when the replicative 
polymerase stalls at a site of damage during replication of the chromosome. 
More specifically, the mycobacterial mutasome is thought to perform TLS 
across DNA lesions to allow the continuation of DNA replication during 
potentially lethal genotoxic stress (Boshoff, et al., 2003).  
 
Although the reason for the upregulation of the replicative DnaE1 during 
genotoxic stress is unknown, the expression of DnaE2 was determined to 
facilitate survival of lethal DNA damage lesions caused by UV irradiation, 
MMC or other genotoxins (Wang, 2001; Boshoff, et al., 2003; Hanawalt, 2015). It 
was additionally established that the mycobacterial mutasome included the 
operonic accessory factors ImuA′ and ImuB, which are required for the 
phenotype of mutagenic DNA repair and damage tolerance (Warner, et al., 
2010). In Mtb and Msm, these three mutasome components are part of the split 
mutagenesis cassette, imuA′-imuB/dnaE2, and are controlled independently by 
two LexA-regulated promoters as part of the SOS response to DNA damage 
(Erill, et al., 2006; Davis, et al., 2002a; Boshoff, et al., 2003; Warner, et al., 2010; 
Galhardo, et al., 2005). 
 
The imuA-imuB-dnaE2 mutagenic cassette is found in many bacteria (Table 1-
4), but never in bacteria that encode Pol V-functioning UmuDC (Timinskas, et 
al., 2013), suggesting that the proteins in each pathway perform analogous 
functions. Therefore, the mycobacterial mutasome is predicted to perform a 
function similar to that of UmuD′2C in E. coli (Jiang, et al., 2009; Erill, et al., 2006), 
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which has also been previously implicated in the development of drug 
resistance in vivo (Cirz, et al., 2005). The mycobacterial mutasome, which 
represents the only inducible mutagenesis pathway in both Mtb and Msm, has 
DNA damage-inducible base-substitution mutagenesis activity (Warner, et al., 
2010), but induces a different spectrum of mutations from that observed in C. 
crescentus (Galhardo, et al., 2005; Boshoff, et al., 2003). Despite the non-
essentiality of the pathway, it was previously shown that each of these three 
components is essential to the function of the mutasome and that strains 
individually deficient in functional DnaE2, ImuA′, or ImuB are phenotypically 
identical and have markedly increased sensitivity to genotoxins such as MMC 
in vitro (Boshoff, et al., 2003; Warner, et al., 2010). Furthermore, an Mtb mutant 
strain deficient in DnaE2 was attenuated in a mouse infection model of TB, and 
exhibited a marked decrease in the ability to yield drug-resistant mutants 
during treatment with RIF in muris (Boshoff, et al., 2003). 
 
2.2.2.1. DnaE2 
Unlike other bacteria, polymerase-encoding genes such as dinB and dinX are 
not known to be upregulated during DNA damage in mycobacteria (Brooks, et 
al., 2001; Boshoff, et al., 2003; see Table 1-2 and Table 1-3); however, in addition 
to dnaE1, dnaE2 (denoted as MSMEG_1633 in Msm and Rv3370c in Mtb), is 
known to be the only other significantly upregulated polymerase in Mtb during 
exposure to genotoxic stressors (Boshoff, et al., 2003). The associated induction 
of dnaE2 is known to be controlled by the LexA repressor as recA-deficient 
strains did not exhibit increased expression of DnaE2 following DNA damage 
with UV, MMC or hydrogen peroxide (Boshoff, et al., 2003). Strains of Mtb and 
Msm that are deficient in dnaE2 phenocopy the inducible mutagenic capacity of 
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recA-deficient mutants and have considerably lower mutation frequencies 
following UV induction of the SOS response than WT (Boshoff, et al., 2003), 
indicating that mutagenic DNA repair was completely dependent on the 
expression of DnaE2 in Mtb and Msm. Furthermore, the study by Boshoff and 
colleagues identified that DnaE2 was neither expressed in vitro under standard 
growth conditions nor functional outside of DNA damaging conditions as 
dnaE2-knockouts exhibited no associated fitness costs in addition to the fact 
that the mutants maintained a WT mutation rate during normal growth 
(Boshoff, et al., 2003).  
 
When compared to WT, ∆dnaE2 strains failed to yield mutated pyrimidine 
dimers from sequential cytosine bases (CC→TT) when exposed to UV 
irradiation (Boshoff, et al., 2003) indicating that this specific type of mutation 
was solely resultant of the function of DnaE2 in the WT background. 
Ultimately, the landmark study by Boshoff et al. identified that following a 
nine-month infection, the total number of ∆dnaE2 Mtb bacilli recovered from 
the lungs of infected C57BL/6 mice was 10-fold lower than that of WT (Boshoff, 
et al., 2003). Additionally, the mice infected by aerosolized ∆dnaE2 Mtb 
exhibited exceptionally longer life-spans than the mice infected with WT 
(median survival time of 384 days and 222 days for mice infected with ∆dnaE2 
and WT, respectively) (Boshoff, et al., 2003). Similarly, S3B6F1 mice infected 
with WT exhibited a 20 % mortality after 150 days while the counterpart mice 
infected with the ∆dnaE2 mutant did not succumb to disease in the same period 
(Boshoff, et al., 2003). This decrease in virulence illustrates the role that 
inducible mutagenic DNA repair plays in pathogenesis and in the survival of 
Mtb during infection, highlighting the potential benefits of DnaE2 inhibition by 
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chemotherapy. To further illustrate the mutagenic role of DnaE2, an 
experiment to determine the number of RIF-resistant mutants recovered from 
infected mice (although far from a conclusive result due to low statistical 
power) showed that dnaE2-deficient bacteria were less likely to develop 
resistance to RIF (Boshoff, et al., 2003). Importantly, this work also provides 
evidence to suggest a link between the oxidative stress-induced role of DnaE2 
and an environment that necessitates its function in vivo, and therefore suggests 
that Mtb does encounter a somewhat oxidative environment during infection 
(reviewed by Warner and Mizrahi, 2006). Overall, the results presented by 
Boshoff and colleagues provide evidence to suggest that DnaE2 (i) plays an 
integral role in mutagenic DNA repair during genotoxic stress; (ii) contributes 
to genotoxic stress survival and the mutagenic capacity of Mtb in vivo; and (iii) 
is involved in a non-redundant, SOS-regulated TLS pathway in Mtb and Msm. 
 
DnaE2 is a C family DNA polymerase III  subunit and is homologous to the 
α-subunit of E. coli Pol III (Figure 1-1), except for the apparent loss of the τ 
clamp-loader subunit-binding region of the C-terminus region which may 
contribute to its low fidelity (Warner, et al., 2010). In addition, when comparing 
mycobacterial DnaE2 to DnaE1, the former is missing both amino acids 
required for proof-reading activity (corresponding to the glutamate and 
aspartate residues at position 133 and 228, respectively, of Mtb DnaE1) as well 
as the polyhistidinol phosphatase (PHP) domain of replicative IIIα 
polymerases – likely further contributing to the low fidelity of DnaE2 (Warner, 
et al., 2010; Wieczorek and McHenry, 2006; Nakane, et al., 2009; Ditse, 2015). 
These key differences found in DnaE2 are likely necessary to allow the protein 
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to perform TLS and enhance the survival of the bacterium during genotoxic 
stress (Boshoff, et al., 2003; Moore, et al., 2017).  
 
When analyzing the sequence information of DnaE2, it is evident that this C 
family polymerase does not contain the typical β clamp-binding domain with 
the sequence of QFDLF (Dalrymple, et al., 2001), as is present in Mtb DnaE1 
(Warner, et al., 2010). The sequence in DnaE2 corresponding to the location of 
this binding site in DnaE1 is occupied by a conserved amino acid sequence of 
RPDRLPGVG not predicted to bind β (Warner, et al., 2010). Therefore, as DnaE2 
is thought not to contain a β clamp-binding domain, it is currently not known 
how DnaE2 is maintained at the replication fork during TLS. However, despite 
this discrepancy, DnaE2 does in fact include a catalytic active site suggesting 
its function as a type IIIα polymerase. The DnaE2 protein includes a series of 
three separated aspartic acid residues (at positions 439, 441, and 579 in Mtb or 
441, 443, and 583 in Msm) that form the catalytic triad that is required for 
function by type IIIα polymerases (Warner, et al., 2010; Bailey, et al., 2006; 
Lamers, et al., 2006). When this catalytic triad was disrupted by mutation of the 
441st and 443rd amino acids from aspartic acid to alanine (441DID443→441AIA443) 
in Msm, UV-induced mutagenesis was restricted in the strain containing the 
chromosomal mutation in alignment with the phenotype of the dnaE2-deletion 
mutant (Warner, et al., 2010). In addition, this dnaE2AIA strain exhibited an 
associated increase in MMC sensitivity suggesting, together with the previous 
result, that polymerization of DNA is the biochemical function of DnaE2 
during mutagenic DNA repair (Warner, et al., 2010). However, the precise 
dynamics of DnaE2 activity following DNA damage remain unknown. 
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2.2.2.2. ImuA′ and ImuB 
As described above, bacterial genomes that encode dnaE2 invariably contain a 
gene encoding ImuB and occasionally a third protein denoted ImuA, 
constituting a three-component imuA-imuB-dnaE2 mutagenic cassette (Erill, et 
al., 2006) (Table 1-4). As expected, both Mtb and Msm encode a gene sharing 
considerable homology with the ImuB homologue found in C. crescentus 
(Rv3394c and MSMEG_1622, respectively) (Erill, et al., 2006; Warner, et al., 
2010). Furthermore, the third component gene, which shares distant homology 
with C. crescentus imuA, is found in both mycobacterial species (Mtb Rv3395c; 
Msm MSMEG_1620), although here (and in other actinobacteria) it is denoted 
as imuA′ to indicate the reduced homology shared with the imuA gene found 
in proteobacteria (Erill, et al., 2006; Galhardo, et al., 2005). Both the accessory 
genes, imuA′ and imuB, were determined to be co-regulated following UV 
damage in exponentially growing Mtb (Warner, et al., 2010) further identifying 
the cassette regulon which was previously identified to be LexA-repressible 
(Rand, et al., 2003; Davis, et al., 2002a). When each accessory protein was 
genetically inactivated in Mtb and Msm, a significant decrease in both inducible 
mutagenic capacity and genotoxic stress survival was observed (Warner, et al., 
2010). That is, imuA′ and imuB knockout mutants effectively phenocopy the 
dnaE2 knockout, which suggests essential contributions of each protein to the 
function of DnaE2 during mutagenic DNA repair (Warner, et al., 2010). 
Furthermore, the components were shown not to contribute to mutagenic DNA 
repair in an additive manner as a ∆dnaE2 ∆imuA′ ∆imuB triple knockout mutant 
did not exhibit a further decrease in UV-induced mutation frequency and 
MMC-tolerance beyond that observed in individual knockout mutants 
(Warner, et al., 2010). The results of Warner et al. (2010) confirmed that the 
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mycobacterial mutasome (i) consists of at least three components (ImuA′, 
ImuB, and DnaE2); (ii) is genetically related to that observed in C. crescentus; 
and (iii) perhaps functions in an analogous manner (Galhardo, et al., 2005). 
When looking at the ImuB component, phylogeny indicates that it is a distant 
member of the Y family polymerases which include DinB and other TLS 
polymerases (Galhardo, et al., 2005); however, homology modeling indicates 
that the active site of ImuB does not include carboxylic acid residues which are 
required for DNA polymerization (Warner, et al., 2010; Ling, et al., 2001; 
Koorits, et al., 2007). Despite this predicted loss-of-function, ImuB contains a 
putative β clamp-binding domain, represented by the QLPLWG amino acid 
sequence motif from position 354 to 359 in Mtb ImuB, a domain that is not 
observed in DnaE2 (Warner, et al., 2010). Overall, these observations suggest 
that ImuB is not directly responsible for DNA polymerization during TLS but 
instead is thought to be essential to the ability of DnaE2 to catalyze TLS by an 
unknown mechanism (Warner, et al., 2010).  
 
Unlike the majority of ImuA proteins found in bacteria which are closely 
homologous to the respective SulA protein of each species, mycobacterial 
ImuA′ is more closely related to RecA than to either mycobacterial SulA or C. 
crescentus ImuA, indicating an early divergence from ImuA found in other 
bacterial species (Figure 1-2) (Warner, et al., 2010; Galhardo, et al., 2005). 
Although ImuA′ shares homology with Mtb RecA, it is missing the C-terminus 
and RecA-homologous regions that would allow it to perform homologous 
functions (Warner, et al., 2010). Despite this, it is predicted that ImuA′ is able to 
bind to DNA as well as to ImuB, making it possible that it performs an 
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analogous function to RecA (Warner, et al., 2010). However, the exact function 
of ImuA′ remains unknown.  
 
 
Figure 1-2 | Representation of the phylogenetic relationship between mycobacterial ImuA′ and related 
RecA and SulA proteins 
There is a clear evolutionary divergence of mycobacterial ImuA′ proteins, which are more homologous 
to RecA proteins. In contrast, ImuA proteins found in bacteria such as C. crescentus, share more 
homology with SulA proteins. 
 
2.2.2.3. Putative Protein Interactions within the Mycobacterial 
Mutasome and an Inferred Model 
In addition to the fundamental genetic and microbiological analyses performed 
by Warner and colleagues, the authors also performed yeast two-hybrid (Y2H) 
analyses to identify possible protein-protein interactions (PPIs) between the 
identified components of the mycobacterial mutasome (Figure 1-3). ImuB was 
observed to interact with the greatest number of other proteins when tested in 
the heterologous yeast host, whereas ImuA′ and DnaE2 each only interacted 
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DnaE2; and ImuB-ImuA′ interactions were detected, in addition to an 
interaction between ImuB and another ImuB monomer (Warner, et al., 2010). It 
makes intuitive sense that a DnaN-DnaE2 signal was not detected as the DnaE2 
polymerase is predicted to lack the necessary β sliding clamp binding domain 
(Warner, et al., 2010). Similarly, ImuB does contain a putative β sliding clamp 
binding domain, further supporting the PPIs detected by these analyses 
(Warner, et al., 2010). Importantly, neither ImuA′ nor DnaE2 is predicted to 
interact with the dnaN-encoded β clamp, making ImuB the only mutagenic 
cassette protein to interact with DnaN in Mtb (Warner, et al., 2010). This result 
highlights the essentiality of ImuB for mutasome function as it is possible the 
protein serves an indispensable central role in the function of the mutasome 
(Figure 1-3). In contrast, the ImuB-DnaE1 and ImuB-ImuB interactions inferred 
from the Y2H analysis are less intuitive and their roles in induced mutagenesis 
and DNA damage tolerance remain unclear. However, the use of a 
heterologous host, which provides a cytosolic environment distinct from that 
of mycobacteria, has the potential to detect false-positive PPIs (Vidal and 
Fields, 2014; Venkatesan, et al., 2009). Therefore, it is necessary to support these 
hypotheses with evidence obtained from mycobacteria. 
 
The Y2H interaction between ImuB and β was thought to be mediated by the 
previously mentioned DinB-specific (a Y family polymerase), conserved β 
clamp-binding motif of QLPLWG located within ImuB (Dalrymple, et al., 2003; 
Warner, et al., 2010). Indeed, a change in the amino acid residue at position 354 
of ImuB from glutamine to alanine prevented the ImuB interaction with β but 
not ImuA′ nor DnaE2, suggesting the specificity of this site to binding DnaN 
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Figure 1-3 | The putative PPIs between the components of the mycobacterial mutasome 
Y2H analyses by Warner, et al. (2010) identified potential interactions between ImuB and DnaN (the 
latter of which is known to form the β clamp dimer), as well as between ImuB and DnaE1, DnaE2, and 
ImuA′. Furthermore, ImuB was also detected to interact with itself. 
 
(Warner, et al., 2010). However, the corresponding change in Msm ImuB 
(Q352A) did not prevent a WT-level of UV-induced mutagenesis in vitro 
(Warner, et al., 2010). In addition, substitution of the hydrophobic or aromatic 
amino acid residues in the putative β clamp-binding site did not affect the 
function of ImuB (Warner, et al., 2010). However, alteration of the first five 
residues in the predicted Msm ImuB β-binding sequence (352QLPLWG357
352AAAAGG357) rendered ImuB nonfunctional, as assessed in damage tolerance 
assays and UV-induced mutagenesis assays (Warner, et al., 2010). The fact that 
imuBAAAAGG phenocopied ∆imuB suggested that ImuB may interact with the β 
clamp through this putative site. It is likely that this interaction is tightly linked 
to the function of ImuB in vivo and that SOS-dependent mutagenic DNA repair 
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More specifically, it can be hypothesized that the putative interaction between 
ImuB and the β clamp is essential for the successful recruitment of the entire 
mutasome to the site of DNA damage, making the expression of imuB 
paramount to the function of DnaE2, the mutagenic function of the mutasome, 
and for the ability of the bacterium to survive DNA damage (Warner, et al., 
2010).  
 
Furthermore, the C-terminal region of ImuB contains an extensive region 
containing structural disorder (Warner, et al., 2010). These intrinsically 
unstructured protein regions are often an indicator of PPI sites (Dyson and 
Wright, 2005), suggesting that DnaE1, DnaE2, and ImuA′ may interact with the 
C-terminus of ImuB during mutagenic DNA repair. Indeed, when stop codons 
were introduce prematurely in the 3′-end of Mtb imuB, immediately preceding 
the putative β clamp binding site mentioned above (yielding imuBCB), Y2H 
experiments failed to indicate interaction between ImuB and any previously 
identified protein partner (DnaE1, DnaE2, ImuA′, and β) excluding full-length 
ImuB, which indicated an interaction between the truncated ImuB and WT 
ImuB (Figure 1-4) (Warner, et al., 2010). Conversely, stop mutations 
immediately after the β-binding site that removed the final 168 amino acids 
only yielded an interaction between ImuBC168 and β (Warner, et al., 2010). This 
result further recapitulates the role of the 52QLPLWG357 domain in binding with 
β, which was present in ImuBC168 but not in the ImuBCB truncation. Together, 
these two results illustrate the association between the C-terminus of ImuB, 
which contains large segments of structural disorder, and the potential role it 
plays in binding other proteins involved in mutagenic DNA repair. 
Intriguingly, ImuBC168 was also identified to interact with full-length ImuB but 
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not with another ImuBC168 protein (Warner, et al., 2010), suggesting that the C-
terminus of ImuB interacts and binds the second ImuB outside the final 168 
residues (Figure 1-4). Corresponding to the Y2H results, when Msm ImuB was 
truncated in a similar fashion, both ImuBCB and ImuBC168 failed to restore the 
UV-induced mutagenic DNA repair and DNA damage tolerance phenotype of 
∆imuB in vitro (Warner, et al., 2010), once again highlighting the importance of 
PPIs with regard to mutasome function. Taken together, this identifies the 
essentiality of protein interactions between ImuB and the other components of 
the mutasome (and potentially proteins involved in replicative DNA synthesis) 
at the C-terminus of ImuB to the function of the mycobacterial mutasome. 
 
 
Figure 1-4 | Potential models of PPI between two ImuB components 
The potential for C-terminus-dependent polymerization or dimerization is illustrated. ImuB with the final 
168 amino acids truncated fail to contact the adjacent ImuB molecule; however, full-length ImuB is able 
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Given the genetic essentiality of imuA′ for mutasome function, it was predicted 
that ImuA′ might interact with other mutasome components to form a 
functional complex that effects repair of DNA in a mutagenic fashion. This 
inference was supported by Y2H data in which ImuA′ was shown to interact 
solely with ImuB (Warner, et al., 2010) (Figure 1-3). Notably, 48 amino acid N-
terminal truncations of ImuA′ maintained the ability to bind to ImuB, whereas 
a truncated ImuA′ protein lacking the C-terminal 44 amino acids (ImuA′C44) did 
not interact with ImuB during Y2H analysis (Warner, et al., 2010). Similarly, 
when the ∆imuA′ mutant strain of Msm containing the truncated imuA′C44 gene 
was exposed to UV irradiation or MMC in vitro, the phenotype did not differ 
from the imuA′-deficient background strain indicating that the C-terminus is 
involved with essential functions of ImuA′ and is involved with, or contributes 
to, an essential interaction with ImuB; however, the possibility that the N-
terminus of ImuA′ plays another role in the function of ImuA′ in vivo cannot be 
excluded (Warner, et al., 2010). Warner and colleagues also investigated the 
potential for ImuA′ to interact with itself, similar in fashion to RecA 
polymerization that occurs during the formation of a nucleoprotein filament; 
however, ImuA′ self-association was not detected by Y2H analysis, further 
differentiating it from the RecA homologue (Warner, et al., 2010). Furthermore, 
mycobacterial ImuA′ does not contain a RecA-like nucleotide-binding domain 
nor a conserved DNA binding loop, which suggests that its function is 
specialized and distinctly different from that of RecA (Warner, et al., 2010). 
 
From the work conducted by Warner and colleagues (2010), a model of the 
mutasome can be constructed to allow insight into the key PPIs required for 
inducible mutagenic DNA repair in mycobacteria (Figure 1-5). This model 
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illustrates the essential interaction between the ImuB pseudopolymerase, 
which is predicted to be incapable of performing DNA polymerization and is 
likely to rather act as a central hub protein, and the β sliding clamp through the 
DinB-like β-binding domain located in the C-terminus of ImuB. This putative 
interaction potentially grants other components of the mutasome access to the 
replication fork. DnaE2, which lacks a conserved β binding domain, potentially 
interacts with ImuB through an unknown motif located in the C-terminus of 
ImuB (Warner, et al., 2010). This putative PPI would allow DnaE2 access to the 
replication fork and allow the function of its conserved, homologous catalytic 
site to perform TLS. Furthermore, ImuA′ also interacts with ImuB through an 
interaction between the C-terminus of both proteins; however, the exact 
contribution and function of ImuA′ is unknown. According to this model, once 
the mutasome complex has formed, it would be able to perform TLS and 
 
 
Figure 1-5 | A model of the mycobacterial mutasome 
Here, a complete overview of the mycobacterial mutasome is presented. The β sliding clamp processivity 
factor (red) allows recruitment of the entire mutasome complex through an interaction with ImuB (green). 
Bound to ImuB is the additional accessory protein, ImuA′ (yellow) and the error-prone C family 
polymerase, DnaE2 (purple). 
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produce random mutations within the repaired DNA sequence. However, this 
model is far from complete and is based on a number of assumptions that 
warrant further investigation. Specifically, the PPIs identified by Y2H need 
further molecular validation within whole mycobacterial cells. Furthermore, 
the exact stoichiometry and order in which the mutasome components interact 
and how this is orchestrated requires elucidation. Similarly, the role, if any, of 
the putative ImuB-ImuB and DnaE1-ImuB interactions illustrates the 
complexity associated with the role of ImuB as a “hub” protein and raises the 
question of whether the mutasome interacts with other proteins of the 
replisome. Finally, the existence of other, unidentified mutasome components 
remains a possibility and requires further investigation in order to fully 
develop the mycobacterial mutasome model. 
 
3. Aim and Objectives of this Study 
The putative PPIs identified by Warner et al. (2010) provided the central axioms 
that guided the experimentation conducted in this work. Therefore, the 
interactions between ImuA′, ImuB, and DnaE2 during DNA damage-inducible 
mutagenic DNA repair were investigated. At the inception of this work, efforts 
to express soluble proteins of all three mutasome components for downstream 
X-ray crystallographic modelling were largely unsuccessful. As a consequence 
of this, the primary aim of this work was to utilize alternative approaches to 
infer and investigate the PPIs predicted in the mycobacterial mutasome model 
(Figure 1-5). Specifically, the following objectives provided a basis for the 
experimental methods used: 
(i) To visualize the location of ImuA′, ImuB, and DnaE2 proteins within 
live mycobacterial cells; 
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(ii) To identify expression and localization dynamics that might indicate 
specialized function of each mutasome component and contribute to 
the development of the mutasome model; 
(iii) To use the genetic evidence available (Boshoff, et al., 2003; Warner, et 
al., 2010), in combination with (i) above, to validate the essentiality 
of the putative PPIs within the mycobacterial mutasome; 
(iv) To develop the foundation of high-throughput screening method for 
mycobacterial mutasome PPI inhibitors. 
 
Upon initial investigation, fluorescence microscopy was selected as the most 
suitable method for achieving objectives (i), (ii), and (iv). Furthermore, 
preliminary results suggested the abandonment of the investigation of DnaE2, 
while correspondingly increasing the research focus of ImuB. Thereafter, the 
aim of this work was extended to include the following objectives: 
(v) To investigate the potential implications of inducible mutagenesis on 
cell physiology and fate; 
(vi) To investigate the effect of novel antitubercular agents on the 
mycobacterial mutasome with particular reference to expression and 
recruitment of ImuB. 
 
4. Importance and Significance of this Research 
The mycobacterial mutasome is of particular interest due to the associated 
decrease in virulence of Mtb strains lacking the mutasome in a mouse infection 
model of TB (Boshoff, et al., 2003), indicating the importance DNA damage 
repair plays during infection. This point alone underpins the value of studying 
the PPIs involved in the mycobacterial mutasome – which represents a 
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significant gap in the literature – with the potential of acquiring knowledge that 
will contribute to the discovery of chemical inhibitors targeted against the 
mutasome. Prior research has already demonstrated the consequences 
following the genetic disruption of the mutasome (Boshoff, et al., 2003; Warner, 
et al., 2010); however, further efforts are required to justify significant pursuit 
of chemical inhibitors, particularly by means of proof-of-concept 
experimentation within mycobacteria using non-genetic-based methods. The 
work conducted in this project represent the first steps undertaken in the 
development of an ‘anti-evolution’ chemotherapy for TB that specifically 
targets the mycobacterial mutasome. Such research might offer potentially 
significant downstream clinical and public health impacts with the ultimate 
goal of contributing toward the knowledge required to reduce the number of 
individuals that develop MDR- and XDR-TB in the future.  
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1. In Silico Techniques 
1.1. Genes 
The coding sequences for genes of interest were obtained from a selection of 
resources such as TubercuList (Lew, et al., 2011), SmegmaList (Kapopoulou, et al., 
2011), TuBerculosis DataBase (Reddy, et al., 2008), and the National Center for 
Biotechnology Information (NCBI) (NCBI RC, 2017) unless otherwise indicated. 
All sequences were obtained in, or converted to, standard ‘.FASTA’ format 
before each sequence was loaded into CLC Main Workbench (v7.6) (QIAGEN 
Aarhus A/S, Denmark). Genes consisting of both open reading frames (ORFs) 
and regulatory sequences were annotated with available information obtained 
from the literature on imuA’ (MSMEG_1620), imuB (MSMEG_1622), and dnaE2 
(MSMEG_1633) (as described in Section 8.1). 
 
1.2. Construct Design 
Parental plasmid maps for pTTP1B::1633, pMCAINT::1619/20, and 
pAINT::1619compPCR (pTTP1B::dnaE2, pMCAINT::imuB, and pAINT::imuA’, 
respectively), were obtained directly from the author, Warner et al. (2010). The 
plasmids were annotated with available sequence data from the literature. 
Restriction endonuclease (RE) restriction sites, that when used to digest the 
plasmid, would grant access to the 5′-end of each ORF (cleavage sites located 
above and below the first codon of each coding sequence), were identified. The 
intervening sequences between the identified RE sites were modified in silico to 
include the encoding region of the fluorescent reporter (either enhanced green 
fluorescent protein, egfp, or meos4a) directly upstream and in-frame of the 
native start codon of the gene of interest. In silico cloning experiments were 
subsequently performed in CLC Main Workbench (v7.6) (QIAGEN Aarhus A/S, 
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Denmark) to ensure feasibility of the cloning method using the identified RE 
sites. The resultant full-length gene sequences were subsequently translated  
in all six frames using the ExPASy online translation tool 
(http://web.expasy.org/translate/). The corresponding translated sequence 
of the protein fusions were identified. The full-length protein sequences were 
then validated by performing a sequence alignment search using NCBI Basic 
Local Alignment Search Tool (BLAST) (Altshcul, et al., 1990) to ensure that the 
encoded protein sequences had been maintained without anomalous changes. 
Confirmed sequences were subsequently synthesized and cloned into pUC57 
plasmid backgrounds by GeneWiz (China). 
 
1.3. Oligonucleotide Design 
1.3.1. Screening Primers 
Primers were designed in silico using either NCBI Primer-Blast (Ye, et al., 2012) 
or manually by identifying primer regions within target regions. Manual 
primers within the sequence of interest that were 16 to 22 bp in length were 
identified. Primer sequences with a guanine-cytosine (GC) content of between 
45 and 60 %, and with a G or C at the 3’ position, were preferentially selected. 
Furthermore, primer sequences that contained potentially self-complementary 
sequences capable of forming hairpin loops were excluded. Primer sequences 
were sent to the Department of Chemistry (University of Cape Town, ZA) where 
they were synthesised. 
 
1.3.2. Sequencing Primers 
Sequencing primers were designed manually for both forward and reverse 
(complementary strand) reactions (Figure 2-1). Target sequences that extended 
at least 100 bp beyond the gene of interest in both directions were identified. 
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Thereafter, primer sequences that would allow for the entire target sequence to 
be sequenced were selected. Primer sequences were all between 18 to 22 bp in 
length, had a guanine:cytosine (GC) content of 55 to 62 %, and contained a 3’ 
guanine (G) or cytosine (C) where possible. The primer sequences were selected 
if approximately 400 bp separated adjacent primers. In addition, adjacent 
forward and reverse primers were selected to be approximately 200 bp apart. 
Primer sequences were sent to the Department of Chemistry (University of Cape 
Town, ZA) where they were synthesised. 
 
 
Figure 2-1 | Schematic diagram representing the distribution of designed sequencing primers 
Forward primers (right arrow) were separated by approximately 400 bp and covered the entire target 
sequence; reverse primers (left arrows) were designed in a similar manner but complementary to the 
opposing strand of DNA and such that adjacent forward and reverse primers were ±200 bp apart. The 
first primer in each direction was designed to start 100 bp before the gene of interest in order to increase 
sequencing data accuracy over the gene of interest. Not drawn to scale. 
 
1.4. Sequence Analysis 
Sequencing reads obtained from the Central Analytical Facility (Stellenbosch 
University, ZA) were aligned to the respective parental plasmid. Thereafter, 
the sequence data were curated in CLC Main Workbench (v7.6) (QIAGEN 
Aarhus A/S, Denmark). Base calling was confirmed by visual assessment and 
regions of poor read quality were excluded (Figure 2-2). Sequence conflicts 






Chapter II 91 
 
Figure 2-2 | Example of the manual curation of sequencing results 
CLC Main Workbench was used to analyze sequence data and exclude poor-quality reads often found 
at the beginning and end of individual sequencing runs. The window illustrates a screenshot of the 
program window. In this example, poor-quality reads were excluded at the beginning and end of 
sequencing runs, which resulted in a read coverage of 3.8 times. 
 
2. Bacterial Growth Conditions 
A number of bacterial strains were utilized in this work (Table 2-1). Both 
Escherichia coli (E. coli) and Mycobacterium smegmatis (Msm) strains were grown 
in controlled media containing selection antibiotics if required. 
 
Table 2-1 | List of strains used in this work 
Strain Description Source 
E. coli (plasmid)   
pMCAINT E. coli–mycobacterium integrating shuttle 




pAINT::imuAʹ Msm imuAʹ complementation vector: pAINT 
carrying full-length Msm imuAʹ 





Episomal cloning vector pUC57 containing 






pMCAINT plasmid carrying the 
PSOS(imuA’)-egfp construct at the HindIII 
RE site within the MCS; KmR 
This study 
Chapter II 92 
pUC57::vfp-imuAʹ’ Episomal cloning vector pUC57 containing 
5’- region of designed PSOS-vfp-FLAG-
imuA’ construct; KmR 
GeneWiz 
(China) 
pAINT::vfp-imuA’ Resulting BstBI and SexAI ligation product 
of pAINT::imuAʹ and pUC57::vfp-imuAʹ’ 
carrying full-length vfp-imuA’ 




pMCAINT::imuB Msm imuAʹ-imuB complementation vector – 
pMC1r carrying full-length Msm imuA’-





Episomal cloning vector pUC57 containing 
5’- region of designed PSOS-egfp-FLAG-





Resulting BlpI and ClaI ligation product of 
pAINT::imuB and pUC57::PSOS(imuA’)-




pTTP1B::dnaE2 Msm dnaE2 complementation vector: 
PTTP1B (Pham, et al., 2007) carrying full-
length Msm dnaE2 (MSMEG_1633); GmR 
Boshoff, et 
al., 2003. 
pUC57::egfp-dnaE2’ Episomal cloning vector pUC57 containing 




pTTP1B::egfp-dnaE2 Resulting KpnI ligation product of 
pTTP1B::dnaE2 and pUC57::egfp-dnaE2’ 
carrying only full-length egfp-dnaE2 




Episomal cloning vector pUC57 containing 
5’- region of designed PSOS-mEos4a-





Resulting BlpI and ClaI ligation product of 
pAINT::imuB and pUC57::PSOS(imuA’)-




pMCAINT::imuBAAAAG pMCAINT::imuB containing mutant Msm 










recombinant, mutant gene; KmR  
This study 
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Msm   
mc2155; wild-type (WT) High-frequency transformation mutant of 
Msm mc26; ATCC 706 
Snapper, et 
al., 1990. 
ΔimuAʹ imuAʹ truncation-deletion mutant of mc2155 Warner, et 
al., 2010. 
ΔimuB imuB truncation-deletion mutant of mc2155 Warner, et 
al., 2010. 
ΔdnaE2 dnaE2 truncation-deletion mutant of mc2155 Boshoff, et 
al., 2003. 
dnaE2AIA mc2155 mutant containing mutant 441AIA443 
substitution in dnaE2 
Warner, et 
al., 2010. 
WT::PSOS(imuA’)-egfp mc2155 carrying pMCAINT::PSOS(imuA’)-
egfp integrated at the genomic attB site; 
imuA’ transcriptional reporter 
This study 
ΔimuAʹ::vfp-imuA’ ΔimuAʹ carrying pAINT::vfp-imuA’ at the 




ΔdnaE2::egfp-dnaE2 ΔdnaE2 carrying pTTP1B::egfp-dnaE2 at the 































egfp-imuBAAAAG at the attB integration 
site; KmR 
This study 
dnaN-mCherry mc2155 with wildtype Msm dnaN 
(MSMEG_0001) replaced by recombinant 
mCherry-dnaN by homologous 
recombination of plasmid pIS225 





pAINT::PSOS(imuA’)-egfp-imuB at the 
attB integration site; KmR 
This study 
KmR=Carrying a kanamycin resistance gene; AmR=Carrying an ampicillin resistance gene; 
GmR=Carrying a gentamycin resistance gene. 
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2.1. Liquid Cultures 
E. coli liquid cultures were grown in Luria-Bertani (LB) broth (with the addition 
of appropriate antibiotics where suitable) in Erlenmeyer flasks or culture tubes 
dependent on the volume of culture required. Growth conditions consisted of 
incubation at 37 °C with mixing at approximately 100 rpm. Growth was 
assessed by measuring the optical density of 1 ml of culture by 
spectrophotometry using 600 nm wavelength light (OD600). 
 
Msm strains were grown in Middlebrook 7H9 broth (BD Science, USA) liquid 
media supplemented with 10 % (v/v) Middlebrook oxidase-albumin-dextrose-
catalase (OADC) (BD Science, USA) and 0.05 % (v/v) Tween-80 (Sigma, USA). 
Antibiotic selection by means of kanamycin (KAN) or gentamycin (GENT) 
supplementation was used where appropriate for strains containing the 
corresponding resistance genes. Cultures were incubated in Erlenmeyer flasks 
at 37 °C with mixing at 100 rpm. Growth was assessed by OD600 measurements. 
 
2.2. Bacterial Growth on Solid Media 
When isolated colonies were required, E. coli cultures of freezer stocks were 
streaked onto LB agar solid media in Petri dishes and incubated at 37 °C. Where 
antibiotic selection was required, molten media was supplemented with the 
appropriate amount of antibiotic. 
 
Msm colonies were grown on Middlebrook 7H10 agar (BD Science, USA) 
supplemented with 10 % (v/v) Middlebrook OADC (BD Science, USA) in Petri 
dishes and incubated at 37 °C to allow bacterial growth and replication. Where 
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antibiotic selection was required, molten media was supplemented with the 
appropriate amount of antibiotic. 
 
2.3. Antibiotic Selection 
Different concentrations of various antibiotics were employed to select for the 
correct bacterial strain as per Table 2-2. 
 
Table 2-2 | Antibiotics and concentrations used in this work 
 E. coli (μg/ml) Msm (μg/ml) 
Solid media   
Kanamycin 50 20 
Gentamycin 20 2.5 
Liquid media   
Kanamycin 50 20 
Gentamycin 20 5.0 
 
3. Molecular Techniques 
3.1. DNA Extractions 
3.1.1. Large-scale Plasmid Extraction 
A positively screened E. coli culture was used to inoculate a 40 ml culture which 
was subsequently cultured overnight at 37 °C. The culture was added to a 50 ml 
centrifuge tube and centrifuged at 3,901 relative centrifugal force (rcf) for 
10 min at 4 °C. The supernatant was poured off and the remaining cell pellet 
was resuspended in 1.0 ml of Solution I by repipetting. Thereafter, 2.0 ml of 
Solution II was added to the solution and inverted to mix. The solution was 
incubated at room temperature (25 °C) for 5 min, after which 1.5 ml of Solution 
III was added. The solution was inverted to mix and kept on ice for 5 min. The 
lysed cell solution was centrifuged at 3,901 rcf for 10 min at 4 °C. Subsequently, 
700 #l of the resulting supernatant was added to each of five 1.5 ml microfuge 
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tubes and 10 #l of 10 mg/ml RNAse A was added. The solutions were 
incubated at 42 °C for 30 min to remove contaminant RNA. Thereafter, 700 #l 
of isopropanol was added to each sample and the solutions were incubated at 
room temperature (25 °C) for 10 min with periodic inversion for mixing. 
Afterwards, the solutions were centrifuged at 16,100 rcf for 10 min. The 
resulting supernatant was poured off and 200 #l of 70 % ethanol was added to 
each DNA pellet. The solutions were centrifuged for a further 10 min at 
16,100 rcf and the supernatant was removed. The microfuge tube was gently 
dabbed on paper towel to remove residual ethanol. Subsequently, 100 #l of 
nuclease-free dH2O was added to each microfuge tube sample and the DNA 
was completely resuspended by heating to 42°C by using a heating block and 
flicking periodically to mix. All five samples were pooled together in a single 
microfuge tube and 700 #l of 24:25 phenol-chloroform was added to the 
sample. The solution was mixed extensively by vortex until the solution 
became milky-white in colour. The sample was centrifuged at 16,100 rcf for 10 
min. The resulting aqueous phase was transferred to a new microfuge tube 
where 50 #l of 3 M sodium acetate was added to the solution. DNA 
precipitation was performed by adding 1.0 ml ice-cold absolute ethanol to the 
sample, whereby it was subsequently kept at -20 °C overnight. The sample was 
then centrifuged at 16,100 rcf for 10 min and resulting supernatant was poured 
off to remove contaminating proteins, polysaccharides, and lipids. Thereafter, 
200 #l of 70 % ethanol was added and the sample was centrifuged at 16,100 rcf 
for 10 min. The supernatant was poured off and the microfuge tube was dabbed 
on paper towel and vacuum centrifuged at 42 °C for 10 min to remove residual 
ethanol. The DNA pellet was resuspended in 50–100 #l of nuclease-free dH2O 
by heating to 42 °C and mixing. The DNA concentration was measured using 
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a spectrophotometer. Working stocks were prepared by dilution with dH2O to 
a final concentration of 1,000 ng/ml. The final DNA plasmid solutions were 
stored at 4 °C for short time periods or -20 °C for extended periods of time. 
 
3.1.2. Small-scale Plasmid Extraction 
A single, isolated E. coli colony was picked from solid media using a sterile 
micropipette tip and used to inoculate 4 ml of LB liquid media containing 
appropriate concentrations of antibiotics. The culture was subsequently 
incubated at 37 °C overnight. After incubation, 1 ml of culture containing the 
desired plasmid was spun down at 16,100 rcf for 60 s in a centrifuge. The 
supernatant is poured off and the remaining cell pellet was resuspended in 
100 #l of Solution I and 200 #l of Solution II was added before the solution was 
mixed by inversion. Thereafter, 150 #l of Solution III was added and the 
solution was mixed by shaking. The solution was centrifuged at 16,100 rcf for 
5 min. The clear supernatant was transferred to a new microfuge tube. 
Contaminant RNA was degraded by adding 1 #l of 10 mg/ml RNAse A to the 
solution before incubation at 37 °C for 10 min. Then 350 #l of isopropanol was 
added and the solution was kept at room temperature (25 °C) for 10 min with 
periodic inversions to mix. The solution was centrifuged at 16,100 rcf for 10 min 
and the supernatant was discarded appropriately. 200 #l of 70 % ethanol was 
added to the pellet within the microfuge tube and was subsequently spun 
down for a further 10 min at 16,100 rcf. Residual ethanol was removed by 
dabbing gently on paper towel and by evaporation in a vacuum centrifuge for 
10 min. Thereafter, purified DNA pellet was completely resuspended in 20 #l 
of nuclease-free dH2O by mixing and heating to 42 °C. DNA concentration was 
determined by measurement with a spectrophotometer. The final DNA 
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plasmid solution was stored at 4 °C for short time periods or -20 °C for extended 
periods of time.  
 
3.1.3. Crude Msm DNA Extraction by Colony Boil 
Isolated Msm colonies were picked and resuspended in 20 #l of sterile dH2O, 
from which 10 #l was used to inoculate 7H9-OADC liquid culture or solid 
7H10-OADC media and incubated at 37 °C overnight for continuation of the 
culture. The remaining aliquot of cell suspension was added to 10 #l of 
chloroform (Sigma, USA) in a microfuge tube and heated to 90 °C for 20 min to 
denature the cells. After denaturation, the cells were centrifuged at 13,400 rcf 
for 1 min and 5 #l of supernatant was used as template for a polymerase chain 
reaction (PCR). 
 
3.2. Polymerase Chain Reactions  
3.2.1. List of Oligonucleotides  
PCR primers were used to amplify specific sequences of DNA. 
Oligonucleotides were used for this function (Table 2-3). 
 
Table 2-3 | Oligonucleotides used in this study 
Oligonucleotide Sequence (5ʹ-to-3ʹ) 
Screening of WT::PSOS(imuA’)-egfp 
GFP_Compl_Forward GTGAACGGCCACAAGTTCTC 
GFP_Compl_Reverse GGGTCGACAGGTAGTGGTTG 
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3.2.2. PCR Amplification 
PCR for primer pair testing and screening were conducted as follows in Table 
2-4 (reaction mixture) and Table 2-5 (cycle reaction conditions): 
 
Table 2-4 | Reaction Mixture 
Reagent Volume 
Template DNA 2.0 μl*# 
10× FastStart™ taq polymerase buffer 2.0 μl 
FastStart™ taq polymerase (20 U/μl) 0.5 μl 
dNTPs (2 mM) 1.0 μl 
Forward primer (10 μM) 2.0 μl 
Reverse primer (10 μM) 2.0 μl 
dH2O 10.5 μl 
Total for master mix 18.0 μl 
TOTAL per reaction 20.0 μl 
* 200 to 1,000 ng/μl of DNA sample. 
# 5.0 μl of colony boil supernatant is used for Msm screening; in this case the amount of dH2O is 
decreased to 7.5 μl and the master mix volume is similarly decreased to 15.0 μl. 
 
Table 2-5 | PCR Cycle Conditions 
Step Temperature Time Cycles 
1. Initial denaturation 95.0 °C 5 min 1 
2.1. Denaturation  95.0 °C 30 s 35 to 40 
2.2. Primer annealing TA OPT 30 s 35 to 40 
2.3. Elongation 72.0 °C 30 s per 500 bp 35 to 40 
3. Final elongation 72.0 °C 5 min 1 
4. Hold 12.0 °C Indefinitely 1 
TA OPT represents the optimal annealing temperature as determined by temperature-gradient PCR. 
 
3.2.3. PCR Temperature Gradient Optimization 
PCR annealing temperature optimizations were conducted by setting up 
replicate PCR reactions as per Section 3.2.2. The reactions were performed as 
prior with the exception of the annealing temperature. For this, gradient 
thermocyclers were used to produce a gradient of differing temperatures at the 
Chapter II 100 
primer-annealing step (TA) for the replicate reaction mixtures. The resulting 
amplicons were then separated through an agarose gel and visualized using a 
Wealtec KetaTM under ultraviolet (UV) light illumination and Ketagalan M 
software (Wealtech Company, USA) to determine the annealing temperature 
that resulted in the greatest yield with minimal non-specific amplification 
(TAOPT) specific to a particular primer pair. The corresponding annealing 
temperature was used in subsequent reactions for each primer pair. 
 
3.3. DNA Digestion by RE Enzymes 
Plasmid DNA was digested with either New England Biolabs or Thermo Fisher 
Scientific RE enzymes as per the manufacturer’s instructions. Briefly, 1,000 to 
4,000 ng of plasmid sample was digested with 0.2 to 2 U of RE in the presence 
of 1× reaction buffer, and BSA if required, at a final volume of either 20 or 50 
#l at the optimal temperature for a minimum of the recommended digestion 
time. After digestion, RE enzymes were inactivated where possible as per the 
instructions of the manufacturers. 
 
3.3.1. Plasmid Screening by RE Digestion 
Small-scale plasmid DNA extraction products were screened by RE digestion 
using a minimum of four separate REs in order to validate the correct 
restriction map of the putative plasmid. All RE reactions were performed as 
per the instructions of the manufacturer. 
 
3.4. Gel Electrophoresis 
Gel electrophoresis was used to separate DNA fragments and amplicons based 
on size. To this end, agarose gels were made to a concentration between 0.8 and 
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4.0 % dependent on the anticipated size of the fragments being separated. Small 
fragments of 50 to 200 bp were separated using 4 % agarose gels, whereas DNA 
fragments approximately 16,000 to 800 bp were separated with 1 % agarose 
gels. Gels were made by dissolving agarose in heated 1× TAE buffer before 
ethidium bromide (EtBr) (Sigma, USA) was added to a final concentration of 
0.25 #g/ml before pouring into molds to allow the gels to set. Thereafter, gels 
were placed in electrophoresis tanks (BioRad, USA) and submerged in 1× TAE 
buffer. DNA samples with volumes of 20 or 50 #l were mixed with 5 or 10 #l 
of loading dye, respectively, before being loaded into wells. Molecular Weight 
Markers III, IV, V, or VI (Roche, Switzerland) were loaded in individual lanes 
where appropriate and used as molecular standards to determine the size of 
each DNA fragment within the gel. An electric current of 80 to 100 V and 200 
ampere was applied across the gel using a PowerPacTM Basic 75W (BioRad, USA) 
until DNA fragments had separated sufficiently. Subsequent DNA migration 
was visualized using Wealtec KetaTM under UV light illumination and Ketagalan 
M software (Wealtech Company, USA) or inspected manually with a blue light 
transilluminator. 
 
3.5. Cloning of Constructs 
Plasmid DNA was digested with appropriate RE enzymes to yield fragments 
with compatible ends that were to be ligated to yield the desired product. After 
RE digestion, DNA fragments were separated using gel electrophoresis and 
unambiguously separated fragments with the correct size were cut out the gel 
using a scalpel while viewing the gel using a blue light transilluminator. DNA 
fragments were extracted using the NucleoSpin® Gel and PCR Clean-up kit 
(Macherey-Nagel GmbH & Co. KG, Germany).  
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3.5.1. Gel Extraction 
DNA was excised from agarose gels as per the instructions of the manufacturer. 
Specifically, each excised block of agarose gel was dissolved in a 1.5 ml 
microfuge tube by adding 2 #l of Buffer NT1 for each milligram of gel and 
heated to 50 °C in a shaking (400 rpm) heating block until the gel had 
completely dissolved. Solutions containing the same DNA digest were pooled 
and placed into a silica membrane extraction column. The column was 
centrifuged at 11,000 rcf for 30 s. The flow-through was discarded and the 
sample was centrifuged for a second time at 11,000 rcf for 30 s. The flow-
through was disposed of appropriately, and 700 #l of Buffer NT3 (with ethanol) 
was added to the column. The column and collection tube was centrifuged at 
11,000 rcf for 30 s to wash the DNA. The flow-through was discarded and the 
sample was centrifuged for a second time at 11,000 rcf for 90 s. The column was 
placed into a new 1.5 ml microfuge tube and heated to 65 °C to evaporate 
residual ethanol. Thereafter, 20 #l of nuclease-free dH2O heated to 65 °C was 
added to the filter of the column. The sample was left at room temperature 
(25 °C) for 4 min to allow the DNA to elute. The column was subsequently 
centrifuged at 11,000 rcf for 2 min to collect the DNA fragment solution in the 
microfuge tube. To maximize DNA yield, the DNA solution was used to elute 
the DNA a second time before elution was completed with a final step using 20 
#l of fresh nuclease-free dH2O.  
 
3.5.2. Vector Dephosphorylation 
To dephosphorylate linear DNA, 5 U of Antarctic Phosphatase (New England 
Biolabs, USA) was used to digest 20 #l of purified, linear vector DNA in the 
presence of 1× Antarctic Phosphatase Buffer (New England Biolabs, USA). The 
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reaction solution was incubated for 30 min at 37 °C to remove the 5′ phosphate 
groups from vector DNA.  
 
3.5.3. Plasmid Clean-up 
Inactivated phosphatase reactions were cleaned up using the NucleoSpin® Gel 
and PCR Clean-up (Macherey-Nagel GmbH & Co. KG, Germany). Namely, 200 
#l of Buffer NT1 was added to each reaction mixture and heated to 50 °C in a 
shaking (400 rpm) heating block for 5 min. The solutions were placed into a 
silica membrane extraction column, which was subsequently centrifuged at 
11,000 rcf for 30 s. The flow-through was discarded and the sample was 
centrifuged for a second time at 11,000 rcf for 30 s. The flow-through was 
disposed of appropriately, and 700 #l of Buffer NT3 (with ethanol) was added 
to the column. The column and collection tube was centrifuged at 11,000 rcf for 
30 s to wash the DNA. The flow-through was discarded and the sample was 
centrifuged for a second time at 11,000 rcf for 90 s. The column was placed into 
a new 1.5 ml microfuge tube and heated to 65 °C to evaporate residual ethanol. 
After evaporation, 20 #l of nuclease-free dH2O heated to 65°C was added to the 
filter of the column. The sample was left at room temperature (25 °C) for 4 min 
to allow the DNA to elute. The column was subsequently centrifuged at 11,000 
rcf for 2 min to collect the DNA fragment solution in the microfuge tube. To 
maximize DNA yield, the DNA solution was used to elute the DNA a second 
time before elution was completed with a final step using 20 #l of fresh 
nuclease-free dH2O.  
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3.5.4. Ligation 
Ligations to combine inserts into linearized vectors were performed as per the 
instructions of the manufacturer. Extracted vector and insert fragments with 
compatible ends were mixed in 1:1; 1:3; and 1:5 molar ratios in addition to a no 
insert control. Thereafter, 10 U of T4 DNA ligase (Roche, Switzerland) and T4 
DNA ligase buffer (Roche, Switzerland) was added to the solution to a final 
concentration of 1× and a final volume of 20 #l. Ligation reactions were carried 
out at 4 °C overnight for both ‘sticky-end’ and ‘blunt-end’ ligations. Prior to 
bacterial transformation, the ligase was inactivated by heating the sample to 
65 °C for 10 min. 
 
3.6. DNA Sequencing  
High-fidelity PCR reactions were conducted to amplify the region of interest 
from either genomic DNA or plasmid DNA using ‘sequence space’ primers to 
amplify the sequence of interest. The PCR products were separated using gel 
electrophoresis to validate the amplification of the target region based on the 
size of the fragment. Subsequently, the PCR product was purified and cleaned 
up as described in Section 3.5.1. Purified amplicons were sequenced by the 
Sanger sequencing method by Central Analytical Facility (Stellenbosch 
University, ZA). 
 
3.7. Nucleic Acid Concentration Determination 
DNA samples were quantified by measuring the concentration of 1.0 #l of 
sample using a NanoDrop™ 2000c spectrophotometer (Thermo Fisher Scientific, 
USA). 
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4. Microbiology Techniques 
4.1. Glycerol Stocks 
All liquid bacterial cultures were stored long term in 33 % (v/v) glycerol by 
combining 500 #l of cell culture with 500 #l of 66 % (v/v) glycerol in dH2O. 
Thereafter, the glycerol stocks were stored at -80 °C indefinitely. 
 
4.2. E. coli 
4.2.1. Rubidium Chloride-competent Cells 
DH5α or dam- strains of E. coli with an OD600 of 0.48 were chilled on ice for 15 
min and pelleted in a 50 ml centrifuge tube by centrifugation at 3,901 rcf for 5 
min at 4 °C. The supernatant was discarded and the pellet was resuspened in 
40 % volume TFB I. The cell suspension was kept on ice for 15 min before the 
cells were pelleted once more by centrifugation at 3,000 rcf for 5 min. The 
supernatant was discarded and the pellet was resuspended in 4 % volume of 
TFB II. The cell suspension was kept on ice for 15 min before immediate use or 
stored at -80 °C indefinitely, whereby the cells were thawed prior to 
transformation experiments.  
 
4.2.2. Heat-shock Transformation 
100 #l of DH5α or dam- rubidium chloride-competent E. coli cell culture was 
added to a 1.5 ml microfuge tube containing 1.0 #l of plasmid suspension 
containing 100 ng of plasmid DNA or 40 #l of purified ligation product. The 
cell solution was kept on ice for 30 min. Thereafter, the cell solution was heat 
shocked at 42 °C for 90 s; after which it was cooled by placing onto ice for 60 s. 
After cooling, 750#l of two yeast tryptone (2YT) broth was immediately added 
and the culture was incubated at 37 °C for 1 h to allow transformed cells to 
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express resistance-associated proteins. Thereafter, cells were pelleted at 16,100 
rcf for 1 min. The resulting cell pellet was resuspended in 100 #l of supernatant 
and was plated on appropriate selective solid media. Viable controls 
(untransformed competent cells) were plated onto standard LB agar plates to 
ensure competent cell viability. Non-plasmid, negative controls were also 
carried out by plating untransformed cells onto selective LB agar plates to 
ensure the absence of contamination and the efficacy of antibiotic selection. The 




Freezer stocks of Msm were used to inoculate 100 ml cultures of 7H9-OADC 
which were grown at 37 °C until an OD600 of 0.6 to 0.8. After growth of liquid 
cultures, a total of 90 ml of culture was centrifuged at 3,901 rcf for 10 min at 
4 °C in two separate 50 ml centrifuge tubes. The resulting supernatant was 
poured off and each cell pellet was resuspended in 40 ml of 10 % (v/v) glycerol 
while keeping the cells on ice. The solutions were centrifuged again at 3,901 rcf 
for 10 min at 4 °C. The resulting supernatant was poured off and each cell pellet 
was again resuspended in 30 ml of 10 % (v/v) glycerol while keeping the cells 
on ice. The cell solution was again centrifuged at 3,901 rcf for 10 min at 4 °C. 
Again, the resulting supernatant was poured off and the cell pellet was 
resuspended in 20 ml of 10 % (v/v) glycerol while keeping the cells on ice. The 
two cell-glycerol solutions were pooled into a single 50 ml centrifuge tube. 
Thereafter, the cells were centrifuged again at 3,901 rcf for 10 min at 4 °C. The 
resultant cell pellet was resuspended in 4 ml of 10 % (v/v) glycerol for the final 
time. 
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Electroporation was then carried out with a BioRad GenePulser Xcell™ 
electroporation unit (BioRad, USA) utilizing the exponential protocol using the 
following parameters: 2,500 V of electric potential difference, 25 #F of 
capacitance, 1,000 & of resistance and a cuvette size of 2 mm. To this end, 10 #l 
of solution containing 0 to 4,000 ng of plasmid was placed in an electroporation 
cuvette with a chamber width of 2 mm (BioRad, USA) and kept on ice. 
Subsequently, 400 #l of cell-glycerol suspension was added to the cuvette, 
which was wiped to remove liquid on the outside of the cuvette. The cuvette 
was placed in the electroporation unit and pulsed with electricity. Immediately 
after electroporation, the cell suspension was rescued with 750 #l of 7H9-
OADC broth and subsequently incubated at 37 °C for 4 h. Thereafter, the cell 
culture was centrifuged at 16,100 rcf for 1 min and the cell pellet was 
resuspended in 100 #l of supernatant prior to streaking onto antibiotic-
selecting 7H10 solid media. Antibiotic-resistant transformants were allowed to 
grow into colonies by incubating the cultures at 37 °C for 3 to 5 days. 
 
4.3.2. Mutagenesis Assays 
Mutagenesis assays were performed as previously described (Boshoff, et al., 
2003; Warner, et al., 2010). Briefly, liquid cultures of Msm were grown to an 
OD600 of 0.6 to 0.8 in 60 ml of 7H9-OADC after inoculation with a glycerol stock. 
Cell density was increased ten-fold by centrifugation of 50 ml of culture at 3,901 
rcf for 10 min before resuspending the resultant pellet in 5 ml of fresh 7H9-
OADC. The concentrated cell solution was pipetted into a Petri dish and spread 
across the entire surface of the dish before being exposed to 25 mJ/cm2 of UV 
irradiation (254 nm) using a StrataGene UV Stratalinker 1800 (StrataGene, USA). 
After irradiation, the concentrated cells were diluted back to 1× by adding 45 
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ml of fresh 7H9-OADC media to the cells in a culture flask. The cells were then 
allowed to recover at 37 °C in a shaking incubator for 4 h. In addition, 5 ml of 
unexposed culture was also cultured this way. In order to quantify the extent 
of DNA damage induced, six repeats of 250 #l of UV-exposed cells were plated 
onto 200 mg/ml rifampicin (RIF)-containing 7H10-OADC solid media. In 
parallel, unexposed cells were diluted by serial, ten-fold dilution seven times 
to yield cell dilutions factors of 100 to 10-7. Thereafter, 100 #l the final three 
dilutions were plated onto standard 7H10-OADC in duplicate in order to 
determine the number of cells in each culture, yielding 10-6, 10-7, and 10-8 
dilutions. The cell enumeration (RIF-deficient) plates were incubated 37 °C for 
2 days before colony counting was performed. The RIF-containing culture 
plates were incubated at 37 °C for 5 to 7 days to allow RIF-resistant mutants to 
grow. After incubation and successful growth, the number of colonies formed 
was counted for each strain and using the dilution series, the total number of 
cells in 1 ml of culture prior to plating out was determined. From this, the 
mutation frequency can be determined by dividing the number of RIF-resistant 
colonies by the number of cells present in the liquid culture prior to UV 
irradiation. 
 
4.3.3. DNA Damage Tolerance Assays 
In parallel to Section 4.3.2 above, following ten-fold serial dilution of 
unexposed cells, 5.0 #l of each of the eight dilutions were spotted onto 
standard, 0.04, and 0.02 mg/ml mitomycin C (MMC)-containing 7H10-OADC 
solid media. These plates were incubated at 37 °C for 5 to 7 days to allow 
colonies to develop. 
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4.3.4. Induction Assays 
For all experiments that required exposure of Msm to a genotoxin, bacterial 
cells were grown in 5 ml 7H9-OADC liquid media supplemented with the 
appropriate genotoxic agent. MMC (Sigma, USA) was dissolved in dH2O to a 
concentration of 0.5 mg/ml. Novobiocin (NVB) (Sigma, USA) was dissolved in 
dH2O to a working concentration of 10 mg/ml. Moxifloxacin (MOX) (Sigma, 
USA) was dissolved in dH2O to a working concentration of 3.2 mg/ml. 4-
Nitroquinoline 1-oxide (NQO) (Sigma, USA) was dissolved in acetone to a 
working concentration of 3.8 mg/ml. Methyl methanesulfonate (MMS) (Sigma, 
USA) was used neat due to the rapid loss of activity in aqueous solution. 
Ciprofloxacin (CIP) (Sigma, USA) was dissolved in 1 M HCl to a working 
concentration of 1.71 mg/ml. EtBr (Sigma, USA) was diluted in dH2O 100-fold. 
Griselimycin (GRS) (Müller Lab, Germany) was dissolved in dimethyl 
sulfoxide (DMSO) (Sigma, USA) to a working concentration of 20 mg/ml prior 
to addition to the culture media. Specifically, a single culture of Msm was 
grown at 37 °C to an OD600 of between 0.2 and 0.4, representing mid log-phase 
growth. Thereafter, the culture was split into numerous 5 ml cultures and the 
genotoxic compound was added to experimental cultures to a final 
concentration relative to the minimum inhibitory concentration (MIC). The 
exposed cultures were further incubated at 37 °C on orbital shakers for varying 
periods of time before further sampling was performed. 
 
4.3.5. Combination Exposure Experiments 
In order to test the effect of GRS- or MOX-mediated DnaN inhibition on EGFP-
ImuB recruitment, a liquid culture of dnaN-mCherry::PSOS(imuA’)-egfp-imuB 
with an optical density of 0.38 was split into nine separate 10 ml cultures as per 
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Figure 2-3. GRS or MOX and MMC were added in combination to each culture 
in various concentrations to produce a combination array of sub- and supra-
inhibitory concentrations of each genotoxin. Thereafter, cultures were 




Figure 2-3 | A graphical representation of a combination exposure experiment set-up  
Culture flasks with equal volumes of cell culture were exposed to an array of either MMC and GRS (shown 
here) or MMC and MOX. The set-up was designed such that there is a combination of 0×, 0.2×, and 5× 
of each of the two test compounds in every combination. 
 
4.3.6. GRS Kill Kinetics 
A liquid culture of mc2155 was grown from a single colony to an OD600 of 0.65 
in 7H9-OADC. Subsequently, 1 ml of culture was diluted 100× by adding it to 
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separate 30 ml cultures: one culture flask contained no GRS; one culture flask 
had GRS added to a final concentration of 4.5 #g/ml; and GRS was added to 
the final culture flask to a final concentration of 22.5 #g/ml. Each culture was 
incubated in a shaking incubator at 37 °C. Thereafter, at 0, 3, 6, 9, 12, 24, 36, and 
48 h, each culture was sampled for cell enumeration. Specifically, 1 ml of 
culture was centrifuged in a microfuge tube at 16,400 rcf for 5 min. The 
resulting cell pellet was resuspended in 1 ml of fresh 7H9-OADC media by re-
pipetting and represented a non-diluted sample with a dilution factor of 100. 
Sequentially, 100 #l of each serial dilution was diluted in 900 #l of fresh media 
and shaken by vortex until a final dilution factor of 10-5. Finally, 100 #l of the 
10-3, 10-4, and 10-5 dilutions of each sample were spread onto 7H10-OADC solid 
media, resulting in a final dilution factor of 104, 105, and 106, respectively. Each 
sample was repeated in duplicate at each time point. Following 2 days of 
incubation, the number of colonies present on each plate was counted and the 
corresponding cell density was calculated by multiplying the colony forming 
units (CFU) of each plate by the corresponding dilution factor. 
 
5. Analytical Experimentation 
5.1. Flow Cytometry 
Cultures of Msm were induced with MMC (as indicated in Section 4.3.4) before 
the cells were fixed in preparation for flow cytometry. To this end, 1 ml of 
culture was centrifuged at 14,600 rcf for 5 min. The resultant cell pellet was 
resuspended in 200 #l of 4 % (v/v) formaldehyde and left to fix in the dark for 
30 min. After fixation, 800 #l of 0.05 % (v/v) Tween-80-phosphate-buffered 
saline (PBS) solution was added to the cell solution. Once more, the solution 
was centrifuged at 14,600 rcf for 5 min and the pellet was resuspended in 200 
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#l of 0.05 % (v/v) Tween-80-PBS solution. Prior to acquiring data with a flow 
cytometer, the cells were centrifuged a final time at 14,600 rcf for 5 min and the 
resultant pellet was resuspended in 200 #l of PBS. Immediately before 
acquisition, the cell solution was filtered through the 30 #m cell strainer lid of 
a 5 ml test tube (Corning, USA) and the tube was mixed by vortex for 5 s. Flow 
cytometry was performed using a FortessaTM flow cytometer (BD Science, USA) 
using FACSDivaTM software (BD Science, USA). A FITC filter set (530/30 nm 
filter with 505 nm long-pass mirror) was used to detect the fluorescence of 
EGFP and had a voltage of 557 V. Forward- (FSC) and side-scatter (SSC) had 
voltages of 400 and 310 V, respectively. A laser window-extension period of 
5.00 ms was used to acquire data. One million events were recorded for each 
acquisition run. Data was analyzed using FlowJo® (v9) (FlowJo, LLC, USA). 
 
5.2. Microscopy and Imaging 
In general, all microscopy images were generated by repeated, manual, 
random sampling of non-filtered liquid cultures by focusing on areas 
containing cells using non-fluorescent methods where possible before imaging 
by fluorescence microscopy in an attempt to avoid bias during sampling. In all 
cases, a minimum of five separate fields of view were imaged for each replicate 
of each strain under each condition. Detailed descriptions of the imaging 
techniques are presented below.  
 
5.2.1. Confocal Fluorescence Microscopy 
Confocal microscopy was performed on a Zeiss LSM 510 Meta Confocal 
Microscope and AxioObserver platform (Carl Zeiss AG, Germany). Samples were 
visualized by pipetting 2 #l of sample culture onto a glass microscope slide 
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(Lasec, ZA) before a #1.5 glass cover slip (Lasec, ZA; Sigma, USA) was placed 
over the sample. Samples were viewed using a 63× oil-immersion, plan-
apochromat objective lens with a numerical aperture (NA) of 1.42 (Carl Zeiss 
AG, Germany). The oil immersion had a refractive index of 1.518 (ImmersolTM 
518 F) (Carl Zeiss AG, Germany). Samples were located using either 
transmitted light and phase contrast or epifluorescent methods. Thereafter, 
confocal imaging was performed on focused field of views. Fields were 
changed according to the rate of photobleaching observed. Filter set properties 
are listed in Table 2-6. Images were captured using ZEN Blue Microscope and 
Imaging Software (Carl Zeiss AG, Germany) and further processed using the 
same software or Fiji (Schindelin, et al., 2012). 
 
Table 2-6 | Confocal fluorescence parameters 
Green fluorescence  
Excitation laser λ 488 nm 
Emission filter λ 525 nm 
Yellow fluorescence  
Excitation laser λ 514 nm 
Emission filter λ 538 nm 
Red fluorescence 
Excitation laser λ 561 nm 
Emission filter λ 603 nm 
 
5.2.2. Wide-field Epifluorescence Microscopy 
To visualize the Msm strain using an Axio.Scope A1 microscope (Carl Zeiss AG, 
Germany), 2 to 5 #l of culture was placed between a glass microscope slide 
(Lasec, SA, or Sigma-Aldrich, USA) and a #1.5 coverslip (Sigma-Aldrich, USA). 
A transmitted mercury lamp light was used together with filter cubes to detect 
fluorescence with a 100× 1.4 NA plan apochromatic oil immersion objective 
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lens; to this end, ImmersolTM 518 F (Carl Zeiss AG, Germany) was used. Images 
were captured with a Zeiss 1 MP monochrome camera (Carl Zeiss AG, 
Germany). Comparable samples were exposed to the same exposure settings 
for respective channels for image acquisition. Green fluorescence was detected 
using a 488 nm excitation filter and a 510 nm emission filter set; while the red 
fluorescence was detected using a 590 nm excitation laser filter and 700 nm 
long-pass emission filter (Carl Zeiss AG, Germany). In addition, brightfield 
imaging was used to detect the position of the bacteria. 
 
5.2.3. Light Microscopy Cell Imaging 
In addition to wide-field epifluorescence microscopy, bacilli were also imaged 
using a ZOETM Fluorescent Cell Imager (BioRad, USA). The instrument was used 
as per the manufacturer’s default hardware and acquisition settings while 
samples were prepared as previously described. 
 
5.2.4. Superresolution, Interferometric Photo-Activated Light 
Microscopy 
Superresolution samples were prepared as follows: A gold fiducial coverslip 
(Shtengel, et al., 2009, supplementary information) was cleaned with 1 M KOH 
and coated with 1 % poly-L-lysine for 60 min at 37.0 °C before submerging the 
coverslip twice in fresh dH2O for 5 min. At this point prepared coverslips were 
stored in dH2O at 4 °C until use. Subsequently, 3.0 ml of bacterial sample was 
added to the fiducial-coated surface of the coverslip and centrifuged onto the 
coverslip at 3,200 rcf for 30 min. Unbound bacterial sample was washed off the 
coverslip by two sequential submersions in Dulbecco's Phosphate-Buffered Saline 
(Thermo Scientific, USA) for 5 min. The sample was fixed with 0.5 % 
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paraformaldehyde for 2 min before immediately being washed with PBS. After 
washing, the gold fiducial coverslip was mounted face-down to a standard #1.5 
glass coverslip with PBS. The coverslips were immobilized together with epoxy 
resin and sealed with petroleum jelly to prevent evaporation. 
 
A custom-built, interferometric photo-activated light microscope (iPALM), 
developed at the Howard Hughes Medical Institute, was used to image 
fluorescent-labelled ImuB foci at a sub-diffraction limited resolution in three-
dimension (3D). The instrument set-up was used as previously reported 
(Shtengel, et al., 2009). The previously prepared sample slide was mounted 
between two opposing 60× 1.4 NA oil immersion lenses to record the data of 
each sample and fluorescence-grade immersion oil (refractive index of 1.518) 
was added to both objective lenses. Bacterial cells were located by differential 
interference contrast (DIC) visualization before imaging each field of view. The 
opposing objectives were focused approximately 200 nm in the Z-axis above 
the gold fiducials present on the surface of the coverslip, a distance empirically 
determined to contain the bacterial sample. Set-up and focus of the objectives 
and beam splitter was performed as previously reported (Shtengel, et al., 2009). 
Briefly, objectives were focused by adjusting the Z-plane of each lens and the 
beam splitter in accordance with the gold fiducial fluorescent signal intensity 
such that all three camera signals resembled Gaussian curves with oscillating 
Z-axis position. Furthermore, the beam splitter was adjusted such that the 
Gaussian fit of each detector was separated by 120° (360°÷3). Thereafter, a 
calibration image of 100 cycles was taken of the gold fiducials using a pulsating 
488 nm laser prior to imaging of the bacteria for 25,000 cycles using alternating 
400 nm and 561 nm laser cycles per frame with an acquisition rate of 
Chapter II 116 
approximately 20 frames per second (exposure time of 0.05 s for 590 nm light 
only). Each frame was recorded sequentially by an electron multiplying charge 
coupled device (EMCCD) monochrome camera (an EM gain of 200× was 
employed). 
 
Prior to image generation, each file was processed within PeakSelector™ (v9.5) 
(Howard Hughes Medical Institute, USA) as follows: Calibration files were 
curated such that only the middle 30 frames (frame 35 to 65), corresponding to 
the most in-focus frames, were used to calibrate the position of the fiducial-
coated coverslip. Furthermore, an upper bound of 60 nm was applied to the 
total change of X- and Y-axis positions for each calibration fiducial to reduce 
pixel uncertainty. A minimum of four fiducials was used as reference positions 
for the calibration of each sample image file. Thereafter, the generated 3D 
sample image was corrected for XYZ-axis tilt by transformation of all Z-axis 
positions by the plane of the coverslip/fiducials. Outlying signals were 
eliminated by restriction of the unwrapped Z-axis error to a symmetrical 
Gaussian curve. Furthermore, ghosting was reduced by removing incorrectly 
localized signal originating from below the coverslip by enforcing a lower 
bound limit on the unwrapped Z-axis position equal to the position of the 
fiducial plane. Each field of view was inspected individually to ensure that no 
biological data was filtered out. 
 
5.3. Cell Measurement 
Micrographs were analyzed using Fiji (v1.50b) (Schindelin, et al., 2012). The 
distances (in pixels) between the poles of clearly defined, unambiguous bacilli 
were measured. Straight bacilli were measured using a single line between the 
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two poles of each cell. Bent or curved cells were measured by taking multiple 
line measures along the center of the bacilli. Thereafter, the pixel distance was 
converted to physical distance (#m) using the scale ratio specific to each image. 
Every undistorted cell in each micrograph was measured. 
 
6. Statistical Methods 
Statistics were determined using GraphPad Prism (GraphPad Software, USA) 
and R Statistics (R Foundation for Statistical Computing, Austria).  
 
7. Routine Instruments 
Spectrophotometry to determine the cell density of liquid cultures was 
measured using a Biochrom WPA CO8000 Cell Density Meter (Biochrom Ltd, 
USA). 
Mixing of samples by vortex was performed using a Vortex Mixer (Stuart, UK). 
PCR was performed using a C1000TM Thermal Cycler (BioRad, USA) or T100TM 
Thermal Cycler (BioRad, USA), with the latter also being used for temperature-
gradient PCR. 
Vacuum centrifugation was performed using a miVac DNA concentrator 
(Genevac Ltd and SP Industries, USA). 
Centrifugation was performed using an AllegraTM X-22R Centrifuge (Beckman 
CoulterTM, USA) for large samples at low rcf and a Centrifuge 5415 D 
(Eppendorf, Germany) for small, microfuge samples at high rcf. 
Techne Dri-Block® DB-2D (Cole-Parmer, UK) heating blocks were used to heat 
liquid samples within microfuge tubes. 
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8. Detailed Strain and Plasmid Development 
8.1. Design of Constructs 
All mutasome constructs (containing either imuA’, imuB, or dnaE2) were 
designed with the following promoter features specific to the genes of the 
mutasome maintained in each respective case (Table 2-7). The sequence of each 
promoter element such as ribosome binding site (RBS), SOS box, -35, -10 sites, 
and transcription start site was identified in the mc2155 genome using 
comparable information from Mtb H37Rv (Davis, et al., 2002; Newton-Foot and 
van Pittius, 2013); and Msm gene information from the J. Craig Venter Institute 
Comprehensive Microbial Resource (Peterson, et al., 2001). All designed constructs 
were synthesized in pUC57 backgrounds by Genewiz (China). 
 
Table 2-7 | The regulatory sequences of mc2155 mutasome components 




P(imuA’-imuB)#    
 -35 TTGACG 1710760..1710765 
 -10 TGTTTACT 1710781..1710788 
 PSOS(imuA’) TCGAACATACATTCGA 1710796..1710811 
 +1 A 1710814 
P(imuA’)    
 RBS CGGGAGG 1710834..1710840 
 Start/Met codon GTG 1710848..1710850 
 Stop codon TAG 1711553..1711555 
P(imuB)    
 RBS AGGGG 1711514..1711518 
 Start/Met codon ATG 1711558..1711560 
 Stop codon TGA 1713133..1713135 
P(dnaE2)    
 -35 Not identified - 
 -10 Not identified - 
 PSOS(dnaE2) TCGAACACGTGTTCGA 1723911..1723926 
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 +1 Not identified - 
 RBS TCGGA 1723969..1723973 
 Start/Met codon ATG 1723975..1723977 
 Stop codon TGA 1727224..1727226 
* Reference to the genome sequence published by Cole, et al. (1998) 
# Promoter elements that regulate both imuA and imuB as part of the imuA’-imuB operon 
 
8.1.1. PSOS(imuA’)-egfp 
The construct PSOS(imuA’)-egfp was designed with the aim of developing a 
fluorescence-based transcriptional reporter in Msm to investigate DNA 
damage-induced gene expression in a bacillus following DNA damage. In 
addition to providing preliminary data in support of the construction of 
mutasome protein-specific translational fusions, the reporter construct would 
itself be used to study the expression dynamics of the imuA’ promoter in the 
mycobacterial SOS response, allowing use of the same promoter for use in 
future constructs if proven successful. The construct consisted of the 267 bp 
upstream promoter region of MSMEG_1620 (mc2155 genomic region 
1710581..1710847) (Figure 2-4), which included all imuA’-specific promoter 
elements such as the RBS and transcription factor-binding sites listed in Table 
2-7. The native, relatively uncommon mycobacterial GTG start codon present 
in MSMEG_1620 was not maintained in this construct and was changed to the 
standard ATG start codon. The remaining coding sequence for egfp (Cormack, 
et al., 1996), which was not codon optimized for expression in Msm, 
immediately followed the start codon. The construct was designed with HindIII 
restriction sites on either end to allow cloning into the multiple cloning site 
(MCS) of pMCAINT for stable integration into the mycobacterial genome 
(Warner, et al., 2010).  
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Figure 2-4 | Design of PSOS(imuA’)-egfp  
The transcriptional reporter construct, PSOS(imuA’)-egfp, is represented in this schematic. The P(imuA’) 
promoter, containing PSOS(imuA’), was designed to drive expression of egfp. The construct was flanked 
by two HindIII RE sites to allow easy cloning of the construct into plasmids, in particular pMCAINT. 
 
8.1.2. PSOS(imuA’)-egfp-imuB’ 
Owing to the fact that imuB is the second gene in a predicted bi-cistronic operon 
comprising imuA’-imuB, the promoter region of gfp-imuB was untested and it 
was likely that the inefficient gene expression by this promotor was the reason 
GFP-ImuB fluorescence was not detected in the previously developed 
∆imuB::gfp-imuB strain. The failure of this strain, together with the subsequent 
success of the PSOS(imuA’)-egfp reporter gene, led to two changes in the design 
of a fluorescently tagged ImuB-expressing construct (illustrated in Figure 2-5). 
Instead of maintaining the operon controlling expression of MSMEG_1622 
(imuB), the tagged-imuB ORF in this construct was preceded by the native 
imuA’ promoter region (as described in Section 8.1.1), which included 
PSOS(imuA’). The second change incorporated in the design of PSOS(imuA’)-
egfp-imuB’ was to utilize EGFP as opposed to the previously used GFP. This 
change was decided due to the more reliable and brighter fluorescence of EGFP 
(Cormack, et al., 1996). The truncated construct PSOS(imuA’)-egfp-imuB’ was 
designed to be synthesized and cloned into pMCAINT::imuB using the BlpI and 
ClaI cloning sites located 1,165 bp downstream of the imuB start and 1,501 bp 
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full upstream promotor sequence of imuA’ as well as the imuB ORF present in 
the pMCAINT::imuB plasmid. Furthermore, a FLAG tag-encoding sequence 
(with the translated sequence of DYKDDDDK) was used as a linker between 
the two components of the fusion gene to prevent steric collision in the 
translated protein and allow native folding of each protein (Gokhale and 
Khosla, 2000) as well as for downstream protein purification purposes 
(Einhauer and Jungbauer, 2001). This construct design was tested by 
performing cloning in silico using CLC Main Workbench (v7.6) (QIAGEN Aarhus 
A/S, Denmark), after which the resulting full-length, translated amino acid 
sequence was validated by NCBI BLASTp (Altshcul, et al., 1990) and the 
Conserved Domain Database (Figure 2-6) (Marchler-Bauer, et al., 2014). 
 
 
Figure 2-5 | Schematic design of EGFP-ImuB encoding gene 
Top: Schematic layout of PSOS(imuA)’-egfp-imuB’ sequence designed to be synthesized. The sequence 
consists of the region immediately upstream of imuA’ (which includes the imuA’ promoter). The start 
codon starts the sequence of egfp. The reading frame is maintained uninterrupted to include the linking 
flag sequence and the 5’-end of imuB. The construct is flanked by a 5’ ClaI site and a 3’ BlpI site. Middle: 
Schematic representation of the imuA’-imuB operon. Bottom: Schematic of the final PSOS(imuA)’-egfp-
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Figure 2-6 | EGFP-ImuB contained conserved domains 
The translated PSOS(imuA’)-egfp-imuB gene was analysed using the NCBI Conserved Domain Database. 
The summary result of the predicted conserved domains of the translated egfp-imuB sequence indicated 
that both EGFP and ImuB were conserved, linked by the FLAG tag. 
 
8.1.3. PSOS(imuA’)-mEos4a-imuB’ 
It was necessary to tag ImuB with an additional fluorescent protein (FP) in 
order to confirm that any observations were a result of the biological function 
of ImuB and not spurious anomalies associated with EGFP. To this end, 
MEos4a was identified as a suitable FP for a number of reasons. Firstly, it is 
derived from the Eos FP isolated from Lobophyllia hemprichii coral making it 
sufficiently different from GFP (Aequorea victoria)-derived FPs (Wiedenmann, 
et al., 2004). MEos4a is also a photoswitchable FP, which is suitable for 
superresolution imaging techniques such as PALM/STORM. In addition, 
MEos4a was selected above similar photoswitchable proteins such as Kaede 
due to the limited impact it has on cell function (Betzig, et al., 2006). Finally, 
MEos4a is also fixation resistant which improves the utility of tagged proteins 
for methods such as flow cytometry and imaging (Paez-Segala, et al., 2015). The 
PSOS(imuA’)-mEos4a-imuB construct was designed by replacing the egfp 
sequence in PSOS(imuA’)-egfp-imuB’ with the Mycobacterium tuberculosis (Mtb) 
codon-optimized sequence of mEos4a (Paez-Segala, et al., 2015). 
 
8.1.4. egfp-dnaE2’ 
As a result of the failure to observe fluorescence from the previously 
constructed cfp-dnaE2 gene despite it providing functional restoration of the 
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mutasome (Reiche, et al., unpublished), it was necessary to design a construct 
that utilized EGFP, which had already been used successfully to tag ImuB. 
Therefore, egfp-dnaE2’ was designed by inserting egfp directly upstream of, and 
in frame with, the native dnaE2 ORF. Once more, the two proteins were linked 
via a FLAG tag-encoding sequence (Einhauer and Jungbauer, 2001). Thereafter, 
the construct sequence was truncated to allow cloning of egfp-dnaE2’ into 
pTTP1B::dnaE2 at the KpnI sites located -353 and +421 relative to the 
MSMEG_1633 ORF. This allowed for the 5’ portion of the native dnaE2 gene to 
be ‘swapped out’ for the modified egfp-dnaE2’ construct. The construct could 
then be complemented by the remaining upstream portion of the gene 
containing the PSOS(dnaE2) promoter and downstream ‘dnaE2 in 
PTTP1B::dnaE2 to yield a single egfp-dnaE2 ORF (Figure 2-7). The construct 
design was tested by performing the intended cloning strategy in silico using 
CLC Main Workbench (v7.6) (QIAGEN Aarhus A/S, Denmark). The resultant 
full-length, translated amino acid sequence was verified by NCBI BLASTp 
(Altshcul, et al., 1990) and a Conserved Domain Database query (Figure 2-8) 
(Marchler-Bauer, et al., 2014). Both the EGFP and DnaE2 domains of the 
resultant protein were present in both in silico validations. 
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Figure 2-7 | Schematic design of egfp-dnaE2’ 
Top: Schematic layout of the egfp-dnaE2’ construct. The sequence consists of the region immediately 
upstream of dnaE2 (which includes the dnaE2 promoter). The start codon starts the sequence of egfp. 
The reading frame is maintained uninterrupted through the linking flag sequence and the 5’-end of 
dnaE2. The construct is flanked at both ends by KpnI recognition sites. Middle: Schematic representation 
of the dnaE2 in the Msm genome. Bottom: Schematic of the final egfp-dnaE2 gene after insertion of the 




Figure 2-8 | EGFP-DnaE2 contained conserved domains 
The translated egfp-dnaE2 gene was analysed using the NCBI Conserved Domain Database. The 
summary result of the predicted conserved domains of the translated egfp-dnaE2 sequence indicated 
that both EGFP and DnaE2 were conserved, linked by the FLAG tag, and contained no sequence 
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prevented genetically. To this end, PSOS(imuA’)-egfp-imuBAAAAG was designed 
to encode a version of EGFP-ImuB that lacked the previously predicted β 
clamp-binding domain within the coding sequence of ImuB (Warner, et al., 
2010). In order to maintain all other characteristics similar to the previously 
tested, non-mutated PSOS(imuA’)-egfp-imuB, the pMCAINT::PSOS(imuA’)-
egfp-imuB plasmid was the backbone for the cloning of 
pMCAINT::PSOS(imuA’)-egfp-imuBAAAAG. The final construct was designed 
such that the locus encoding the predicted QLPLWG β clamp-binding domain 
within imuB (position 1712234..1713043 in the mc2155 genome) could be excised 
from pMCAINT::PSOS(imuA’)-egfp-imuB by digestion with MauBI. Similarly, 
the corresponding locus within pMCAINT::imuBAAAAG (Warner, et al., 2010) 
could be isolated similarly by digestion with MauBI. Thereafter, the linear, 
truncated pMCAINT::PSOS(imuA’)-egfp-imuB molecule could be ligated with 
the DNA fragment containing the mutant AAAAGG allele from imuBAAAAG to 
form a single ORF encoding egfp-imuBAAAAG. The designed construct was 
validated by alignment and comparison of the WT sequence against that of the 
mutant β clamp-binding domain using Clustal Omega (Sievers and Higgins, 
2014). 
 
8.2. Generation of an imuA’ Transcriptional Reporter Strain of Msm 
The construct pMCAINT::PSOS(imuA’)-egfp was generated by ligating the 996 
bp fragment of HindIII-digested pUC57::PSOS(imuA’)-egfp with the 
dephosphorylated 3,995 bp HindIII-linearized pMCAINT vector (Figure 2-9). 
The cloning strategy is indicated in Figure 2-10. 
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Figure 2-9 | Cloning of pMCAINT::PSOS(imuA’)-egfp 
The portion of the gel extracted (clear) indicates the corresponding sizes of the bands used during 
cloning. Reaction products were separated on a 1 % (w/v) agarose TAE gel supplemented with 0.01 % 
(w/v) EtBr by electroporation under a 100 V electric field in TAE buffer. Gel picture was recorded and 
imaged using UV light illumination. The sizes of the product fragments (both excised and visible bands) 
are indicated. The symbol ‘⨂’ indicates that the plasmid was digested by the indicated RE. 
 
 
Figure 2-10 | Cloning strategy of pMCAINT::PSOS(imuA’)-egfp 
The schematic represents that steps under taken to clone pMCAINT::PSOS(imuA’)-egfp from pMCAINT 
and pUC57::PSOS(imuA’)-egfp. The final product could yield plasmids with the insert ligated in either 
direction. 
 
Ligation product was used to heat-shock transform competent DH5α cells and 
small-scale plasmid extractions were conducted on the resulting colonies. The 
RE enzyme XhoI was used as a preliminary screen of pMCAINT::PSOS(imuA’)-
egfp (Figure 2-11). Positive clones are differentiated from self-ligated vector by 
the presence of two restriction sites – one in the insert and one in the vector. 
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This maps to fragments of 2,286 and 2,713 bp for orientation 1 (green) and 2141 
and 2,858 bp for orientation 2 (blue), in comparison to the 3,995 bp digestion of 
self-ligated vector (red). After large-scale plasmid extractions, additional 
screening of pMCAINT::PSOS(imuA’)-egfp was performed by digestion with 
BstBI and SmaI which yielded inconclusive results (Figure 2-12). For further 
clarification and to rule out the presence of concatamer inserts, both plasmids 
were screened with BglII, BamHI, and PvuI (Figure 2-13); and rescreened with 
XhoI (Figure 2-14). 
 
 
Figure 2-11 | XhoI screen of pMCAINT::PSOS(imuA’)-egfp 
Reaction products were separated on a 1 % (w/v) agarose TAE gel supplemented with 0.01 % (w/v) EtBr 
by electroporation under a 100 V electric field in TAE buffer. Gel picture was recorded and imaged using 
UV light illumination. The sizes of selected Roche molecular weight marker IV fragments are indicated. 
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Figure 2-12 | pMCAINT::PSOS(imuA’)-egfp screened with BstBI and SmaI 
Gel image indicating the resulting fragment pattern of both orientation 1 (1) and orientation 2 (2) of 
pMCAINT::PSOS(imuA’)-egfp following digestion with either BstBI or SmaI. Positive result for BstBI 
digestion for orientation 1 is 770 and 4,225 bp; and 238 and 4,757 bp for orientation 2. SmaI is predicted 
to linearize (4,991 bp) the plasmid of both orientations. Reaction products were separated on a 1 % (w/v) 
agarose TAE gel supplemented with 0.01 % (w/v) EtBr by electroporation under a 100 V electric field in 
TAE buffer. Gel picture was recorded and imaged using UV light illumination. The sizes of selected Roche 
molecular weight marker IV fragments are indicated. Dotted rectangles indicate the position of bands 
clearly visible with altered contrast settings. The symbol ‘⨂’ indicates that the plasmid was digested by 
the indicated RE. 
 
 
Figure 2-13 | pMCAINT::PSOS(imuA’)-egfp screened with BamHI, BglII and PvuI 
Gel image indicating the resulting fragment pattern of both orientation 1 (1) and orientation 2 (2) of 
pMCAINT::PSOS(imuA’)-egfp following digestion with either BamHI, BglII or PvuI. Both plasmid 
orientations should fragment into 1,711 and 3,288 bp after digestion with BamHI; 2,248 and 2,751 bp 
following digestion with BglII; and 2,437 and 2,558 bp (indistinguishable) after digestion with PvuI. 
Reaction products were separated on a 1 % (w/v) agarose TAE gel supplemented with 0.01 % (w/v) EtBr 
by electroporation under a 100 V electric field in TAE buffer. Gel picture was recorded and imaged using 
UV light illumination. The sizes of selected Roche molecular weight marker IV fragments are indicated. 
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The dotted rectangle indicates the position of a band clearly visible with altered contrast settings. The 
symbol ‘⨂’ indicates that the plasmid was digested by the indicated RE. 
 
 
Figure 2-14 | Rescreen of pMCAINT::PSOS(imuA’)-egfp by digestion with XhoI 
Orientation 1 and 2 products of the pMCAINT::PSOS(imuA’)-egfp were digested with XhoI. Reaction 
products were separated on a 1 % (w/v) agarose TAE gel supplemented with 0.01 % (w/v) EtBr by 
electroporation under a 100 V electric field in TAE buffer. Gel picture was recorded and imaged using 
UV light illumination. The sizes of selected Roche molecular weight marker IV fragments are indicated. 
The symbol ‘⨂’ indicates that the plasmid was digested by the indicated RE. 
 
Verified plasmids were subsequently electroporated into WT Msm to allow 
plasmid integration into the genome (see time constants presented in Table 2-
8). Of the resultant transformed Msm colonies, two of each insert orientation 
were screened by PCR following genome release by colony boil. Primers FP_for 
and FP_rev were used to amplify the 71 bp region specific to the EGFP-
encoding sequence of egfp (Figure 2-15) and the amplicons were visualized 
following separation by gel electrophoresis on a 4 % (w/v) agarose gel (Figure 
2-16). Positive strains were identified, and future experimentation was 
conducted only with positively identified clones containing the PSOS(imuA’)-
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Time constant, μ 
Orientation 1 0.0 24.3 
Orientation 1 1000 24.4 
Orientation 1 2000 24.2 
Orientation 1 4000 24.0 
Orientation 2 0.0 24.1 
Orientation 2 1000 23.8 
Orientation 2 2000 23.8 
Orientation 2 4000 23.8 
 
 
Figure 2-15 | Rationale of WT::PSOS(imuA’)-egfp PCR screen  
Schematic representation of the PCR screening strategy used to screen WT::PSOS(imuA’)-egfp. The 
primers FP_for and FP_rev were used to amplify a 71 bp region specific to egfp. 
 
 
Figure 2-16 | PCR screen of putative WT::PSOS(imuA’)-egfp  
PCR was conducted using primer FP_for and FP_rev to screen for the presence of a 71 bp region specific 
to egfp in putative Msm transformants. Two colonies (a or b) with either orientation 1 or 2 insert were 
screened. Positive control (+) was conducted on 200 ng of pUC57::PSOS(imuA’)-egfp plasmid. PCR 
products were separated on a 4 % (w/v) agarose TAE gel supplemented with 0.01 % (w/v) EtBr by 
electroporation under a 70 V electric field in TAE buffer. Gel picture was recorded and imaged using UV 
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8.3. Fluorescent Fusion Proteins of Mutasome Components Expressed in 
Msm 
8.3.1. Tagged Variants of ImuB 
8.3.1.1. GFP-ImuB 
pUC57::gfp-imuB’ was digested with DraI, ClaI and BlpI. The resultant 
fragments were separated in a 1 % (w/v) agarose gel (Figure 2-17) before the 
band corresponding to the fragment of interest (1,991 bp) was excised from the 
gel and purified. Simultaneously, pMCAINT::imuB was digested with the RE 
enzymes ClaI and BlpI. Following separation of the fragments on a 1 % (w/v) 
agarose gel, the 4,994 bp band corresponding to the complementary vector 
region of the plasmid was purified from the gel. The cloning strategy 
implemented in the development of pMCAINT::gfp-imuB is indicated in Figure 
2-18. It was necessary to digest pUC57::gfp-imuB’ with an additional, non-
cloning RE enzyme (DraI) in order to resolve the desired gfp-imuB’ fragment 




Figure 2-17 | Cloning of pMCAINT::gfp-imuB 
The portion of the gel extracted (clear) indicates the corresponding sizes of the bands used during 
cloning. Reaction products were separated on a 1 % (w/v) agarose TAE gel supplemented with 0.01 % 
(w/v) EtBr by electroporation under a 100 V electric field in TAE buffer. Gel picture was recorded and 
imaged using UV light illumination. The sizes of the excised fragments are indicated. Dotted rectangles 
indicate the position of bands clearly visible with altered contrast settings. The symbol ‘⨂’ indicates that 




pUC57::gfp-imuB’  DraI, ClaI and BlpI    pMCAINT::imuB   DraI and ClaI 
4994 bp 
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Figure 2-18 | Cloning strategy of pAINT::gfp-imuB 




The two extracted fragments were ligated using T4 DNA ligase and the 
resultant reaction product was used to transform DH5α cells. Small-scale 
plasmid extractions were performed on the resultant KAN-resistant colonies, 
containing the putative pMCAINT::gfp-imuB plasmid. Thirty-two colonies 
were preliminary screened by RE digestion with BamHI (Figure 2-19), of which 
six clones yielded the positive, visible bands corresponding to 3,284, 1,734, 
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Figure 2-19 | BamHI screen of putative pMCAINT::gfp-imuB plasmids 
Green lanes indicated positively identified clones and were selected for further screening. Reaction 
products were separated on a 1 % (w/v) agarose TAE gel supplemented with 0.01 % (w/v) EtBr by 
electroporation under a 100 V electric field in TAE buffer. Gel picture was recorded and imaged using 
UV light illumination. The sizes of selected Roche molecular weight marker IV fragments are indicated. 
Dotted rectangles indicate the position of bands clearly visible with altered contrast settings. 
 
The positively identified cultures (green lanes in Figure 2-19) were screened by 
digestion with BlpI and separated by electrophoresis on a 1 % (w/v) agarose 
gel (Figure 2-20). After a large-scale plasmid extraction, the putative plasmid 
was further characterized and validated by RE digestion with DraIII, NspI, 
PvuII, and PstI (Figure 2-21). The positively identified pMCAINT::gfp-imuB 
plasmid was subsequently electroporated into the ∆imuB mutant (Warner, et 
al., 2010) (Table 2-9). 
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Figure 2-20 | BlpI screen of selected putative clones of pMCAINT::gfp-imuB  
Positive pMCAINT::gfp-imuB plasmids would be linearized by BlpI, yielding a single fragment of 6,986 
bp. Reaction products were separated on a 1 % (w/v) agarose TAE gel supplemented with 0.01 % (w/v) 
EtBr by electroporation under a 100 V electric field in TAE buffer. Gel picture was recorded and imaged 




Figure 2-21 | Additional RE screening of pMCAINT::gfp-imuB 
Top: Selected putative pMCAINT::gfp-imuB clones screened with either DraI or NspI. Positive DraI 
digestion would yield a linearized plasmid of 6,986 bp; while positive NspI digestion would yield 947, 
1,144, 2,130, and 2,781 bp. The DraI digest exhibited a degree of star-activity. 
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digestion would yield fragments of 90, 636, 741, 924, and 4,595 bp; while positive PstI digestion would 
yield 1,132, 2,620, and 3,246 bp. 
Reaction products were separated on a 1 % (w/v) agarose TAE gel supplemented with 0.01 % (w/v) EtBr 
by electroporation under a 100 V electric field in TAE buffer. Gel picture was recorded and imaged using 
UV light illumination. The sizes of selected Roche molecular weight marker IV fragments are indicated.  
 
Table 2-9 | Record of time constants generated during the electroporation of pMCAINT::gfp-imuB into 
ΔimuB 
pMCAINT::gfp-imuB amount (ng) Time constant, μ 
0.0 22.9 







The electroporation yielded more than 50 individual, KAN-resistant colonies 
(colonies were absent from the negative control in which no plasmid DNA was 
included in electroporation mixture), of which 13 colonies were randomly 
selected for screening by PCR after colony boil (Figure 2-22). Primers 
GFP_Comlp_Forward and GFP_Compl_Reverse were designed to amplify a 547 
bp region specific to the gfp gene (Figure 2-23). Selected PCR-positive colonies 
of ∆imuB::gfp-imuB were cultured and used for further characterization.  
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Figure 2-22 | Colony boil PCR screen of putative ΔimuB::gfp-imuB colonies 
PCR was conducted using primers GFP_Comlp_Forward and GFP_Compl_Reverse to screen for the 
presence of a 547 bp region specific to gfp-imuB in putative Msm transformants. Positive control (+) was 
conducted on 200 ng of pUC57::gfp-imuB’ plasmid. PCR products were separated on a 2 % (w/v) agarose 
TAE gel supplemented with 0.01 % (w/v) EtBr by electroporation under a 100 V electric field in TAE 
buffer. Gel picture was recorded and imaged using UV light illumination. The sizes of selected Roche 
molecular weight marker VI fragments are indicated.  
 
 
Figure 2-23 | Rational behind PCR screening of ΔimuB::gfp-imuB  
Schematic of the strategy used for screening of ΔimuB::gfp-imuB by PCR amplification. The primers 




pUC57::PSOS(imuA’)-egfp-imuB’ was digested with DraI, ClaI and BlpI and the 
resulting 2,401 bp band was extracted and ligated with the 4,994 bp fragment 
extracted after the digestion of pMCAINT::imuB with ClaI and BlpI (Figure 2-
24). The cloning strategy implemented is presented in Figure 2-25. After heat-
shock transformation of competent DH5α cells with the ligation product, 
twenty-four isolated colonies were preliminarily screened for the presence of 
pMCAINT::PSOS(imuA’)-egfp-imuB by digestion of small-scale plasmid 
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large-scale plasmid extractions were performed on putative positively 
identified candidates and the samples were further screened with HindIII 
(Figure 2-27) and NaeI (Figure 2-28). Clone 12 was selected for final 
confirmation by digestion with SmaI (Figure 2-29). 
 
 
Figure 2-24 | Cloning of pMCAINT::PSOS(imuA’)-egfp-imuB 
The portion of the gel extracted (clear) indicates the corresponding sizes of the bands used during 
cloning. Reaction products were separated on a 1 % (w/v) agarose TAE gel supplemented with 0.01 % 
(w/v) EtBr by electroporation under a 100 V electric field in TAE buffer. Gel picture was recorded and 




Figure 2-25 | Cloning strategy of pMCAINT::PSOS(imuA’)-egfp-imuB 
The schematic represents that steps under taken to clone pMCAINT::PSOS(imuA’)-egfp-imuB from 
pMCAINT::imuB and pUC57::PSOS(imuA’)-egfp-imuB’. 
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Figure 2-26 | PvuI screen of putative pMCAINT::PSOS(imuA’)-egfp-imuB clones 
Positive screen of the pMCAINT::PSOS(imuA’)-egfp-imuB plasmid would generate fragments with sizes 
665, indistinguishable 1,274 and 1,355, 1,668, and 2,437 bp. The unambiguous, differential band is 1,355 
bp. Green lanes indicate clones that were deemed positive due to a thick band at approximately 1,300 
bp (third band from top of lane), representing the two indistinguishable bands. Reaction products were 
separated on a 1 % (w/v) agarose TAE gel supplemented with 0.01 % (w/v) EtBr by electroporation under 
a 100 V electric field in TAE buffer. Gel picture was recorded and imaged using UV light illumination. 
The sizes of selected Roche molecular weight marker IV fragments are indicated. Dotted rectangles 
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Figure 2-27 | HindIII screen of putative pMCAINT::PSOS(imuA’)-egfp-imuB clones 
Negative (-) samples were included to verify the previous PvuI digestion result. Owing to the presence 
of the PSOS(imuA’)-egfp portion of the construct (HindIII site absent), which replaced the imuA’ gene 
upstream of imuB (HindIII present), a positive screen would result in a single, linearized fragment with a 
size of 7,389 bp, while a negative result (pMCAINT::imuB) would be digested at two positions on the 
plasmid, yielding two indistinguishable bands of 3,669 and 3,999 bp. Reaction products were separated 
on a 1 % (w/v) agarose TAE gel supplemented with 0.01 % (w/v) EtBr by electroporation under a 120 V 
electric field in TAE buffer. Gel picture was recorded and imaged using UV light illumination. The sizes 
of selected Roche molecular weight marker IV fragments are indicated.  
 
 
Figure 2-28 | NaeI screen of selected pMCAINT::PSOS(imuA’)-egfp-imuB clones 
Negatively identified clone number 4 was included as a negative reference. A positive NaeI screen 
yielded a 4,424 bp band and a distinguishable 2,965 bp band. In contrast, pMCAINT::imuB yielded 
1,280, 1,956, and 4,424 bp sized fragments when digested with NaeI. Reaction products were separated 
on a 1 % (w/v) agarose TAE gel supplemented with 0.01 % (w/v) EtBr by electroporation under a 100 V 
electric field in TAE buffer. Gel picture was recorded and imaged using UV light illumination. The sizes 
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Figure 2-29 | Confirmation of pMCAINT::PSOS(imuA’)-egfp-imuB (clone 12) by NspI and SmaI digest 
Positive NspI screen of pMCAINT::PSOS(imuA’)-egfp-imuB yields 2,130, distinguishable 2,490, and 2,781 
bp fragments. A positive SmaI screen yielded 678, 3,126, and distinguishable 3,585 bp fragments. HpaI 
was also included in this screen; however, it did not digest completely but still proved useful in confirming 
clone number 12 (compare lane 5 to lane 6). For comparison purposes, a negative control plasmid was 
also digested and is indicated by an asterisk. Reaction products were separated on a 1 % (w/v) agarose 
TAE gel supplemented with 0.01 % (w/v) EtBr by electroporation under a 100 V electric field in TAE 
buffer. Gel picture was recorded and imaged using UV light illumination. The sizes of selected Roche 
molecular weight marker IV fragments are indicated.  
 
 
pMCAINT::PSOS(imuA’)-egfp-imuB was electroporated into multiple strains of 
Msm (time constants presented in Table 2-10) and, following 4 days of 
incubation at 37 °C, over 1,000 colonies formed, of which 20 were screened by 
PCR. However, genotypic confirmation of successful transformation by PCR 
proved problematic due to a persistent failure of the negative control. Positive 
bands were consistently amplified in controls containing no DNA (data not 
shown), likely due to contamination of laboratory equipment with DNA. 
Therefore, screening was performed by direct observation of green 
fluorescence under a confocal fluorescent microscope following exposure of 
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method of screening could only confirm positive results and negative results 
would need to be further screened by genotype to confirm. Due to subsequent 
results and time constraints, this was not performed. 
 
Table 2-10 | Record of time constants generated during the electroporation of pMCAINT::PSOS(imuA’)-




imuB amount (ng) 
 
Time constant, μ 
ΔimuB 0.0 23.6 
ΔimuB 1000 23.9 
ΔimuB 2000 23.8 
ΔimuB 4000 23.5 
ΔdnaE2 2000 23.2 
dnaE2AIA 0.0 24.3 
dnaE2AIA 1000 24.4 
dnaE2AIA 4000 24.0 
ΔimuA’ 0.0 21.5 
ΔimuA’ 1000 22.0 
ΔimuA’ 2000 22.1 
ΔimuA’ 4000 22.0 
 
8.3.1.3. MEos4a-ImuB 
pUC57::PSOS(imuA’)-mEos4a-imuB’ was digested with DraI, ClaI and BlpI and 
the resultant 2,354 bp fragment was extracted following separation by gel 
electrophoresis. Additionally, pMCAINT::imuB was digested with ClaI and 
BlpI to yield a 4,995 bp fragment that was similarly purified after separation of 
digestion products through a 1 % agarose gel (Figure 2-30). Ligation reactions 
were conducted with 50 ng of the digested pMCAINT::’imuB vector and either 
23.6, 70.8 or 118.0 ng of PSOS(imuA’)-mEos4a-imuB’ fragment insert for 1:1, 1:3, 
and 1:5 vector-to-insert ratios. The cloning strategy adopted is illustrated in 
Figure 2-31. The ligation product was transformed into competent DH5α by 
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the heat-shock method. After 24 h of incubation, 600 isolated colonies formed 
on 2 plates, while 50 colonies formed on the negative control (no insert) plate. 
Subsequently, 10 colonies were selected for screening and small-scale plasmid 
samples of each clone were digested with NspI (Figure 2-32). Clone number 5, 
with a putative pMCAINT::PSOS(imuA’)-mEos4a-imuB plasmid, was further 
confirmed by digestion with NcoI (Figure 2-33). 
 
 
Figure 2-30 | Gel extraction performed during the cloning of pMCAINT::PSOS(imuA’)-mEos4a-imuB 
The portion of the gel extracted (clear) indicates the corresponding sizes of the bands used during 
cloning. Reaction products were separated on a 1 % (w/v) agarose TAE gel supplemented with 0.01 % 
(w/v) EtBr by electroporation under a 100 V electric field in TAE buffer. Gel picture was recorded and 
imaged using UV light illumination. The sizes of excised bands are indicated. Dotted rectangles indicate 




pUC57::PSOS(imuA’)-mEos4a-imuB’   DraI, BlpI and ClaI 
pMCAINT::imuB  BlpI and ClaI 
4995 bp 
2354 bp 
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Figure 2-31 | Cloning strategy of pMCAINT::PSOS(imuA’)-mEos4a-imuB 
The schematic represents that steps under taken to clone pMCAINT::PSOS(imuA’)-mEos4a-imuB from 




Figure 2-32 | Preliminary NspI screen of putative pMCAINT::PSOS(imuA’)-mEos4a-imuB transformants 
Clone number Lane 5 was selected for further screening due to the positively identifiable restriction 
fragment products of 890, a distinct 1,568, 2,130, and 2,781 bp in size. Reaction products were separated 
on a 1 % (w/v) agarose TAE gel supplemented with 0.01 % (w/v) EtBr by electroporation under a 100 V 
electric field in TAE buffer. Gel picture was recorded and imaged using UV light illumination. The sizes 
of selected Roche molecular weight marker IV fragments are indicated. Dotted rectangles indicate the 
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Figure 2-33 | Final confirmation of pMCAINT::PSOS(imuA’)-mEos4a-imuB by NcoI digestion 
The two NcoI restriction sites of pMCAINT::PSOS(imuA’)-mEos4a-imuB would result in three fragments 
with sizes 211, 2,574, and 4,580 bp. The parental pMCAINT::imuB is only linearized by this RE. Reaction 
products were separated on a 1 % (w/v) agarose TAE gel supplemented with 0.01 % (w/v) EtBr by 
electroporation under a 100 V electric field in TAE buffer. Gel picture was recorded and imaged using 
UV light illumination. The sizes of selected Roche molecular weight marker IV fragments are indicated.  
 
Thereafter, the confirmed plasmid was electroporated into ∆imuB (time 
constants presented in Table 2-11) and, after growth of colonies, two were 
selected to be screened by direct observation of photoswitchable MEos4a 
fluorescence following exposure of resultant KAN-resistant liquid cultures to 
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With the aim of introducing the 352AAAAGG357 mutated beta clamp binding 
site of ImuB (Warner, et al., 2010) into the EGFP-ImuB protein, the 
corresponding encoding nucleotide sequence from pMCAINT::imuBAAAAG 
containing the mutant sequence was designed as previously described. Vector 
construction and screening was performed by a third-party. Briefly, the mutant 
AAAAG-encoding sequence of pMCAINT::imuBAAAAG (Warner, et al., 2010) was 
swapped into the corresponding position of PSOS(imuA’)-egfp-imuB by 
digestion of both plasmids with MauBI (Figure 2-34). The 810 bp fragment 
derived from pMCAINT::imuBAAAAG was ligated with the 6,587 bp product 
derived from PSOS(imuA’)-egfp-imuB to produce a single ORF encoding EGFP-
FLAG-ImuBAAAAG contained within the mycobacterial integrative shuttle 
vector, pMCAINT, which was cloned in DH5α E. coli with KAN 50 mg/ml 
selection. The isolated pMCAINT::PSOS(imuA’)-egfp-imuBAAAAG plasmid was 
screened by RE digestion verification (data not shown). Electroporation of the 
pMCAINT::PSOS(imuA’)-egfp-imuBAAAAG plasmid into Msm was performed by 
a third-party (data not shown). 
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Figure 2-34 | Cloning strategy of pMCAINT::PSOS(imuA’)-egfp-imuBAAAAG 
The schematic represents that steps under taken to clone pMCAINT::PSOS(imuA’)-egfp-imuBAAAAG from 
pMCAINT::imuBAAAAG and pMCAINT::PSOS(imuA’)-egfp-imuB. The final ligation step yields two potential 
plasmids with opposite insert orientations. 
 
 
8.3.2. Tagged variants of DnaE2 
8.3.2.1. EGFP-DnaE2 
To generate the construct pTTP1B::egfp-dnaE2, both the parental plasmids 
pTTP1B::dnaE2 and pUC57::egfp-dnaE2’ were digested with KpnI. The digested 
vector with a size of 10,749 bp (derived from pTTP1B::dnaE2) and the insert 
fragment with a size of 1,525 bp (derived from pUC57::egfp-dnaE2’) were 
purified after separation by gel electrophoresis (Figure 2-35). The two extracted 
DNA fragments were non-directionally ligated together before the ligation 
(Figure 2-35) product was used to transform competent DH5α cells. Zero 
colonies formed on the no insert control plate (data not shown), and the 
plasmids of 21 isolated colonies were extracted by small-scale extraction in 
preparation of screening. The extracted plasmids were screened by digestion 
with BlpI (Figure 2-37). Thereafter, large-scale plasmid extractions of putatively 
correct clones were performed, and the plasmids were screened with BstBI and 
AatII (Figure 2-38). 
Restriction endonuclease digestion 
with MauBI with purification by gel 
electrophoresis and extraction
Restriction endonuclease digestion 
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Figure 2-35 | Cloning of pTTP1B::egfp-dnaE2 
Both plasmids were digested in the same reaction before being unambiguously separated by gel 
electrophoresis. The portion of the gel extracted (clear) indicates the corresponding sizes of the bands 
used during cloning. Reaction products were separated on a 1 % (w/v) agarose TAE gel supplemented 
with 0.01 % (w/v) EtBr by electroporation under a 100 V electric field in TAE buffer. Gel picture was 




Figure 2-36 | Cloning strategy implemented for the development of pTTP1B::egfp-dnaE2 
A schematic diagram representing the steps taken to clone pTTP1B::egfp-dnaE2 from pTTP1B::dnaE2 
and pUC57::egfp-dnaE2. The final ligation reaction results in two possible products owing to the non-
directional cloning utilizing a single KpnI restriction site. 
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Figure 2-37 | Preliminary screen of pTTP1B::egfp-dnaE2 with BlpI 
Clone number 5 (lane 5) resulted in the predicted positive restriction pattern (1,587, distinct 2,004, and 
8,684 bp) and was selected for further screening. Reaction products were separated on a 1 % (w/v) 
agarose TAE gel supplemented with 0.01 % (w/v) EtBr by electroporation under a 100 V electric field in 
TAE buffer. Gel picture was recorded and imaged using UV light illumination. The sizes of selected Roche 
molecular weight marker IV fragments are indicated.  
 
 
Figure 2-38 | Final screen of putative pTTP1B::egfp-dnaE2 plasmid by digestion with BstBI and AatII 
Positive result of BstBI yielded fragments with sizes corresponding to 611 (unseen), 2,110, distinct 4,339, 
and 5,214 bp. Digestion of pTTP1B::egfp-dnaE2 with AatII was expected to result in 331 (unseen), 2,342, 
distinct 3,796, and 5,813 bp bands. However, upon further inspection, it was identified that 
pTTP1B::dnaE2 had not been fully sequenced. The sequence of a 2,284 bp region was unknown. If an 
AatII recognition site were present in this unsequenced region, the predicted 3,796 bp fragment would 
be cleaved. This is evident by the unaccounted bands with approximate sizes of 2,600 and 1,100 bp 
which when added together produce the missing 3,796 bp band, thereby confirming the identity of 
pTTP1B::egfp-dnaE2. Reaction products were separated on a 1 % (w/v) agarose TAE gel supplemented 
with 0.01 % (w/v) EtBr by electroporation under a 100 V electric field in TAE buffer. Gel picture was 
recorded and imaged using UV light illumination. The sizes of selected Roche molecular weight marker 
IV fragments are indicated. Dotted rectangles indicate the position of bands clearly visible with altered 
contrast settings. 
 
The confirmed plasmid was electroporated into the ∆dnaE2 mutant (time 
constants presented in Table 2-12) and resulting GENT-resistant clones were 
IV 
7743 bp 
IV 1 2 3 4 5 6 7 8 9 10 
1882 bp 
1469 bp 
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screened by direct observation of EGFP fluorescence following exposure of 
liquid cultures to MMC at MIC for 4 h. This method of screening did not 
identify positive results and negative results were not screened by genotype to 
confirm, due to changes in experimental aims of the project. 
 
Table 2-12 | Record of time constants generated during the electroporation of pTTP1B::egfp-dnaE2 into 
ΔdnaE2 






9. Reagents, Preparations and Solutions 
Agarose gel (1 %): 
• 1× TAE buffer is used to dissolve 1 % w/v of agarose (Sigma, USA) by 
heating in a microwave 
• Evaporated water is replaced by adding the required amount of dH2O 
• 0.5-1.0 #l of 10 mg/ml EtBr (E1510-10ML; Sigma, USA) is added per 40 
ml of agarose 
• Pour gel into gel cast (BioRad, USA) and is allowed to set 
 
Agarose gel (4 %): 
• 1× TAE buffer is used to dissolve 4 % w/v of agarose (Sigma, USA) by 
slow heating in a 60 °C water bath  
• Evaporated water is replaced by adding the required amount of dH2O 
• Solution is heated in a 60 °C water bath again and slowly mixed 
• 0.5-1.0 #l of 10 mg/ml EtBr (E1510-10ML; Sigma, USA) is added per 40 
ml of agarose 
• Solution is heated in a 60 °C water bath again and slowly mixed 
• Pour gel into gel cast (BioRad, USA) and is allowed to set 
 
DNA molecular weight markers: 
• 10 #l marker (Roche, UK) 
• 10 #l loading dye 
• 40 #l dH2O 
 
dNTPs (200 #M): 
• dATPs, dTTPs, dCTPs and dGTPs (New England Biolabs, USA) are 
made to a final total concentration of 200 #M by dilution with dH2O. 
• Stored at 4 °C 
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Ethanol (70 %): 
• Dilute 7 parts absolute ethanol (Sigma, USA) with 3 parts dH2O 
• Store at room temperature  
 
Ethylenediaminetetraacetic acid disodium salt dihydrate (EDTA, 0.5 M): 
• 93.06 g of EDTA (Sigma, USA) dissolved in 400 ml dH2O 
• Adjust pH to 8.00 with NaOH (Sigma, USA) 
• Make up to final volume of 500 ml 
• Autoclave to sterilise 
• Store at room temperature 
 
Gentamycin (GENT): 
• Dissolve gentamycin (Sigma, USA) in dH2O to a final concentration of 
50 mg/ml 
• Filter sterilise with 0.22 #m filter (Merck Millipore, USA) 
• Store in aliquots at –20 °C for long-term storage or 4 °C for frequent use 
 
Glucose (0.5 M): 
• 9.01 g of D-(+)-glucose (Sigma, USA) dissolved in 100 ml of dH2O 
• Sterilise through 0.22 #m filter 
 
Glucose salt solution (100×): 
• 20 g D-(+)-glucose (Sigma, USA) 
• 8.5 g NaCl (Sigma, USA) 
• Dissolve in 10 ml dH2O 
• Sterilise through 0.22 #m filter (Merck Millipore, USA) 
 
Glycerol (10 %): 
• 10 ml glycerol (Sigma, USA) 
• Dissolve in 70 ml dH2O 
• Mix 
• Make up to final volume of 100 ml with dH2O 
• Filter sterilise with 0.22 #m filter syringe (Merck Millipore, USA) 
• Store at room temperature 
 
Glycerol (66 %): 
• 66 ml glycerol (Sigma, USA) 
• Make up to final volume of 100 ml with dH2O 
• Mix 
• Filter sterilise with 0.22 #m filter syringe (Merck Millipore, USA) 
• Store at room temperature 
 
Isopropanol: 
• Procured from Sigma (USA) 
• Store at room temperature 
 
Kanamycin sulphate (Kanamycin, KAN):  
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• Dissolve Kanamycin sulphate (Sigma, USA) in dH2O to a final 
concentration of 50 mg/ml 
• Filter sterilise with 0.22 #m filter (Merck Millipore, USA) 
• Store in aliquots at –20 °C for long-term storage or 4 °C for frequent use 
 
Loading Dye: 
• 4.5 ml glycerol (Sigma, USA) 
• 10.5 ml dH2O 
• 0.04 g bromophenol blue (Sigma, USA) 
• Mix well 
• Filter sterilise (0.22 #m filter) (Merck Millipore, USA) 
• Store at 4 °C 
 
Luria-Bertani (LB) Agar: 
• 10 g Bacto™ Tryptone (BD Biosciences, USA), 10 g sodium chloride 
(Sigma, USA), 5 g Difco™ Yeast Extract (BD Biosciences, USA) and 15 g 
Bacto™ Agar (BD Biosciences, USA) is dissolved in 1,000 ml of dH2O 
• Autoclave to sterilise 
• Appropriate amount of antibiotic after the media has cooled sufficiently 
• Pour 20 ml into Petri dish 
• Allow to solidify 
 
Luria-Bertani (LB) Broth: 
• 10 g Bacto™ Tryptone (BD Biosciences, USA), 10 g sodium chloride 
(Sigma, USA) and 5 g Difco™ Yeast Extract (BD Biosciences, USA) is 
dissolved in 1,000 ml of dH2O 
• Autoclave to sterilise 
• Appropriate amount of antibiotic after the media has cooled sufficiently 
• Filter through a 0.02 #m filter to sterilize (Merck Millipore, USA) 
• Store at 37 °C 
 
Mitomycin C (MMC): 
• Dissolve mitomycin C from Streptomyces caespitosus (Sigma, USA) in 
dH2O to a final concentration of 0.04 #g/ml 
• Filter sterilise with 0.22 #m filter (Merck Millipore, USA) 
• Store in aliquots at –20 °C for long-term storage or 4 °C for frequent use 
• Light sensitive 
 
NaCl (5 M): 
• Dissolve 292.2 g sodium chloride (Sigma, USA) in 800 ml dH2O 
• Adjust final volume to 1,000 ml with dH2O 
• Autoclave 
• Store at room temperature 
 
NaOH (10 M): 
• 40 g sodium hydroxide (Sigma, USA) dissolved in 100 ml dH2O 
• Autoclave to sterilise 
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Phenol-chloroform (24:25): 
• Mix 120 ml of phenol (Sigma, USA) with 125 ml of chloroform (Sigma, 
USA) 
• Filter sterilise with 0.02 #m filter (Seperations, ZA) 
• Store at 4 °C 
 
Potassium acetate (5 M): 
• 49.075 g of potassium acetate (Sigma, USA) is dissolved in 100 ml dH2O 
• Autoclave to sterilise 
 
Rifampicin (RIF): 
• Dilute RIF (Sigma, USA) to a final stock concentration of 100 #g/ml 
• Filter sterilise with 0.22 #m filter (Merck Millipore, USA) 
• Store in aliquots at 4 °C for frequent use 
• Light sensitive 
 
RNAse A: 
• Dilute stock 100 mg/ml RNAse A (Sigma, USA) to 10 mg/ml with dH2O 
• Boil for 10 min at 100 °C 
• Store at -20 °C 
 
Sodium acetate (3 M, pH 5.20): 
• Dissolve 408.24 g sodium acetate trihydrate (Sigma, USA) in 800 ml 
dH2O 
• Adjust the pH to 5.20 with acetate (Sigma, USA) 
• Make up to final volume of 1,000 ml with dH2O 
• Autoclave and store at room temperature 
 
Sodium dodecyl sulfate (SDS, 10 %): 
• 10 g of SDS (Sigma, USA) is dissolved in 100 ml of dH2O on heat 
• Store at room temperature 
 
Solution I (Lysis buffer): 
• 10 ml of 0.5 M glucose, 2.5 ml Tris·HCl (1 M; pH 8.00) and 2.0 ml EDTA 
(0.5M; pH 8.00) is dissolved in 85.5 ml dH2O 
• Filter sterilise with 0.22 #m filter syringe 
• Store at 4 °C 
 
Solution II (Neutralisation buffer): 
• 4 ml 10 M NaOH and 20 ml 10% (w/v) SDS is dissolved in 176 ml dH2O 
• Autoclave to sterilise 
• Store at room temperature 
 
Solution III (Precipitation buffer): 
• 60 ml of 5 M potassium acetate and 11.5 ml of glacial acetic acid (Sigma, 
USA) is dissolved in 28.5 ml dH2O 
• Autoclave to sterilise 
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• Store at 4 °C 
 
Standard Transformation Buffer I (TFB I): 
• 0.588 g of potassium acetate (Sigma, USA), 2.42 g of rubidium chloride 
(Sigma-Aldrich), 0.294g of calcium chloride dihydrate (Sigma, USA), 2.0 
g of manganese chloride (Sigma, USA) and 30 ml of glycerol (Sigma, 
USA) is dissolved in 100 ml of dH2O. 
• The pH is adjusted to 5.80 with dilute acetic acid (Sigma, USA) 
• Make up to final volume of 200 ml 
• Filter sterilise with 0.22 #m filter (Seperations, ZA) 
• Store at room temperature 
• Bring to 4 °C before use 
 
Standard Transformation Buffer II (TFB II): 
• 0.21 g of 3-(N-morpholino)propanesulfonic acid (MOPS; Sigma, USA), 
1.1 g of calcium chloride dihydrate (Sigma, USA), 0.121 g of rubidium 
chloride (Sigma, USA) and 15 ml of glycerol (Sigma, USA) is dissolved 
in 50 ml of dH2O 
• The pH is adjusted to 6.50 with dilute NaOH (Sigma, USA) 
• Filter sterilise with 0.22 #m filter (Merck Millipore, USA) 
• Store at room temperature 
• Bring to 4 °C before use 
 
Tris-acetic-EDTA buffer (TAE buffer, 50×): 
• Dissolve 242 g of Tris(hydroxymethyl)aminomethane (Sigma, USA) 
in 500 ml distilled water 
• Add 100 ml 0.5M EDTA (pH 8.00) and 57.1 ml glacial acetic acid 
(Sigma, USA)  
• Adjust volume to 1,000 ml with distilled water 
• Store at room temperature 
• Make up 1´ working solution for gel electrophoresis by mixing 1 
part with 49 parts dH2O 
 
Tris-EDTA buffer (TE buffer, 10×): 
• 20 ml 1 M, pH 8.00 Tris·HCl 
• 4 ml 0.5 M EDTA 
• Dissolve in 150 ml dH2O 
• Make to final volume of 200 ml with dH2O 
• Adjust pH to 7.50 sodium hydroxide (Sigma, USA) 
• Autoclave to sterilise 
• Store at room temperature 
 
Tris·HCl (1 M, pH 8.00): 
• 60.56 g Tris·HCl (Sigma, USA) dissolved in 400 ml dH2O 
• Adjust pH to 8.00 with HCl (Sigma, USA) 
• Make up final volume of 500 ml 
• Autoclave to sterilise 
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Tween® 80 (25 %):  
• 25 ml Tween® 80 (Sigma, USA) 
• Make up to final volume of 100 ml with dH2O 
• Mix thoroughly 
• Filter sterilise with 0.22 #m filter syringe (Merck Millipore, USA) 
• Store at room temperature 
 
7H10 Agar (OADC): 
• 5.7 g Difco™ Middlebrook 7H10 Agar (BD Biosciences, USA) and 1ml of 
glycerol (Sigma, USA) is dissolved in 270 ml of dH2O 
• Autoclave 
• Add 30 ml BBL™ Middlebrook OADC Enrichment (BD Biosciences, USA) 
• Add appropriate amount of antibiotic if required 
• Pour 20 ml into Petri dish 
• Allow to solidify 
 
7H9 Broth (OADC): 
• 2.35 g Difco™ Middlebrook 7H9 Broth (BD Biosciences, USA), 1 ml glycerol 
(Sigma, USA) and 1 ml 25 % (v/v) Tween® 80 dissolved in 450 ml dH2O 
• Autoclave to sterilise 
• Add 50 ml BBL™ Middlebrook OADC Enrichment (BD Biosciences, USA) 
• Add required amount of antibiotic 
• Mix 
• Filter sterilise with 0.22 #m filter  
• Store at 37 °C 
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1. Analysis of Mycobacterium smegmatis SOS Response Regulation 
In preliminary work conducted during my BSc(Med)(Hons) degree, a 
translational reporter construct comprising Mycobacterium smegmatis (Msm) 
ImuA’ tagged at the N-terminus with Venus fluorescent protein (VFP) 
(∆imuA’::vfp-imuA’) had been constructed but not extensively tested in live 
Msm cells (Reiche, et al., unpublished). Moreover, the tagging of ImuB with a 
fluorescent protein (FP) had not been attempted since it posed a greater design 
challenge given the location of imuB within a putative imuA’-imuB operon 
(Warner, et al., 2010) that was predicted to be regulated by a single SOS box 
located as part of the imuA’ gene (Davis, et al., 2002). Therefore, prior to the 
development of a labelled ImuB-expressing construct, it was necessary to 
identify a suitable FP to be used to tag ImuB. To confirm that the selected FP 
was functional within Msm, a construct that did not include ImuB was 
developed as an experimental control. In addition, it was necessary to define a 
suitable promoter that would result in DNA damage-dependent expression of 
ImuB alone in future experiments. To this end, PSOS(imuA’)-egfp was designed 
and consisted of the imuA’ promoter, P(imuA’), driving expression of the 
enhanced green fluorescent protein gene (egfp) alone. The upstream promoter 
sequence exclusively included imuA’ regulatory sequence to prevent potential 
complications associated with employing the operonic imuB promoter in the 
absence of an upstream imuA’ open reading frame (ORF) (Chapter II, Section 
8.1). The use of the imuA’ promoter was considered appropriate for the 
following reasons: (i) as noted above, the imuA’-imuB operon was predicted to 
be regulated by a single SOS box located within the imuA’ gene (Davis, et al., 
2002) (see Chapter II, Table 2-7); and (ii) the ORF of imuB overlaps with that of 
imuA’, therefore altering the 5’ sequence of imuB would result in the alteration 
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the 3’-end of imuA’. Refer to Figure 3-1 for a graphical depiction of the genomic 
context of imuA’ and imuB within Msm and for a comparison of selected 
fluorescent constructs presented in this chapter. 
 
 
Figure 3-1 | Schematic representation of Msm imuA’ and imuB genes and fluorescent constructs  
a) The genomic context of wild-type Msm imuA’ and imuB. The promoter elements as well as ORFs are 
presented. Here, the over-lapping imuA’-imuB ORFs are transcribed from two different frames (denoted 
by the asterisk). Undefined imuB-specific promoter elements are located within imuA’. (b) The design of 
vfp-imuA’ utilizes the promoter of Msm imuA’ and controls a single VFP-ImuA’-encoding ORF. (c) The 
imuA’ promoter is again used to drive expression of egfp in the PSOS(imuA’)-egfp reporter construct and 
is the basis of (d) the PSOS(imuA’)-egfp-imuB construct that encodes EGFP-ImuB in the absence of imuB-
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EGFP was selected and used to design the PSOS(imuA’) fluorescent reporter 
owing to its excellent fluorescent properties (Cormack, et al., 1996) and 
consistent use in the literature. The purpose of the resultant PSOS(imuA’)-egfp 
construct was three-fold: (i) to identify whether the imuA’ promoter could be 
used as a robust promoter to regulate expression of egfp in the presence of 
genotoxic stress, and so could be applied in the design of future constructs; (ii) 
to validate EGFP for use in hybrid constructs and as an experimental control in 
the event that fluorescence was lost following tagging of a specific mutasome 
protein such as ImuB; and (iii) to study the regulatory dynamics of P(imuA’) 
using flow cytometry to assess induction of the mutasome SOS response in 
individual bacilli.  
 
1.1. Detection of imuA’ Promoter-dependent EGFP Expression by 
Microscopy 
Following the introduction of the PSOS(imuA’)-egfp transcriptional reporter 
construct into wild-type (WT) Msm, the first objective was to demonstrate DNA 
damage-inducible fluorescence of the resultant WT::PSOS(imuA’)-egfp strain, 
thus confirming both the function of EGFP and the use of P(imuA’) in future 
constructs. To this end, WT::PSOS(imuA’)-egfp and a WT (negative 
fluorescence) control were assessed by fluorescence confocal microscopy 
following exposure to mitomycin C (MMC) to induce genotoxic stress (1× 
minimum inhibitory concentration, MIC, for 2.5 h) (Figure 3-2). Both MMC-
treated and untreated WT bacilli were indistinguishable, indicating that the 
presence of MMC in the media did not inherently induce auto-fluoresence of 
Msm. By comparison, when WT::PSOS(imuA’)-egfp was exposed to 1× MIC  
 
Chapter III 164 
 
Figure 3-2 | Exposure of Msm to MMC induces expression from the imuA’ promoter 
Confocal fluorescent micrograph of the indicated Msm strains before and after exposure to genotoxic 
stress. Green fluorescence was detected by imaging WT (left) and WT::PSOS(imuA’)-egfp (right), both 
without (top) and with (bottom) exposure to 1× MIC MMC for 2.5 h. Images were captured at 100× 
magnification using a 1.4 NA oil objective lens. Overlaying fluorescent signal onto brightfield images 
generated micrographs. The scale bar in the bottom-right of each frame indicates 10 μm. 
 
MMC for 2.5 h, sample-wide green fluorescent bacilli were observed. Previous 
transcriptional studies (Warner, et al., 2010) demonstrated that imuA’ was 
tightly regulated as part of the mycobacterial SOS response; therefore, the 
considerable increase in green fluorescence in WT::PSOS(imuA’)-egfp bacilli 
following exposure to MMC indicated that the promoter was functional. This 
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future constructs requiring the expression of mutasome components. In 
addition, it validated the use of EGFP as a fluorescent protein in Msm and 
suggested the potential utility of WT::PSOS(imuA’)-egfp as an SOS reporter 
mutant. 
 
1.2. Using Flow Cytometry to Quantify the Level of Expression from the 
imuA’ Promoter 
Next, it was necessary to validate the use of WT::PSOS(imuA’)-egfp as an SOS 
reporter. To this end, flow cytometry was adopted in the expectation that it 
would allow rapid, population-wide investigation of changes in mutasome 
expression in Msm bacilli in response to varying conditions of genotoxic stress 
by detection of green fluorescence within individual bacilli. It would also 
enable insight into the level of induction of P(imuA’) and confirm the use of the 
PSOS(imuA’)-egfp construct for downstream analyses of mutasome expression, 
recruitment, and localization. Specifically, it was envisaged that flow cytometry 
would be used to quantify the level of expression from P(imuA’) and to test the 
hypothesis that different MMC concentrations and exposure periods would 
result in different levels of EGFP expression in Msm as a function of induction 
of the imuA’ promoter (a proxy of mutasome expression) by the SOS response. 
 
1.2.1. Flow Cytometry Can be Used to Detect Differences in 
Expression of EGFP 
A pilot experiment was conducted to validate the use of flow cytometry as an 
analytical tool to measure EGFP expression levels. The secondary aim of this 
experiment was to determine if changes in the EGFP expression level of 
individual bacilli within an entire population could be detected by flow 
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cytometry. This would prove beneficial over other batch-culture methods such 
as real-time polymerase chain reaction (PCR) which provide average readings 
for a large number of cells. The pilot experiment was based on the premise that 
an increasing concentration of MMC would result in detectable changes in 
P(imuA’) induction, as suggested by previous transcriptional data (Warner, et 
al., 2010). The underlying experimental hypothesis was that the population-
wide green fluorescent signal in WT::PSOS(imuA’)-egfp bacilli would respond 
proportionally to the amount of MMC applied. 
 
Bacilli were exposed to MMC at a concentration of 0, 0.5, 1.0, 2.0, or 10× MIC 
for 2.5 h before cells were fixed in 4 % formaldehyde and analysed by flow 
cytometry. Figure 3-3a presents the increase in EGFP signal measured in 
WT::PSOS(imuA’)-egfp cells in response to the increasing dose of MMC. 
Unexposed cells had a baseline geometric mean of 100 arbitrary fluorescence 
units (AFU), which was 20 AFU more than WT and indicated a low-level basal 
expression during normal growth conditions. In comparison, all cultures of 
WT::PSOS(imuA’)-egfp exposed to MMC exhibited elevated levels of green 
fluorescence signal. Cells exposed to 0.5, 1.0, 2.0, and 10× MMC yielded 
increasing geometric mean EGFP signal levels of 890, 1100, 1400, and 1800 AFU, 
respectively. A direct comparison of 0× and 10× MMC is presented in Figure 
3-3c. As before, WT was included as a fluorescence negative control for 
comparison purposes (Figure 3-3b and Figure 3-3d). Regardless of the MMC 
dose, the detectable green fluorescence signal in WT cells did not vary: WT 
exposed to 0×, 1.0×, and 10× MIC MMC resulted in geometric mean EGFP 
signal levels of 64, 84, and 80 AFU, respectively. This pilot experiment therefore 
indicated that EGFP expressed following induction of P(imuA’) could be 
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detected at the individual cell level,  reinforcing the utility of WT::PSOS(imuA’)-
egfp as a fluorescence-based reporter. 
 
 
Figure 3-3 | Changes in EGFP expression level in the imuA’ reporter strain can be detected using flow 
cytometry 
The x-axis of each graph represents the relative intensity/magnitude of green fluorescence signal 
detected; the y-axis represents the histogram, indicating the percent of the maximum that falls into each 
category in the x-axis. (a) WT::PSOS(imuA’)-egfp treated with different concentrations of MMC. Red = 
0×; navy blue = 0.5×; green = 1.0×; orange = 2.0×; and light blue = 10× MIC. (b) WT treated to 0× 
(red); 1.0× (navy blue); or 10× (green) MIC MMC. (c) Comparison of WT::PSOS(imuA’)-egfp (red) and 
WT (navy blue) exposed to 10× MIC. (d) Comparison of WT::PSOS(imuA’)-egfp (red) and WT (navy blue) 
without exposure to MMC. Events were detected by forward (400 V) and side scatter (310 V) correlation 
until 1,000,000 events had been recorded. EGFP signal was detected under the FITC parameters 
(excitation: 488 nm; emission: 507 nm; 557 V) with no compensation. The associated event rate was 
15,000 events per second. Cells were fixed in 4 % formaldehyde prior to acquisition. 
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1.2.2. Expression Dynamics of imuA’ 
Having established the utility of flow cytometry in measuring the response of 
the WT::PSOS(imuA’)-egfp reporter strain to genotoxic stress, the next step was 
to perform more elaborate and accurate dose- and time-response experiments 
to determine whether imuA’ was transcribed proportionally to the amount of 
DNA damage incurred. These experiments would also serve the purpose of 
identifying the optimal conditions (i.e., MMC dose and exposure time) that 
yield detectable levels of fluorescent protein for future analyses. 
 
1.2.2.1. Induction of imuA’ Increases as a Function of Time 
During Genotoxic Stress 
In the first of two large-scale experiments, the aim was to quantify the extent to 
which P(imuA’) was induced following exposure of bacilli to genotoxic stress 
for increasing periods of time. This was achieved by measuring the level of 
EGFP expressed by WT::PSOS(imuA’)-egfp as a proxy for ImuA’ (and 
mutasome) expression. The hypothesis was that the magnitude of 
PSOS(imuA’)-egfp induction would be proportional to the duration of MMC 
exposure. To this end, cultures of WT::PSOS(imuA’)-egfp were treated with 
MMC at 1× MIC for varying periods of time (5,  15, and 30 min, and 1, 2, 4, 6, 
12, and 24 h) before being fixed in 4 % formaldehyde for 30 min. Each sample 
was then filtered through a 30 %m cell strainer to remove objects that would 
obstruct the flow through the instrument or cause blockage, before analysis by 
flow cytometry. The green fluorescence (FITC-A:GFP) intensity of each 
acquisition was recorded and, after acquisition, the geometric means for FITC-
A:GFP (green fluorescence) intensity were determined as the data acquired in 
a single run were log-normally distributed. The mean and 95 % confidence 
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interval (CI) calculated from all six geometric mean fluorescence intensities at 
each time point is plotted in the graph in Figure 3-4 as a function of the 
treatment duration. The cells required approximately 30 min of exposure to 
MMC before increased expression of EGFP was detectable. Between 30 min and 
6 h there was a positive linear correlation between the mean fluorescence of the 
population and the duration of exposure to MMC (∆y/∆x = 356.48 AFU per 
hour, R2 = 0.92). Maximal EGFP expression was detected after 6 h, which 
correlated with approximately two generation times in exponential growth- 
phase Msm (Aldridge, et al., 2012; Santi, et al., 2013). In addition, a decrease in 
fluorescence intensity of 25.78 % was observed between 6 and 12 h. Bacilli 
exposed to MMC for 24 h could not be analysed using flow cytometry as the 
cells could not be passed through a 30 %m cell strainer, suggesting the possible 
induction of a filamentous state (Section 3, below). 
 
 
Figure 3-4 | Time response of the imuA’ promoter to MMC 
Level of EGFP expression from PSOS(imuA’) as a function of time following exposure to MMC. The time-
response graph presents the results of flow cytometric analysis of the level of EGFP expressed by 
WT::PSOS(imuA’)-egfp following exposure to the MIC of MMC (y-axis) for various periods of time (x-
axis, log scale). Each point represents the average geometric mean of 6 repeats. The error bars represent 
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1.2.2.2. The imuA’ Promoter Responds Proportionally to the 
Dose of Genotoxic Stress 
The second aspect of characterising the imuA’ promoter required an assessment 
of the genotoxic dose response of P(imuA’). The aim of this experiment was to 
quantify the level of EGFP expression under control of P(imuA’) following 
exposure of WT::PSOS(imuA’)-egfp to different concentrations of MMC for a 
fixed period of time. It was expected that this would yield insight into the 
expression dynamics of the imuA’ promoter and was based on the hypothesis 
that EGFP expression would increase in proportion to the amount of DNA 
damage incurred. Therefore, WT::PSOS(imuA’)-egfp cultures were treated to 
varying concentrations of MMC for 4 h before fixation and analysis by flow 
cytometry. An exposure duration of 4 h was selected to ensure sufficient time 
for the SOS response to be induced and for detectable levels of EGFP to be 
translated (see Section 1.2.2.1). As before, the FITC-A:GFP detection 
parameters were used to quantify the relative levels of EGFP expressed in 
individual cells. The geometric mean green fluorescence intensity of each 
acquisition for each sample was determined (Figure 3-5), with mean and 95 % 
CI of the geometric mean level of EGFP signal plotted as a function of MMC 
concentration. From these results, it was apparent that the dose response 
comprised three different phases: a positive linear relationship was evident 
between 0 and 0.1× MIC (∆y/∆x = 5563.7.48 AFU per MIC factor, R2 = 0.99); 
between 1 and 5× MIC, a static relationship existed whereby no statistically 
significant change in the level of EGFP expression in the population was 
detected (P = 0.095, Student’s t-test); finally, at 10× MIC and greater, there was 
a rapid decrease in the mean green fluorescence intensity detected by flow 
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cytometry. This established that maximal expression of EGFP from the imuA’ 
promoter corresponded with inhibitory but sub-lethal concentrations of MMC. 
 
 
Figure 3-5 | Dose-response of the imuA’ promoter to MMC 
SOS-dependent fluorescence intensity correlates with genotoxin dose over sub-MIC range in Msm. This 
dose-response graph represents the results of the cytometric analysis of the level of EGFP expressed by 
WT::PSOS(imuA’)-egfp (y-axis) following exposure to various concentrations of MMC (x-axis, log scale) 
for 4 h. Each point represents the average geometric mean of 6 repeats. The error bars represent the 
95 % CI.  
 
2. A Modified Sequence Encoding EGFP-ImuB 
The demonstrated utility of the PSOS(imuA’)-egfp construct supported the 
continuation of efforts to develop a fluorescently tagged ImuB translational 
reporter construct. In addition, the WT::PSOS(imuA’)-egfp transcriptional 
reporter (Figure 3-2) provided a useful control in evaluating any attempt to link 
a mutasome component such as ImuB to EGFP in constructing a translational 
reporter. To this end, a new construct was designed to express EGFP-tagged 
ImuB and was based on the PSOS(imuA’)-egfp construct (Figure 3-1). As before, 
the imuA’ promoter was utilized to drive expression of the downstream ORF, 
which consisted of egfp – thus far identical to the PSOS(imuA’)-egfp construct – 
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spacer sequence. The full-length PSOS(imuA’)-egfp-imuB construct was inserted 
into a mycobacterium-specific integrative plasmid, pMCAINT (Warner, et al., 
2010), and the resulting construct was electroporated into Msm DimuB (Warner, 
et al., 2010) in order to assess the function of the encoded EGFP-ImuB protein 
in the absence of the WT imuB allele. It was imperative to confirm that the 
respective hybrid proteins maintained biological function to ensure that any 
inferences from fluorescence localization experiments were representative of 
the biological response being assessed.  
 
2.1. N-terminally Labelled ImuB Controlled by P(imuA’) Maintains 
Function in Inducible Mutagenic DNA Repair 
Mutagenesis assays to assess the mutagenic capacity of experimental Msm 
strains were performed as previously described (Warner, et al., 2010; Boshoff, 
et al., 2003), and involved the determination of rifampicin (RIF)-resistance 
frequencies following exposure to genotoxic stress. In this assay, the ability of 
the mutasome to generate mutations following DNA damage is measured 
through the development of RIF-resistance (conferred as single nucleotide 
polymorphisms, SNPs, and insertion-deletion events, indels, in rpoB; Boshoff, 
et al., 2003) after ultraviolet (UV) irradiation of bacilli. Experiments were  
conducted on ∆imuA’::vfp-imuA’ (Reiche, et al., unpublished) and 
∆imuB::PSOS(imuA’)egfp-imuB, as well as WT, and ∆imuA’ and ∆imuB deletion 
mutants as experimental controls. The previously developed ImuA’ reporter 
strain, ∆imuA’::vfp-imuA’, was included here to confirm function of VFP-
ImuA’. The mean frequencies and associated standard deviations (SDs) of RIF-
resistance are indicated in Figure 3-6. WT Msm exposed to 25 mJ.cm-2 exhibited  
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Figure 3-6 | Labelled mutasome components maintain mutagenic capacity 
Inducible mutation frequencies of various fluorescent strains of Msm. (a) Representative photographs of 
the number of colonies grown on 200 μg/ml RIF-containing plates. The visible colonies represent the 
number of RIF-resistant mutants in 250 μl of UV-exposed culture after 5 days of growth. (b) The mutation 
frequency is represented by the frequency of RIF resistance (y-axis, log-scale) for each strain (x-axis). 
Each point represents the result of a single sample and the error bar represents the SD calculated for 
each strain. Zero-values are not presented on the log-scale. 
 
a mean inducible mutation frequency (MIMF) of approximately 9.49×10-7 while 
∆imuA’ and ∆imuB had MIMFs of 3.99×10-8 and 2.66×10-8, respectively. 
Specifically, the MIMF for WT was 23.8-fold and 35.7-fold greater than ∆imuA’ 
and ∆imuB, respectively, consistent with previous observations (Warner, et al., 
2010). The corresponding deletion mutants complemented with experimental 
FP-tagged alleles yielded MIMFs of 2.05×10-6 for ∆imuA’::vfp-imuA’ and 
1.27×10-6 for ∆imuB::PSOS(imuA’)-egfp-imuB. The MIMF of ∆imuA’::vfp-imuA’ 
was 2.16-fold greater than WT and 51.3-fold greater than ∆imuA’. Similarly, the 
MIMF of ∆imuB::PSOS(imuA’)-egfp-imuB was 1.33-fold and 47.6-fold greater 
than those of WT and ∆imuB, respectively. Therefore, both complemented 
strains exhibited mutation frequencies that were comparable to WT, thus 
confirming function of the FP-tagged mutasome proteins. This was an 
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fluorescent tag did not appear to impede the function of either ImuA’ or ImuB 
during mutasome-dependent mutagenesis and further established the 
potential utility of the FP-tagged proteins for downstream assays of expression 
dynamics and protein localization in live Msm cells. 
 
2.2. N-terminal Labelling of ImuB Impacts DNA Damage Tolerance 
A second functional role of the mutasome is to increase the tolerance of Msm 
bacilli to genotoxic stress. That is, prior work has demonstrated that deletion 
mutants lacking any one of the mutasome components (DnaE2, ImuB, or 
ImuA’) are hypersusceptible to genotoxic stress (Warner, et al., 2010; Boshoff, 
et al., 2003). Therefore, it was necessary to test whether the EGFP tag had 
impacted this function of the ImuB protein in the ∆imuB::PSOS(imuA’)-egfp-
imuB complemented strain. The DNA damage tolerance of the ∆imuA’::vfp-
imuA’ mutant had been characterized as part of previous work (Section 6.1, 
Supplementary Figure S1) (Reiche, et al., unpublished); therefore, DNA 
damage tolerance assays were conducted on ∆imuB::PSOS(imuA’)-egfp-imuB 
(Figure 3-7). WT Msm exhibited growth at a maximum dilution factor of 103 
(~2.7×107 colony forming units, CFU, per ml) on 0.04 %g/ml MMC and 105 on 
0.02 %g/ml MMC. In comparison, ∆imuB was at least 10-fold more susceptible, 
failing to grow beyond a dilution of 101 and 103 on 0.04 %g/ml and 0.02 %g/ml 
MMC, respectively. Again, these results were consistent with prior 
observations (Warner, et al., 2010). Unexpectedly, despite the ability of the 
PSOS(imuA’)-egfp-imuB allele to complement loss of mutagenic capacity 
(Figure 3-6), the same construct did not result in a detectable decrease in MMC 
susceptibility when compared to the ∆imuB parental strain. Instead, the 
∆imuB::PSOS(imuA’)-egfp-imuB and ∆imuB strains had similar growth on 
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MMC-supplemented solid media: growth at a maximum dilution of 103 on 0.02 
%g/ml and 101 on 0.04 %g/ml MMC. This was 2-log10 less than the growth of 
WT on 0.02 %g/ml MMC and 1-log10 less than the growth of WT Msm on 0.04 
%g/ml MMC. This result was surprising and indicated that the modified imuB 
allele of PSOS(imuA’)-egfp-imuB did not maintain WT functionality with respect 
to tolerance of DNA damage. The reason for this was not clear and may have 
resulted from the EGFP tag partially disrupting function of the ImuB N-
terminus or from a change in the regulation and expression of the fusion 
protein under sustained genotoxic stress on solid medium. 
  
 
Figure 3-7 | DNA damage tolerance assay of ΔimuB::PSOS(imuA’)-egfp-imuB 
The photographs indicate the growth of Msm colonies (white) on 0.02 μg/ml (top) and 0.04 μg/ml 
(bottom) MMC-containing media (black) after serial dilution. The spotting order of each dilution factor 
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2.3. EGFP Linked to the N-terminus of ImuB Maintains Fluorescent 
Capacity 
The restoration of mutagenic capacity in ∆imuB::PSOS(imuA’)-egfp-imuB 
indicated that the EGFP-ImuB fusion protein retained biological function in 
mutgenesis assays, but not damage tolerance. This result supported 
progression of this work to an evaluation of the fluorescence function of the 
EGFP tag. To this end, Msm strains were visualized under a fluorescent 
confocal microscope following induction of the SOS response by exposure to 
MMC for 4 h (equating approximately to one generation time and one round 
of chromosome replication; Aldridge, et al., 2012; Santi, et al., 2013). In this 
experiment, the hypothesis was that, upon exposure of ∆imuB::PSOS(imuA’)-
egfp-imuB to MMC for 4 h, green fluorescent signal generated by EGFP-ImuB 
would be detected, indicating functional fluorescence of the hybrid reporter 
protein. In addition, the previously generated ∆imuA’::vfp-imuA’ strain was 
assessed for yellow fluorescent signal the same way by growing 5 ml cultures 
in the presence of 2× MIC MMC for 4 h to incur DNA damage. Representative 
images of both untreated and MMC-exposed ∆imuA’::vfp-imuA’ and 
∆imuB::PSOS(imuA’)-egfp-imuB are presented in Figure 3-8. Following 
exposure of ∆imuA’::vfp-imuA’ to MMC, a diffuse yellow fluorescent signal (514 
nm excitation and 538 nm emission) was observed throughout each bacillus. 
This suggested that VFP-ImuA’ signal was present throughout the cytoplasm 
of the cell. In contrast, visualisation of ∆imuB::PSOS(imuA’)-egfp-imuB after 
exposure to MMC revealed confinement of the green fluorescent signal to 
specific punctate foci within each bacillus. That is, cells with detectable levels 
of EGFP signal were characterized by clearly defined green fluorescence ‘foci’.  
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Figure 3-8 | Expression and location of fluorescently tagged mutasome components 
Fluorescent micrographs of the ImuA′ and ImuB localization. The in vivo localization of the mutasome 
accessory proteins during mutagenic DNA repair. (a) VFP-ImuA′ fluorescence of ΔimuA’::vfp-imuA’ in 
the presence (top row) or absence of MMC (bottom row). Left pane illustrates brightfield micrographs 
of bacilli; middle pane shows detected yellow fluorescence; right pane is an overlay of yellow 
fluorescence signal and brightfield micrographs. (b) EGFP-ImuB fluorescence of ΔimuB::PSOS(imuA’)-
egfp-imuB in the presence (top row) or absence of MMC (bottom row). Left pane illustrates brightfield 
micrographs of bacilli; middle pane shows detected green fluorescence; right pane is an overlay of green 
fluorescence signal and brightfield micrographs. Scale bars represent 5 μm. 
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In general, these foci appeared to be located within the interior of the bacilli as 
opposed to near the cell poles. A large majority of cells exposed to MMC 
contained at least one focus of EGFP-ImuB signal. Bacilli with cell lengths 
greater than the standard Msm size of ~4 %m (Gordon and Smith, 1953; Santi 
and McKinney, 2015) were associated with multiple, distinct foci. In these 
cases, it appeared that one focus was often larger than the others. The 
contrasting fluorescence profiles of ∆imuB::PSOS(imuA’)-egfp-imuB and 
∆imuA’::vfp-imuA’ indicated a difference in the location of each respective 
protein. Notably, the fact that the same focus formation was not observed with 
the PSOS(imuA’)-egfp reporter construct (which expressed EGFP without being 
linked to the ImuB protein; Figure 3-2) suggested that localization was due to 
the presence of ImuB, and not due to the formation of non-specific EGFP 
aggregations or inclusions. A third mutasome reporter strain, ∆dnaE2::egfp-
dnaE2 was also constructed, but this did not yield observable green 
fluorescence after multiple attempts (data not shown) and was abandoned in 
favor of a thorough investigation of ImuB, the predicted, central adapter 
protein of the mutasome (Warner, et al., 2010) (Chapter I, Figure 1-5). 
 
2.4. ImuB Localizes to Specific Points within Bacilli During the DNA 
Damage Response 
To confirm that the apparently specific localization of EGFP foci following 
exposure of ∆imuB::PSOS(imuA’)-egfp-imuB to MMC was a function of ImuB, it 
was necessary to generate an alternative reporter in which ImuB was tagged 
with a different FP. To this end, ∆imuB::PSOS(imuA’)-mEos4a-imuB was 
developed by replacing egfp with a gene encoding the photoconvertible FP, 
MEos4a. This FP was chosen as it is not derived from GFP, and thus does not 
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share significant sequence homology with EGFP. Consequently, the potential 
for non-physiological localization of the fusion protein as a consequence of 
fluorescence tagging with unrelated FPs was considered highly unlikely. 
 
The hypothesis for this experiment was that fluorescent foci of MEos4a would 
be visible, replicating the foci observed previously during EGFP-ImuB 
expression. Confocal fluorescent micrographs of representative 
∆imuB::PSOS(imuA’)-mEos4a-imuB cells in the absence or presence of MMC are 
presented in Figure 3-9. Similar to EGFP-ImuB, fluorescence foci were present 
following the exposure of ∆imuB::PSOS(imuA’)-mEos4a-imuB to 1× MIC MMC 
for 4 h (Figure 3-9a, middle panel). As a photoconvertible fluorescent protein, 
exposure of MEos4a to low levels of UV light converted the fluorophore into a 
‘converted’ state (Paez-Segala, et al., 2015). Specifically, MEos4a is converted 
from a native, green fluorescent state to a red fluorescent state. This was 
achieved by exposing the field of view to low-intensity UV light (390 nm 
epifluorescent light) for 30 s (Figure 3-9a, right panel; and Figure 3-9b, bottom). 
It was evident that the green MEos4a-ImuB foci photoconverted to the red- 
fluorescent state (Figure 3-9a), resulting in congruent red fluorescent foci that 
exhibited an activation contrast of 10.16× (Figure 3-9b and Figure 3-9c), defined 
as the ratio of the signal intensity after UV-photoconversion to the signal 
intensity before conversion. The presence of MEos4a-ImuB foci following 
MMC treatment strongly suggested that the location of the fluorescent focus 
was a function of SOS-dependent ImuB expression and recruitment, and was 
not a spurious consequence of the FP tag. This observation was further 
supported by the previous demonstration that untagged EGFP protein 
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expressed from P(imuA’) during DNA damage did not localize into observable 
foci within the WT::PSOS(imuA’)-egfp bacilli. 
 
 
Figure 3-9 | Photoconverion of MEos4a tagged ImuB 
(a) Micrographs of MEos4a-ImuB foci fluorescence conversion. Each micrograph consists of a brightfield 
image overlayed with both green and red fluorescent signal from ΔimuB::PSOS(imuA’)-mEos4a-imuB. 
The left-hand pane indicates the lack of fluorescence observed in the absence of MMC. The two panes 
on the right illustrate different fluorescent states of the MEos4a-ImuB protein before (center) and after 
(right) UV light photoconversion following exposure to 1× MIC MMC for 4 h. Scale bars represent 5 μm. 
(b) Red fluorescent micrographs of MEos4a-ImuB-expressing bacilli before (top row) and after (bottom 
row) conversion by UV light. The left pane illustrates a full field of view, while the right pane indicates a 
single bacillus (demarcated by the grey dotted line). The area marked by the yellow rectangle indicates 
the region of interest used to plot the fluorescent intensity profile represented in the graph in (c). In this 
graph, the red plotted line illustrates the red fluorescent intensity following UV light conversion of 
MEos4a; while the black plot illustrates the red fluorescent intensity before photoconversion. The peak 
of red fluorescence following UV conversion corresponds to the location of the fluorescent MEos4a-
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2.5. Superresolution Imaging Confirms Formation of ImuB Foci in SOS-
active Mycobacterial Cells 
The photoswitchable MEos4a tag provided the opportunity to visualize ImuB 
foci using superresolution three-dimensional interferometric photo-activated 
light microscopy (3D-iPALM) (Shtengel, et al., 2009). Indeed, because the large 
photoconversion activation contrast of MEos4a-ImuB was in excess of the 
requisite four-fold difference (Jesse Aaron, personal communication, 2015), 
∆imuB::PSOS(imuA’)-mEos4a-imuB presented an ideal sample for iPALM 
imaging. Consequently, cultures of ∆imuB::PSOS(imuA’)-mEos4a-imuB were 
exposed to 5× MIC MMC for 8 h to induce maximal expression of the mutasome 
before cells were fixed in 0.5% paraformaldehyde and prepared for iPALM 
imaging.  
 
Bacilli were imaged and fluorescent MEos4a-ImuB foci were resolved with a 
resolution near 20 nm (comparison presented in Figure 3-10a). Despite the 
increase in resolving power, an underlying macromolecular structure was not 
easily resolved in any cells imaged. Clearly separated foci were determined to 
be 287 ± 32.75 nm (mean ± SD) in size as measured by full-width, half maximum 
along the axis of the cell (data not shown). It was also evident that large foci 
observed under epifluorescence microscopy often consisted of two separate 
foci when resolved using iPALM localization (Figure 3-10b). An interesting 
observation was made during the imaging of Msm by this technique: that is, it 
consistently appeared that the bacilli were located ~200 nm above the coverslip, 
preventing the use of total internal reflection fluorescence (TIRF) imaging for 
data acquisition. Addressing this anomaly was not within the scope of this 
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Figure 3-10 | Superresolution images of ImuB foci in Msm 
3D-iPALM images of bacilli expressing MEos4a-ImuB. (a) The fluorescent signals imaged from MEos4a-
ImuB foci were resolved to 20 nm, allowing detailed observation of foci (right) – marked increase over 
standard fluorescent microscopy (left). However, no underlying structure was observed. Scale bars 
represent 200 nm. Signal intensity of 2D iPALM render represents the Total Molecule Probability and 
ranges from minimum (black) to maximum (white) red fluorophore molecules/nm2. (b) A single bacillus 
(demarcated by grey, dotted line) when imaged by 3D-iPALM illustrates that often large MEos4a-ImuB 
foci consisted of two smaller foci. Scale bars represent 1 μm.  
 
work nor supportable given the limited time frame for accessing the iPALM 
system at the Janelia Research Campus of the Howard Hughes Medical Institute. As 
a result, the cause and potential solution were not investigated; however, it is 
important to note that this could represent a biologically significant 
observation or that the sample preparation affected the sample in an unknown 
manner. Regardless, iPALM imaging further illustrated specific recruitment of 
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b)
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ImuB within Msm; however, it was not possible to discern any clear pattern of 
distribution of foci, nor did the foci themselves permit any inference regarding 
mechanism of polymerization or aggregation. However, limited and time-
restricted access to the iPALM instrument precluded further investigation, and 
future work into exploring a possible pattern of ImuB recruitment is 
recommended. Future iPALM experiments should utilise a second protein of 
interest, such as dronpa-dnaN, to view recruitment of ImuB to the β clamp in 
superresolution and resolve the association of the two proteins. Additionally, 
it would be worthwhile to consider statistical methods (i.e., Rubin-Delanchy, et 
al., 2015) to analyse and identify if there is any pattern that could indicate a 
mechanism of ImuB-DnaN assembly. 
 
2.6. ImuB Co-localizes with the β clamp in Msm During Mutagenic DNA 
Repair  
The observation that ImuB localized to specific locations within bacilli 
suggested that these foci might indicate sites of active mutagenic DNA repair. 
Previous work (Warner, et al., 2010) provided compelling genetic evidence for 
a direct protein-protein interaction (PPI) between ImuB and the dnaN-encoded 
β clamp, and further suggested that this interaction was essential for 
mutasome-dependent mutagenesis. To investigate the inferred ImuB-β clamp 
interaction further, we utilized the Msm mCherry-dnaN strain expressing an 
MCherry-tagged variant of DnaN, which homodimerizes to form the β clamp 
processivity factor. The mCherry-dnaN reporter mutant has been used 
previously to visualize the location of the replicative machinery and active 
replication forks (Santi, et al., 2013; Santi and McKinney, 2015). Both the 
pAINT::vfp-imuA’ and pMCAINT::PSOS(imuA’)-egfp-imuB plasmids were 
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introduced into the mCherry-dnaN mutant, resulting in the generation  
of mCherry-dnaN::vfp-imuA’ and mCherry-dnaN::PSOS(imuA’)-egfp-imuB, 
respectively. Please refer to Table 3-1 for a clarification of strains used in this 
experiment.  
 
Table 3-1 | Phenotypes of and alleles present within fluorescent mutants of Msm 
Strain name Genotype Fluorescence phenotype 
imuA’ allele imuB allele dnaN allele 
mc2155 wt wt wt ImuA’  ImuB  DnaN 





wt ImuA’  ImuB  DnaN 
mCherry-dnaN wt wt mCherry-dnaN ImuA’  ImuB  DnaN 
mCherry-dnaN::vfp-imuA’ wt, 
vfp-imuA’ 







mCherry-dnaN ImuA’  ImuB  DnaN 
wt, wild-type allele of the corresponding gene found in mc2155 (Cole, et al., 1998) 
 
As the mCherry-dnaN strain already contained a full complement of Msm genes, 
the resulting dual reporter mutants contain the WT alleles (wt) of both imuA’ 
or imuB (at the native genomic location) as well as the hybrid gene vfp-imuA’ or 
PSOS(imuA’)-egfp-imuB located at the attB-integrative site, respectively. 
Therefore, mutagenesis assays were conducted on both mutants to confirm that 
the merodiploids retained biological function, and to evaluate the potential 
impact of the MCherry-DnaN protein on inducible mutagenesis (Figure 3-11a). 
All three DnaN-tagged strains resulted in similar MIMFs after exposure to UV 
irradiation: the MIMF of mCherry-dnaN was 5.40×10-7, while mCherry-dnaN::vfp-
imuA’ and mCherry-dnaN::PSOS(imuA’)-egfp-imuB had MIMFs of 7.32×10-7 and 
4.75×10-7, respectively. This result indicated that the merodiploids had similar 
inducible mutation frequencies to mutants that contained only one variant of 
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the mutasome genes, albeit with a log10 decrease of 0.431 when compared to 
WT mc2155.  
 
 
Figure 3-11 | DnaN-MCherry and EGFP-ImuB associate during genotoxic stress 
(a) Validation of mCherry-dnaN by mutagenesis assay. The inducible mutation frequency is represented 
by the frequency of RIF-resistance (y-axis, log-scale) for each strain (x-axis). Each point represents the 
result of a single sample and the error bar represents the SD calculated for each strain. Zero-values are 
not presented on the log-scale. (b) Co-localization of EGFP-ImuB and MCherry-DnaN. Individual 
micrographs represent different light detection of the same field of view of mCherry-
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After confirming the mutagenic capacities of the mCherry-dnaN mutants, the 
mCherry-dnaN::PSOS(imuA’)-egfp-imuB dual reporter was visualized by 
confocal microscopy following induction of the SOS response with 1× MIC 
MMC (Figure 3-11b). Green fluorescent foci were detected which indicated the 
location of EGFP-ImuB while red fluorescent foci were used to infer the location 
of the β clamp (MCherry-DnaN) and, by implication, the active replication fork. 
When combined, the red and green fluorescent signals are viewed as yellow 
foci (Figure 3-11b, third frame), strongly indicating that EGFP-ImuB and 
MCherry-DnaN were in close proximity within a single bacillus, consistent 
with the physical interaction inferred previously by yeast two-hybrid (Y2H) 
analysis (Warner, et al., 2010). Notably, ImuB foci (green fluorescence) were 
always located where there was corresponding β clamp (red fluorescence) 
signal; from analysis of numerous fields of view, this requirement was never 
relaxed, suggesting the absolute dependency of ImuB on β for accurate 
recruitment. In turn, this observation supported the hypothesis that the 
location of EGFP-ImuB foci represent the sites of active mutagenic DNA repair. 
 
2.7. The Development of an ImuB Foci is Independent of a Functional 
Mutasome 
The use of recombinant fluorophore-protein fusions revealed the possibility 
that multiple mutasome complexes (inferred from EGFP-ImuB foci) could form 
in association with multiple replication forks (MCherry-DnaN) in a single 
bacillus during prolonged genotoxic stress. This prompted the hypothesis that, 
despite induction of the SOS response, genome replication continued – thereby 
explaining why multiple foci appeared to develop in a time-dependent 
manner. If this were the case, the only way the entire chromosome could be 
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replicated in the presence of extensive DNA damage would be if repair 
mechanisms allowed DNA synthesis to continue despite the presence of DNA 
lesions. In turn, this raised the intriguing possibility that a non-functional 
mutasome might result in stalled genome replication in the presence of severe 
DNA damage. That is, it might be plausibly predicted that multiple 
chromosomes would not form in a mutasome-deficient Msm strain during 
MMC treatment and multiple mutasome foci would not be visible. To test this 
hypothesis, ∆imuA’::PSOS(imuA’)-egfp-imuB, dnaE2AIA::PSOS(imuA’)-egfp-imuB, 
and ∆dnaE2::PSOS(imuA’)-egfp-imuB, all of which lack a functional mutasome 
(Warner, et al., 2010), were exposed to inhibitory concentrations of MMC for 3 
h and visualized using an epifluorescent light microscope (Figure 3-12). In 
contrast to the experimental hypothesis, more than one focus was evident in 
cells of all three mutasome-deficient strains (∆imuA’, ∆dnaE2, and dnaE2AIA) 
after only one generation. This result indicated that the formation of multiple 
 
 
Figure 3-12 | DNA damage-induced formation of multiple ImuB foci is independent of ImuA’ or DnaE2 
during prolonged MMC exposure 
Fluorescent EGFP-ImuB was imaged in different backgrounds of Msm following exposure to 1× MMC 
for 3 h. Left: Green fluorescence derived from ΔdnaE2::dnaE2AIA::PSOS(imuA’)-egfp-imuB bacilli after 
induction of the SOS response. Middle: Green fluorescent micrograph of ΔdnaE2::PSOS(imuA’)-egfp-
imuB. Right: Green fluoreacent signal detected from ΔimuA’::PSOS(imuA’)-egfp-imuB indicates the 
formation of multiple fluorescent foci in individual bacilli. Images were captured with a monochrome 
camera, with an 80× 1.2 NA objective lens. Scale bars represent 5 μm. 
 
dnaE2AIA ΔdnaE2 ΔimuAʹ
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mutasome complexes was not dependent on the repair of the chromosome by 
a functional mutasome. Importantly, this result also indicated that the 
formation of ImuB foci was independent of functional DnaE2 and ImuA’. 
 
2.8. ImuB Recruitment is Dependent on a Functional β Clamp-binding 
Domain 
In order to validate the inferred association between EGFP-ImuB and MCherry-
DnaN, it was necessary to confirm that the recruitment of ImuB to the β clamp 
could be prevented by a rational, genetic disruption. To this end, the putative 
β clamp-binding motif located within ImuB was mutated as described 
previously (Warner, et al., 2010), by alanine replacement of the essential 
QLPLWG residues  (Figure 3-13a). The resulting mutant, denoted 
∆imuB::PSOS(imuA’)-egfp-imuBAAAAG, contained a nonfunctional β clamp-
binding domain that would nevertheless allow visualisation of ImuB 
localization in the absence of the putative interaction with DnaN. Following 
induction of the SOS response in ∆imuB::PSOS(imuA’)-egfp-imuBAAAAG by 
exposure of bacilli to 2× MIC MMC for 4 h (Figure 3-13b, right panel), diffuse 
green fluorescence was observed throughout the cells and there was a clear 
absence of defined foci. When the level of fluorescence throughout randomly 
selected individual bacilli was quantified (Figure 3-13c), it was evident that 
there was increased fluorescence in the EGFP-ImuBAAAAG mutant, confirming 
induction of the egfp-imuBAAAAG allele, but that the mutant had lost the capacity 
to form clearly-defined foci. 
 
 
Chapter III 189 
 
Figure 3-13 | Disruption of ImuB-β clamp interaction eliminated EGFP-ImuB focus formation in Msm 
(a) Illustration of the mutated β clamp binding domain (AAAAG) in Msm. Red letters represent altered 
nucleotides and amino acids different from the WT (QLPLW) sequence. (b) The fluorescent reporter 
strain containing a mutated β clamp binding site within the imuB gene was exposed to MMC and imaged 
using an epifluorecscent microscope. Although ΔimuB::PSOS(imuA’)-egfp-imuBAAAAG exhibited green 
fluorescence, the bacilli did not produce observable foci following exposure to MMC and induction of 
the SOS response. Scale bars represent 5 μm. (c) Green fluorescent intensity profiles of randomly 
selected bacilli illustrating the lack of fluorescent foci and increased cell-wide fluorescence observed in 
ΔimuB::PSOS(imuA’)-egfp-imuBAAAAG. Light and dark green lines represent ΔimuB::PSOS(imuA’)-egfp-

















































































































































WT amino acid seq. · · · A   A   L  Q   L   P   L   W   G G · · ·
‘QLPLWG’ allele · · · GCG GCG CTG CAG TTG CCG TTG TGG GGT GGT · · ·
‘AAAAGG’ allele · · · GCG GCG CTG GCG GCG GCG GCG GGG GGT GGT · · ·
Mutant amino acid seq. · · · A   A   L  A   A   A   A   G G G · · ·
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3. DNA Replication and Repair in Filamentous Msm Cells During 
Prolonged DNA Damage  
While investigating the response of Msm to genotoxic stress as a function of 
time (Section 1.2.2.1), it became evident that Msm cells exposed to inhibitory  
 concentrations of MMC for 24 h were not able to pass through a 30 %m cell 
strainer. This suggested that the cells might be clumping or may have grown 
longer than 30 %m. To investigate these possibilities, the cells that were 
prepared for cytometric analysis were visualized using a brightfield cell 
imaging microscope (Figure 3-14). It was immediately evident that prolonged 
exposure to the genotoxin had induced a cell elongation phenotype, with many 
cells characterized by lengths in excess of 25 %m; in contrast, cells not exposed 
to MMC exhibited normal cell lengths of ±4 %m (Gordon and Smith, 1953; Santi 
and McKinney, 2015). In turn, this observation prompted a more thorough 
investigation into the genotoxicity-mediated cell elongation phenotype in Msm. 
 
 
Figure 3-14 | Light micrograph of Msm cell elongation following prolonged MMC exposure 
Brightfield images of WT::PSOS(imuA’)-egfp cells grown for 24 h either in the absence (left) or presence 
of 1× MIC MMC (right) as part of the time response experiment. Scale bars represent 25 μm. 
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3.1. Retrospective Analysis of Cell Length During MMC-exposure 
Experiments 
To test the hypothesis that exposure of Msm to MMC for extended durations 
resulted in cell elongation, all previous micrograph images were analyzed 
retrospectively. To achieve this, the length of every undistorted and discernible 
Msm bacillus exposed to inhibitory concentrations of MMC was manually 
measured and stratified by exposure duration. Figure 3-15a illustrates the 
individual cell lengths for samples not exposed to MMC (untreated), as well as 
cultures exposed to inhibitory concentrations of MMC for differing time 
periods from 3 to 48 h. It is necessary to point out that these results reflected 
the cell lengths of all Msm strains imaged during the course of this work (with 
the exception of the mutasome deletion mutants ∆imuA’, ∆imuB, and ∆dnaE2). 
Owing to the retrospective nature of this analysis, compounding factors such 
as growth phase, cell viability, and cell density were not accounted for: the aim 
was to obtain a cumulative picture of the propensity for filamentation in MMC-
treated bacilli. From this analysis, it was evident that cells grown in the absence 
of MMC had a median length of 4.7 %m and an interquartile range (IQR) of 1.8 
%m. The morphology of these cells represented the expected size of rod-shaped 
Msm bacilli over all phases of growth in 7H9-oxidase-albumin-dextrose-
catalase (OADC). When observing the lengths of cells exposed to inhibitory 
concentrations of MMC, it was clear that cell length increased with increasing 
duration of exposure. Msm exposed to MMC for 3 h exhibited a median cell 
length of 7.1 %m (IQR: 2.6 %m). The median cell length of bacilli exposed to 
MMC for 4 h was 1.71 times greater than that of unexposed cells (8.0 %m 
median; IQR of 2.6 %m). Exposure of Msm to MMC for 24 h was associated with  
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Figure 3-15 | Exposure of Msm to inhibitory concentrations of MMC increases the average cell length 
over time. 
(a) The length of cells measured during MMC exposure experiments. The length of individual cells was 
measured for Msm grown in the absence of MMC (untreated) (n = 196) and cells exposed to inhibitory 
concentrations of MMC (1× or 5× MIC) for 3 h (n = 189); 4 h (n = 160); 24 h (n = 48); and 48 h (n = 26). 
The median and IQR are indicated by the error bars. The classification of cell length is indicated on the 
right of the graph. (b) Stacked-bar graph representing the proportional population composition of Msm 
following exposure to MMC for different periods of time. Differing supra-inhibitory concentrations (1× 
or 5× MIC) of MMC was deemed not to significantly affect the length of cells (presented in 
Supplementary Figure S2). 
 
a considerable increase in median cell length (19.5 %m, 4.1 times greater than 
untreated cells) as well as distribution (IQR of 19.9 %m). Conversely, cells 
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lengths with a median of 5.7 %m but a comparatively large IQR of 5.5 %m. This 
discrepancy was likely due to the decreased stability of MMC in liquid growth 
media and, potentially, the death of bacilli owing to accumulated DNA 
damage. To investigate this, future experiments consisting of extended time 
points should include wash steps and resuspension of bacilli in media 
containing fresh MMC at regular intervals of 12 h. Furthermore, a dead-cell 
stain such as propidium iodide (Krämer, et al., 2016) could be used to 
enumerate the number of cells killed during extended MMC exposure times to 
determine if this was the cause of the decreased cell lengths following 48 h 
exposure periods. 
 
When comparing the frequency distribution of each subset of cells (Figure 3-
15a), it was evident that, with increasing duration of MMC exposure, there was 
a corresponding shift in the distribution towards longer cell lengths. The 
composition of each population could be arbitrarily categorized into newly 
divided daughter cells (lengths between 2 and 4 %m); mother cells capable of 
cell division (4 to 8 %m); or division-inhibited cells (greater than 8 %m). The cell 
distribution of each population is presented in Figure 3-15b. Here, 27.04 % of 
untreated Msm represented newly divided bacilli, while 71.43 % of cells in the 
population were actively growing in preparation of cell division and only 
1.53 % exhibited inhibition of cell division. In comparison, 2.12 % of the cells 
present after 3 h of MMC exposure represented newly divided cells, 67.20 % 
represented cells ready for cell division and 30.69 % presented with inhibited 
cell division. Of the cells exposed to MMC for 4 h, 1.88 % represented newly 
divided daughter cells, 46.88 % were ready for cell division and 51.25 % 
indicated a division arrest/elongation phenotype. Only 4.17 % of cells observed 
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after exposure to MMC for 24 h were newly formed daughter cells, while 
16.67 % were ready for division and 79.17 % had inhibited cell division. In 
comparison, 19.23 % of cells visible after 48 h of MMC exposure were newly 
divided daughter cells, 53.85 % were mother cells capable of division, and 
26.92 % had the cell division inhibition phenotype. The apparent loss of the 
MMC effect at 48 h is likely due to loss of potency of the drug over the time 
course of the experiment. This is illustrated by the frequency distribution of 
cells exposed to MMC for 48 h, which more closely resembled that of normal 
Msm populations or those exposed to MMC for a short period of time, 
suggesting the commencement of cell division between 24 and 48 h. This is also 
supported by the sample of cells exposed to MMC for 48 h which had a higher 
proportion of ‘daughter cells’, mimicking that of untreated cells. Overall, the 
decrease in frequency of newly divided cells in the presence of MMC indicated 
inhibition of cell division. This was associated with an increase in the number 
of abnormally long cells, suggesting that genotoxic stress resulted in inhibition 
of cell division which, over prolonged periods of time, resulted in filamentous 
bacilli. 
 
3.2. Individual Cell Elongation as a Response to Prolonged Genotoxic 
Stress 
It was evident that prolonged exposure to genotoxic stress had induced a cell 
elongation phenotype, with many cells characterized by lengths in excess of 
25 %m. In turn, this observation suggested the possibility that cell elongation as 
a result of DNA damage in Msm may additionally result in the development of 
multiple mutated (mutasome-associated) genomes within individual cells, 
potentially allowing for the rapid emergence and selection of resistant mutants 
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by providing an environment suitable for DNA recombination between 
differentially-mutated chromosomes. For this to be a plausible hypothesis, it 
was necessary first to test whether the observed elongated cell phenotype was 
a consequence of the continued growth of bacilli in the absence of cell division 
(i.e., elongated cells that lacked division septa), or whether multiple, distinct 
daughter cells of normal lengths were forming concatenated structures owing 
to a failure to separate physically after normal cytokinesis. To this end, the 
wag31-gfp strain of Msm was utilized, which expressed a recombinant GFP-
tagged Wag31 protein. This protein has been identified to localize to the cell 
poles during cell growth as part of peptidoglycan synthesis (Santi, et al., 2013; 
Santi and McKinney, 2015); therefore, localization of a green fluorescence 
signal to the cell poles in this strain can be used to delineate individual cells. 
The wag31-gfp reporter strain was exposed to 1× or 5× MIC MMC for 24 h before 
visualisation under a confocal fluorescent microscope (Figure 3-16). Once 
more, the cell elongation phenotype was evident in cells exposed to MMC, with 
the length of single cells exceeding 35 %m in some cases. Importantly, green 
fluorescence was detected at the cell poles of each elongated structure. In 
addition, most elongated cells also exhibited small green fluorescent foci at 
positions internal to the cell poles, perhaps indicating failed or inhibited 
septation. There was no difference between cells exposed to 1× or 5× MIC 
MMC. In combination, these observations supported the hypothesis that 
elongated filaments represented individual mother cells which, despite 
remaining metabolically active and retaining the capacity for chromosomal 
replication, were incapable of completing cell division through several cycles 
of growth and DNA replication. 
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Figure 3-16 | Cell elongation phenotype of individual bacilli expressing wag31-gfp 
Visualization of wag31-gfp after growth for 24 or 48 h in the absence and presence of 1× and 5× MIC 
MMC. Micrographs represent green fluorescence overlayed onto phase contrast images. Scale bars 
represent 5 μm. 
 
3.3. Multiple ImuB Foci Form During Prolonged Genotoxic Stress in 
Elongated Bacilli 
The observation that individual cells could elongate in excess of 10 times their 
normal lengths during genotoxic stress raised the possibility that this 
filamentous state might be associated with the development of multiple 
mutasome foci – in turn, suggesting the opportunity for recombination 
between differentially mutated genomes during periods of genotoxic stress. 
For this purpose, mCherry-dnaN::PSOS(imuA’)-egfp-imuB was exposed to 
inhibitory concentrations of MMC (1× and 5× MIC) for 24 h before being 
7H9-OADC; 24 hr
5×MIC MMC; 48 h1×MIC MMC; 48 h
1×MIC MMC; 24 h
Chapter III 197 
visualised using a confocal fluorescent microscope (Figure 3-17). As before, it 
was evident that the bacilli grew in length but failed to divide under applied 
genotoxic stress. In addition, it was evident that all elongated cells contained 
multiple foci comprising overlapping EGFP-ImuB and MCherry-DnaN signals. 
Additionally, when exposed to sub-inhibitory concentrations (0.25× MIC) of 
MMC for 6 h, mCherry-dnaN::PSOS(imuA’)-egfp-imuB bacilli exhibited multiple 
foci as well (data not shown). This result indicated that the mutasome 
assembled during exposure to sub-inhibitory and inhibitory concentrations of 
MMC. Therefore, it is possible that the function of the mutasome contributes to 
the survival of the cell when exposed to sub-inhibitory levels of genotoxic 
 
 
Figure 3-17 | Multiple mutasome foci develop in response to prolonged genotoxic stress in Msm 
Visualization of a mCherry-dnaN::PSOS(imuA’)-egfp-imuB bacillus after growth for 24 h in the presence 
of 1× MIC MMC. Micrograph represents green (EGFP-ImuB) and red (MCherry-DnaN) fluorescence 
overlayed onto phase contrast. Scale bar represents 5 μm. 
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stresses, and aids in preserving cell viability when exposed to inhibitory 
concentrations by maintaining chromosome integrity. However, it was evident 
that the dynamics of the mutasome and replication machinery in Msm needed 
to be studied in more detail over the course of smaller time intervals to 
determine if there was a correlation between foci number and cell length or 
treatment duration. Nonetheless, multiple replication fork-associated ImuB 
foci appeared to develop within individual, elongated bacilli when exposed to 
genotoxic compounds for extended periods of time. 
 
4. The Effect of Different Genotoxic Stressors on ImuB Recruitment 
The antibiotic effect of MMC is mediated by inter-strand cross-linking of 
genomic DNA caused by the formation of covalent bonds between the 
compound and the component nucleotides (Papavinasasundaram, et al., 2001). 
To test whether the observed EGFP-ImuB foci formed exclusively as a response 
to this specific type of DNA lesion, or if ImuB was commonly recruited to other 
types of DNA damage, mCherry-dnaN::PSOS(imuA’)-egfp-imuB was treated 
with the MIC of various compounds that have been reported to impact bacterial 
DNA metabolism in different ways. The specific focus was on mutagenic 
compounds or antibiotics known to inhibit DNA replication (Table 3-2). These 
included: 
(i) 4-nitroquinoline 1-oxide (NQO), which has been shown to cause 
transversions in Escherichia coli (E. coli) (Fronza, et al., 1992). Although the 
associated hydroxydeoxyguanosine nucleotides have been reported to be 
repaired by nucleotide excision repair (NER) mechanisms, NQO was 
included to evaluate if the mycobacterial mutasome was involved in the 
response to this type of damage.  
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Table 3-2 | Expression of EGFP-ImuB foci following exposure of Msm to various genotoxins 
Compound MIC equivalent in Msm Reference ImuB foci Foci with MMC 
NQO 20 mM Warner, et al. (2010) Yes Yes 
MMS 0.1 % Stephanou, et al. (2007) Yes Yes 
CIP 1.25 μg/ml Naran, unpublished Yes Yes 
EtBr 6.25 μg/ml Rodrigues, et al. (2011) No No 
NVB 8.0 μg/ml Naran, unpublished No Yes 
GRS  4.5 μg/ml Jungmann, unpublished No No 
NQO, 4-nitroquinoline 1-oxide; MMS, methyl methanesulfonate; CIP, ciprofloxacin; EtBr, ethidium bromide; NVB, 
novobiocin; GRS, griselimycin. 
 
(ii) Methyl methanesulfonate (MMS) methylates specific nitrogen atoms in 
purine bases, thereby inhibiting DNA replication by alkylation and was 
included in this experiment (Beranek, 1990; Lundin, et al., 2005).  
(iii) Ciprofloxacin (CIP) is a second-generation quinolone that was included 
in this experiment as the compound functions by inhibiting DNA gyrase 
and topoisomerase IV, which consequently inhibits DNA replication 
(Drlica and Zhao, 1997; Pommier, et al., 2010).  
(iv) Ethidium bromide (EtBr) is an intercalating agent that is thought to cause 
DNA deformations and cause mutations in Salmonella enterica serovar 
Typhimurium (S. typhimurium) following the breakdown of the 
compound into various metabolites (Waring, 1965; McCann, et al., 1975; 
Rodrigues, et al., 2011).  
(v) Novobiocin (NVB) is a coumarin class antibiotic that inhibits GyrB 
function without triggering the classic fluoroquinolone (FLQ)-induced 
SOS response in Staphylococcus aureus (S. aureus) (Schröder, et al., 2012) 
and mycobacteria (Chatterji, et al., 2001; Chopra, et al., 2012).  
(vi) The recently described DnaN (b clamp) inhibitor, griselimycin (GRS) 
(Kling, et al., 2015), was also included to test the effect of b clamp 
inhibition on the recruitment of ImuB to the replication fork.  
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For ease of comparison, all agents were exposed to mCherry-
dnaN::PSOS(imuA’)-egfp-imuB at 1× MIC for 4 h before the cells were imaged 
using an epifluorescent microscope (data not shown). Foci were detected 
following treatment with NQO, MMS, and CIP while GRS induced expression 
of EGFP-ImuB and MCherry-DnaN without foci formation, indicating that 
these four compounds were capable of inducing the mutagenic DNA repair 
pathway in Msm; however, GRS exposure did not induce clearly defined foci 
formation while NQO and CIP did not induce foci as abundant as previous 
MMC experiments. As a control to prevent false-negatives, cultures were 
exposed to 1× MIC MMC in addition to the compound of interest to determine 
if exposure of the cells to any of the test compounds prevented expression and 
recruitment of EGFP-ImuB. It was notable that GRS treatment prevented EGFP-
ImuB foci formation during MMC co-treatment. Of the compounds that did not 
result in EGFP-ImuB foci formation, NVB did not prevent mutasome formation 
as a function of MMC co-treatment. Conversely, only EtBr prevented the 
formation of foci in the presence of MMC. This result may indicate that EtBr is 
extremely toxic to Msm, as highly toxic antibiotic levels have been associated 
with little or no transcriptional remodeling in Saccharomyces cerevisiae (Fry, et 
al., 2005). Thus, in this case, the bacilli may have been rapidly killed by the effect 
of EtBr prior to expression of EGFP-ImuB. It should be noted, though, that these 
results were tentative, but did suggest the potential value in investigation GRS 
further. 
 
4.1. Investigation into the Effect of GRS on ImuB Recruitment 
As GRS was the only compound tested to show induction of the SOS response 
and failure to form EGFP-ImuB foci in the presence of MMC, it was decided to 
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investigate this novel antibiotic further. The GRS compound and its 
pharmacologically more stable analog, cyclohexyl-griselimycin, were reported 
to be bactericidal in Mtb (Kling, et al., 2015). Therefore, to validate that GRS had 
a similar effect on Msm, a kill-kinetic assay was conducted on WT mc2155 
(Figure 3-18a). Following enumeration of surviving cells following exposure to 
1× or 5× MIC GRS over time, it was evident that, after 48 h of exposure, there 
was a 2-log10 reduction in cell viability, indicating that GRS was in fact weakly 
bactericidal to Msm (Kaur, et al., 2009). Having illustrated similar effects of GRS 
on Msm, and due to the demonstrated inhibition of the replicative DnaN by 
GRS (Kling, et al., 2015), the effect of this drug on the recruitment of ImuB in 
Msm was evaluated. To achieve this, ∆imuB::PSOS(imuA’)-egfp-imuB was 
exposed to 2× MIC GRS for 4 h and imaged by epifluorescence microscopy to 
visualise EGFP-ImuB expression and recruitment. The micrograph of 
∆imuB::PSOS(imuA’)-egfp-imuB exposed to GRS (Figure 3-18b, right panel) 
indicated expression of EGFP-ImuB (as observed by the increased green 
fluorescence detected within bacilli). Furthermore, GRS appeared to prevent 
EGFP-ImuB focus formation as seen during MMC exposure (Figure 3-18b, 
middle panel). This result was further validated in ∆imuB::PSOS(imuA’)-
mEos4a-imuB exposed to 5× MIC GRS for 8 h and imaged by superresolution 
3D-iPALM (Figure 3-18c). Here, the lack of high-density fluorophore signal 
and the presence of evenly distributed, cell-wide signal indicated that MEos4a-
ImuB was not recruited to DnaN during exposure to GRS. These results 
established that GRS exposure appears to prevent recruitment of ImuB to the β 
clamp despite induction of P(imuA’).  
 
 
Chapter III 202 
 
Figure 3-18 | GRS inhibits EGFP-ImuB foci formation 
(a) Kill kinetics of GRS in Msm. Cell viability of WT growin in the presence of 0× (grey), 1× (blue), and 5× 
(green) MIC GRS over time was determined. GRS was determined to be slightly bactericidal in Msm as  
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Figure 3-18 | Continued  
cultures exposed to inhibitory concentrations of GRS had reduced numbers of viable cells over time. (b)  
GRS does not induce EGFP-ImuB foci formation. Cultures of Msm were imaged using fluorescence 
microscopy. WT exposed to GRS (left) exhibited no fluorescence. The experimental 
ΔimuB::PSOS(imuA’)-egfp-imuB strain exhibited green fluorescent foci when exposed to 2× MIC MMC 
(middle) but failed to produce a similar phenotype when exposed to 2× MIC GRS (right). Scale bar 
represents 5 μm. (c) 3D-iPALM imaging identified that, despite formation of MEos4a-ImuB foci following 
exposure of ΔimuB::PSOS(imuA’)-mEos4a-imuB to 5× MIC MMC (top), the same strain did not produce 
high-density fluorophore signal that could be interpreted as MEos4a-ImuB foci when exposed to 5× 
MIC GRS for 8 h (bottom). Intensity bar represents the Total Molecule Probability and ranges from 
minimum (black) to maximum (white) red fluorophore molecules/nm2. 
 
4.2. Co-treatment with GRS and MMC or Moxifloxacin 
As GRS was shown not to be inherently mutagenic while also indicating a 
capacity to prevent ImuB foci formation in Msm during MMC co-exposure, it 
was hypothesized that GRS may be able to prevent ImuB recruitment and 
interaction with DnaN. In order to test this hypothesis, a combination assay 
was developed such that two DNA damaging agents – MMC and the clinically 
relevant antibiotic, moxifloxacin (MOX) – were co-administered with GRS. The 
assay was constructed such that each compound could be administered to 
mCherry-dnaN::PSOS(imuA’)-egfp-imuB in two-dimensional combination at 
sub- (0.2× MIC) and supra- (5× MIC) inhibitory concentrations. This 
experimental set-up allowed for direct visual observation of the effect different 
concentrations of the genotoxic agent had on EGFP-ImuB foci formation in the 
presence of different concentrations of GRS. Following exposure of bacilli to 
the drug combinations for 4 h, green and red epifluorescent images were 
acquired for each experimental condition (Figure 3-19). The bacilli exposed to 
no compound exhibited no expression of EGFP-ImuB, as previously observed. 
As expected, bacilli exposed only to MMC (at either concentration) exhibited 
the development of green fluorescent EGFP-ImuB foci indicating recruitment 
of ImuB to DnaN.  
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Notably, MOX exposure alone also induced the formation of EGFP-ImuB foci 
at both concentrations, consistent with the result of CIP and the known capacity 
of FLQ drugs to induce an SOS response (Cirz, et al., 2007; O'Sullivan, et al., 
2008). Furthermore, increased cell-wide red fluorescence was also detected in 
these cells – potentially as a result of increased expression of mCherry-dnaN due 
to collapsed replication forks. When imaging cells exposed solely to 0.2× MIC 
GRS, EGFP-ImuB foci were observed in the majority of cells. Similarly, bacilli 
exposed to either concentration of MMC or MOX in addition to 0.2× MIC GRS 
exhibited a similar phenotype of EGFP-ImuB foci formation in greater than 
50 % of cells. In contrast, all bacteria exposed to inhibitory concentrations (5× 
MIC) of GRS exhibited cell-wide green fluorescence and the absence of clearly 
defined EGFP-ImuB foci, regardless of the type or concentration of the co-
exposed genotoxic compound. Furthermore, MCherry-DnaN foci were also 
absent in all cells exposed to 5× MIC of GRS. As above, it was notable that all 
cells exposed to MOX (regardless of concentration) showed increased levels of 
whole-cell, red fluorescent signal, suggesting highly induced expression of 
dnaN under FLQ treatment. 
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Figure 3-19 | Combination assay microscopy 
Different concentrations of MMC or MOX and GRS were administered to mCherry-dnaN::PSOS(imuA’)-
egfp-imuB cells prior to imaging with fluorescence microscopy. Green EGFP-ImuB and red DnaN-
MCherry fluorescent foci are not evident in cells exposed to inhibitory concentrations (5× MIC) of GRS 
– regardless of the presence of a secondary compound. Furthermore, cells exposed solely to MOX (0.2× 
and 5× MIC) induced formation of EGFP-ImuB foci, indicating potential mutasome-mediated 
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6. Supplementary Results 
6.1. Previous Validation of VFP-ImuA′ Function 
 
 
Supplementary Figure S1 | DNA damage tolerance of ΔimuA’::vfp-imuA’ 
The photographs indicate the growth of Msm colonies (white) on 0.02 and 0.04 μg/ml MMC-containing 
media (black) after serial dilution. The spotting order of each dilution factor is 100 to 107 from top to 
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Supplementary Figure S2 | Comparison of the effect of supra-inhibitory concentrations of MMC on cell 
length following 24 h of exposure 




















Effect of increased inhibitory concentration
of MMC on Msm cell length
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Chapter III 211 
6.3. Statistical Data of P(imuA′) Flow Cytometric Analyses  
 
Supplementary Table S1 | Stats and data from time response flow cytometry 
Time 5 min 15 min 30 min 1 h 2 h 4 h 6 h 12 h 
n 6 6 6 6 6 6 6 6 
Minimum 126 120 129 231 626 1400 1770 1129 
Lower Quartile 127.5 125.3 132.8 236.3 652.3 1441 1837 1275 
Median 129.5 129.5 140.5 241.5 668.5 1516 1917 1435 
Upper Quartile 135.3 134.3 146.8 248.3 690.8 1527 2231 1668 
Maximum 142 135 155 258 705 1532 2364 2056 
Mean 131.3 129.2 140.5 242.5 669.2 1490 2002 1486 
SD 5.715 5.636 8.961 9.006 26.45 52.32 226.6 315 
SEM 2.333 2.301 3.658 3.677 10.8 21.36 92.5 128.6 
Lower 95% CI of mean 125.3 123.3 131.1 233 641.4 1435 1764 1155 
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Supplementary Table S2 | Stats and data from dose response flow cytometry 
Dose (× MIC) 0.0001 0.001 0.01 0.05 0.1 1 5 10 100 
n 6 6 6 6 6 6 6 6 6 
Minimum 140 135 179 369 594 1400 1482 1163 118 
Lower Quartile 142.3 141.8 179 425.3 637.5 1441 1482 1174 120.3 
Median 144 147.5 194 470.5 680.5 1516 1561 1338 127.5 
Upper Quartile 145.3 154.3 200.3 516.3 740.3 1527 1617 1383 133 
Maximum 146 161 216 568 768 1532 1694 1455 136 
Mean 143.7 147.8 192.8 470.2 684.3 1490 1562 1305 127 
SD 2.16 8.612 13.63 65.34 63.3 52.32 79.01 113.1 7.043 
SEM 0.8819 3.516 5.564 26.68 25.84 21.36 32.26 46.19 2.875 
Lower 95% CI of mean 141.4 138.8 178.5 401.6 617.9 1435 1479 1186 119.6 
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1. Overview 
Previous work based predominantly on genetic approaches had established 
that inducible mutagenesis in mycobacteria is mediated by the ImuA′, ImuB, 
and DnaE2 proteins (Boshoff, et al., 2003; Warner, et al., 2010). Together, it is 
thought that these proteins function as part of a single pathway, with yeast 
two-hybrid (Y2H) interaction data suggesting the potential for protein-protein 
interactions (PPIs) between the components (Figure 1-3). The working model, 
therefore, predicted ImuB as central adapter protein, which facilitates access of 
ImuA’ and DnaE2 to the chromosome via its essential interaction with the β 
clamp (Figure 1-5). Although suggesting some similarities in component 
complexity with Escherichia coli (E. coli) Pol V (Jiang, et al., 2009), this model 
remained skeptical, with multiple unanswered questions when compared to 
that of the model organism system. For example, it was unknown if the 
mutasome proteins co-localized or interacted within mycobacterial bacilli. 
Furthermore, the regulatory dynamics dictating stoichiometry, timing, and 
activity of the putative mutasome complex are not understood. While DnaE2 
is postulated to perform nucleotide polymerization, the functional role of the 
accessory proteins ImuA’ and ImuB remained unexplored. Overall, the 
understanding of the mycobacterial mutasome has previously been limited to 
genetic observations and required new insight to support the mycobacterial 
mutasome model. 
 
While the aim of this study was to investigate the PPIs predicted between each 
component of the mycobacterial mutasome, many aspects of the mycobacterial 
mutasome model have been reinforced including the predicted DnaN-ImuB 
PPI, which was directly observed by the co-recruitment of ImuB and DnaN foci 
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(Figure 3-11). This identified ImuB as the central adapter component of the 
mutasome in Mycobacterium smegmatis (Msm) and highlighted the necessity to 
further investigate the protein at the center of the mycobacterial mutasome and 
the potential to inhibit similar PPI in an effort to restrict the mutagenic capacity 
of mycobacteria. Indeed, it was observed that the novel antitubercular drug 
griselimycin (GRS) was able to prevent recruitment of ImuB to DnaN (Figure 
3-18), paralleling genetic inhibition of the DnaN-ImuB binding interface 
(Figure 3-13; and Warner, et al., 2010). Furthermore, the insights into the 
molecular dynamics of the mutasome supported a hypothesis for the swapping 
of replicative and mutagenic DNA polymerase systems at the site of the 
replication fork; while other evidence presented in this work raises the 
intriguing possibility of a highly adaption-mediating environment during 
genotoxic stress as a result of the interplay between mutagenic DNA repair and 
cell division inhibition in mycobacteria (Figure 3-17). 
 
2. Regulatory Dynamics of the imuA’ Promoter During Genotoxic Stress 
The genes encoding imuA′ and imuB constitute a predicted two-gene operon 
under the regulation of a single SOS box (Davis, et al., 2002). The imuA’ 
promoter, P(imuA’), was used to drive expression of enhanced green 
fluorescent protein (EGFP) with the aim of establishing if it was suitable for use 
in constructing fluorescently labelled variants of ImuB in addition to providing 
an EGFP-only control to compare to EGFP-ImuB. Quantification by flow 
cytometry of the green fluorescence generated by EGFP proved useful for 
determining the regulatory dynamics of P(imuA’). Here, the response of Msm 
to mitomycin C (MMC) was robust with the majority of cells exposed to 
inhibitory conditions of MMC exhibiting levels of green fluorescence above 
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that of untreated bacilli. Moreover, it was observed that EGFP expression (as 
determined by fluorescence intensity) corresponded to both the duration 
(Figure 3-4) and concentration (Figure 3-5) of MMC exposure. Notably, 
maximal expression of EGFP was attained at MMC concentrations 
corresponding to cell growth inhibition. It appeared, therefore, that inhibition 
of growth by genotoxins such as MMC occurred subsequent to maximal 
induction of the responding repair mechanisms (i.e., the SOS response, which 
includes the mutasome). Expression in this scenario may be limited by factors 
such as the rate of RecA activation, formation of a steady state between LexA 
repressor degradation and synthesis, or saturation of DNA damage. 
Regardless, the result of the PSOS(imuA’)-egfp transcriptional reporter 
suggested that the inhibitory effect of MMC occurred as a consequence of a 
failure to repair extensive DNA damage, which resonates with observations in 
E. coli that identified a correlation between DNA damage and activity of SOS 
gene promoters (Friedman, et al., 2005).  
 
The response of Msm to genotoxic stress was rapid, with induction of imuA’ 
gene expression detected within the first hour following exposure to MMC. 
Although the initial response at 1 h was only 12.1 % of the maximal expression 
(at 6 h), it indicated that an initial response to inhibitory concentrations of DNA 
damage occurred within one generation time (~3 h) (Aldridge, et al., 2012; Santi, 
et al., 2013). As the rate of diffusion or uptake of MMC across the mycobacterial 
cell membrane is not known, it is possible that this delayed maximal induction 
of imuA’ (occurring at 2 generation times) represented an accumulation of 
MMC over time, resulting in increased DNA damage over time (Friedman, et 
al., 2005), in addition to a potential delay caused by RecA/LexA regulation 
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dynamics which delayed induction of PSOS(imuA’)-egfp (Kamenšek, et al., 2010; 
Schnarr, et al., 1991). The decrease in fluorescence signal observed after cells 
were exposed to 1× minimum inhibitory concentration (MIC) MMC for longer 
than 6 h might be the result of two factors: (i) MMC is known to be relatively 
unstable and precipitate in culture media over time (Beijne, et al., 1990), 
therefore the decrease in PSOS(imuA’) induction may represent degradation of 
MMC beyond 6 h; or (ii) during extended experimental time periods, cell 
division is more likely to occur stochastically, resulting in a decrease in total 
fluorescence signal per measured cytometric event as two daughter cells 
effectively inherit half the total fluorescence signal of the mother cell. This 
second possibility is supported by the increased variation within each sample 
as the standard deviation (SD) increased from 8.96 arbitrary fluorescence units 
(AFU) at 30 min to 315.0 AFU at 12 h (Chapter III, Supplementary Table S1) 
indicating a large variation in the EGFP levels of each cell at 12 h. The increase 
in event variation is likely dependent to a greater extent on time than signal 
magnitude, as the maximal variation observed in the dose-dependent study 
was not as large, with a SD of 113.1 AFU (Chapter III, Supplementary Table 
S2). 
 
An important caveat to acknowledge here, however, is that these results only 
represent induction and expression of imuA’. The other component genes of the 
mutasome, imuB and dnaE2, may be controlled by additional transcriptional 
and post-translational regulatory processes, one of which may be mediated by 
ImuA’ itself. At the transcript level, there is already a disparity between the 
level of induction for Mycobacterium tuberculosis (Mtb) imuA’ and imuB, which 
exhibited a 32-times and 80-times increase in transcript level, respectively, 6 h 
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post ultraviolet (UV) irradiation (Warner, et al., 2010). This suggests the 
existence of unknown, differential regulatory systems controlling the 
transcription of each open reading frame (ORF) of the imuA’-imuB operon, 
further contributing to the complexity of the mycobacterial mutasome. 
Moreover, there exists the possibility of post-translational regulation of any 
mutasome component – as seen with the sub-cellular sequestration of Pol V 
within E. coli (Robinson, et al., 2015), the requirement of ATP as a co-factor for 
Pol V function (Jiang, et al., 2008), and post-translational processing of UmuD 
(Nohmi, et al., 1988) – which may further contribute to the complexity 
surrounding function and regulation of the mutasome. The total extent of 
regulatory mechanisms controlling expression of the mutasome and how this 
regulation affects the function of the complex and mutational load remains 
unknown and warrants further investigation.  
 
3. Visualising the Mutasome in Live Bacilli: the Role of ImuB and ImuA’ 
Overall, the fluorescent tagging of individual mutasome components was 
successful. The addition of the fluorescent tag to ImuA’ in the ∆imuA’::vfp-
imuA’ mutant appeared not to interfere with mutasome function, 
phenocopying wild-type (WT) mc2155 in both induced mutagenesis (Figure 3-
6) and DNA damage tolerance assays (Chapter III, Supplementary Figure S1). 
In contrast, ∆imuB::PSOS(imuA’)-egfp-imuB exhibited an ‘uncoupled’ 
phenotype:  the inducible mutagenesis capacity of the strain was retained 
whereas damage survival (as measured by growth on solid medium containing 
MMC) was impaired (Figure 3-7). The reason for the apparent uncoupling of 
inducible mutagenesis and DNA damage repair is unclear but may be 
explained by the respective assays employed. The former is tested by 
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challenging bacilli with a single dose of UV irradiation to induce DNA damage; 
while the latter is assayed by exposing Msm to MMC for the duration of the 
experiment. This means that during periods of extended DNA damage (such 
as 3 to 5 days), the ∆imuB::PSOS(imuA’)-egfp-imuB bacilli were not able to 
consistently and repeatedly repair the lesions caused by MMC. Although it is 
possible that the EGFP domain of the complementing hybrid protein may have 
restricted the function of the mutasome, the observed restoration of mutagenic 
capacity suggested that this uncoupling resulted from dysregulation of egfp-
imuB in contrast to the native imuB gene, which is the second ORF of the imuA’-
imuB operon (Warner, et al., 2010). As noted above, the promoter of 
PSOS(imuA’)-egfp-imuB consisted solely of imuA’ upstream elements and did 
not include all potential promoter elements of MSMEG_1622 (imuB) found 
within MSMEG_1620 (imuA’) (Figure 3-1). This may render the bacterium 
unable to consistently express the appropriate levels of (EGFP-)ImuB required 
to endure the extended presence of MMC. In addition to this, the stability of 
EGFP-ImuB relative to ImuB might be a factor contributing to the decreased 
DNA damage tolerance of ∆imuB::PSOS(imuA’)-egfp-imuB, though this requires 
further investigation. Quantitative, reverse transcription (qRT-)PCR is 
warranted for future investigations to determine if egfp-imuB transcript levels 
are comparable to WT imuB transcript levels during a time-course experiment 
following exposure of bacilli to MMC. This approach will also enable an 
evaluation of the potential impact of the additional EGFP-encoding sequence 
on the stability of the transcript or if promoter sequences were inadvertently 
disrupted during the design of the construct, therefore accounting for the 
susceptibility of ∆imuB::PSOS(imuA′)-egfp-imuB to MMC in solid media over 
prolonged periods. Furthermore, an alternative method should be considered 
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when evaluating MMC-sensitivity in future experiments: MIC determinations 
of different reporter strains of Msm could be used to highlight more accurately 
the difference in sensitivities to MMC in both solid and liquid media. 
 
The observed inducible mutagenesis of ∆imuB::PSOS(imuA’)-egfp-imuB 
nevertheless suggested that EGFP-ImuB retained sufficient functional activity 
to warrant microscopic visualization and analysis of the protein within live 
cells. These analyses revealed that EGFP-ImuB localized to specific regions or 
‘foci’ within each bacillus (Figure 3-8). In contrast, the VFP-ImuA’ protein was 
seen to disperse throughout the mycobacterial cell. The differential localization 
patterns of VFP-ImuA’ and EGFP-ImuB during inducible mutagenesis may 
indicate differing functions: ImuB was previously predicted to serve as an 
adapter protein, providing structural support to enable access of ImuA’ and 
DnaE2 to the replication fork through its own β clamp binding capacity, while 
the weak homology of ImuA’ to RecA implied the potential for an analogous 
DNA scanning function to identify specific markers of DNA damage. It may 
also reveal a difference in binding time of each respective protein within the 
mutasome complex. If the binding time of VFP-ImuA’ with the mutasome 
complex is lower than the exposure time of the microscope camera, the protein 
will be observed to disperse throughout the cell. Furthermore, as ImuB is 
predicted to function as a ‘hub protein’ within the mutasome complex (Warner, 
et al., 2010), it is likely that it would have a greater binding time and be detected 
as ‘foci’ – as observed in this study. However, there is the possibility that the 
discrepancy of ImuA’-ImuB localization is indicative of differing functions. In 
this regard, the evidence presented in this study suggested that ImuB 
maintained a central role within the mutasome. In contrast, the location of VFP-
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ImuA’ suggested that the protein contributed to mutagenic DNA repair by 
means of a more transient function – potentially requiring only short-lived 
interactions with other proteins or DNA. The cell-wide dispersal of ImuA’ may 
indicate that the protein functions as part of a mutasome regulation mechanism 
and operates in multiple regions of a bacillus: either sensing DNA damage or 
performing post-translational regulation of the system. Both of these 
regulatory possibilities are supported by the homology shared between the 
mycobacterial ImuA’ and RecA (Warner, et al., 2010; Galhardo, et al., 2005). 
However, it must be pointed out that ImuA’ was not required for localization 
of EGFP-ImuB (Figure 3-12), indicating that ImuA’ is not required for post-
translational processing of ImuB. Again, the caveat exists that, in this study, 
EGFP-ImuB was expressed under control of a non-native promoter and 
perhaps ImuA’ is capable of regulating the genetically linked imuB gene. This 
hypothesis is supported by the differential increase in transcript levels of imuA’ 
and imuB in Mtb mentioned previously (Warner, et al., 2010). In a final scenario, 
ImuA’ may function as a cell architecture regulator, similar in function to the 
more distant homologue SulA (Galhardo, et al., 2005), which inhibits cell 
division as part of the SOS response; however, all speculation into the function 
of ImuA’ requires future investigation. These latter possibilities suggest that 
ImuA’ is potentially not a component of the mutasome. Indeed, the data 
presented in this thesis do not support any inference of specific sub-cellular 
localization of ImuA’. However, it is not possible to rule out definitely the 
possibility that ImuA’ is incorporated into the mutasome. Further work is 
required to determine the exact composition of the mutasome and, moreover, 
whether it does comprise multiple proteins in addition to ImuB and DnaE2. 
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In contrast to ImuA’, this study did afford new insight into the function of 
ImuB. When visualized together with the labelled β clamp (Figure 3-11), it was 
evident that both EGFP-ImuB and MCherry-DnaN were recruited to the same 
location within Msm. Previous Y2H evidence suggested an interaction between 
ImuB and DnaN (Warner, et al., 2010), and the microscopy data presented here 
appeared to support the inferred PPI. This conclusion is reinforced by the 
observation that alteration of the putative β clamp binding domain within 
ImuB in EGFP-ImuBAAAAG prevented foci formation via association with DnaN 
(Figure 3-13). In turn, this suggests that ImuB enables access of the other 
mutasome components (particularly DnaE2) to the replication fork, explaining 
its essentiality for mutagenic DNA repair. Again, this is supported by 
observations that DnaE2, which possesses DNA polymerase function, does not 
contain a β clamp binding domain (Warner, et al., 2010). Therefore, the function 
of ImuB has been identified as contributing to the structural formation of the 
mutasome complex through the interaction with DnaN and a putative 
interaction with the DnaE2 polymerase (Figure 4-1). However, the exact reason 
ImuB fulfills this role, as well as the evolutionary consequence thereof, is not 
known and requires further study. It is intriguing to postulate that the primary 
role of ImuB is to out-compete other polymerases for access to the β clamp at 
stalled replication forks. This can further explain the greatly increased 
transcript levels of imuB in Mtb observed following UV damage (Warner, et al., 
2010), which may be required to out-compete other polymerases such as DnaE1 
and DinB during genotoxic stress. This notion is further supported by the 
recent observation that different polymerases ‘share’ access to the replication 
fork through the rapidly successive binding of replicative and mutagenic 
polymerases in E. coli (Zhao, et al., 2017; Beattie, et al., 2017). In this vein, a high 
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concentration of ImuB proteins might be required to ensure temporal out-
competition of (stalled) polymerases and overall function of the mutasome 
during periods of genotoxic stress (Figure 4-1). 
 
 
Figure 4-1 | Model for recruitment of the mycobacterial mutasome 
The schematic representation of the predicted mutasome model illustrates how the mycobacterial 
mutasome might assemble and function. (a) DnaE1 preferentially binds to the β-clamp and polymerizes 
DNA under normal circumstances. (b) DnaE1 is unable to synthesize DNA opposite DNA lesions and the 
replication fork stalls. (c) The stalled replicative DnaE1 is unstable and replaced by the more abundant 
ImuB. (d) Once ImuB has bound to the β-clamp, DnaE2 is able to bind to ImuB. (e) The fully formed 
mutasome complex is able to perform translesion DNA synthesis (TLS) across the DNA lesion, producing 
error-prone DNA. (f) The actively progressing mutasome is outcompeted by DnaE1. (g) The replicative 
DnaE1 resumes chromosome replication. This model is supported by observations in the recent 
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Furthermore, the theorized scaffold (or adapter) function of ImuB can be 
compared to another Y family polymerase found in eukaryotes, Rev1, which is 
also postulated to perform an essential, non-catalytic, structural role during 
TLS across 6-4 thymine photodimers (Nelson, et al., 2000; Haracska, et al., 2001; 
Otsuka, et al., 2005; Kuang, et al., 2013). Although Rev1 has catalytic activity 
and functions by inserting cytosine nucleotides opposite abasic sites during 
DNA repair (Nelson, et al., 1996), this activity is not required for TLS function 
of Rev3/7 (Pol ζ). Instead, Rev1 is thought to interact with other catalytic 
polymerases (such as Pol ζ) through the BRCA1 C-terminal (BRTC) and C-
terminal domains of Rev1 (Acharya, et al., 2005; D’souza and Walker, 2006; 
Kikuchi, et al., 2012), thereby enabling effective TLS strand extension 
(Budzowska, et al., 2015). If a comparable situation indeed occurs between 
ImuB and DnaE2 during mutagenic DNA repair in actinobacteria, this may 
indicate a propensity for polymerase swapping – a phenomenon that itself 
warrants investigation at the molecular level. The evidence for the Rev1-
essentiality in TLS sets a molecular and evolutionary precedent for the theory 
of the mycobacterial mutasome, whereby ImuB provides the ‘landing pad’ 
required for the recruitment of the catalytically active DnaE2 polymerase. 
Furthermore, the Rev1- and ImuB-adapter models, although comprised of non-
related proteins, may provide insight into the evolution of DNA metabolism 
pathways (specifically those involved in TLS), in turn, helping identify 
potential PPIs to guide rational drug design.   
 
Although moxifloxacin (MOX) is known to cause double-stranded DNA breaks 
by the inhibition of DNA gyrase (Mduli and Ma, 2007; Reece and Maxwell, 
1991), evidence presented in this work has identified that ImuB (and potentially 
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the whole mutasome) is recruited during MOX exposure (Figure 3-19). This 
result suggests that the DNA lesion associated with MOX might also be 
repaired by the TLS mechanism of the mycobacterial mutasome, which 
contradicts the model proposed in this thesis. However, the exact reason for 
induction of PSOS(imuA′)-egfp-imuB and recruitment of EGFP-ImuB is 
unknown and may be a result of either direct repair of the MOX-induced 
double-stranded break by the mutasome or subsequent correction of 
previously repaired intermediate DNA adducts formed by other repair 
processes. To investigate this further, qRT-PCR experiments are required to 
confirm that all three component genes of the mutasome are up-regulated in 
WT Msm during MOX exposure. Furthermore, it is necessary to determine if 
the frequency of EGFP-ImuB foci following MOX exposure is comparable to 
that following MMC exposure. In this regard, it is possible that the contribution 
to overall DNA repair of double-stranded breaks is less than that of DNA cross-
linked lesions or occurs with different timing. 
 
4. Genotoxic Stress Induces Dysregulated Bacterial Cell Fission and 
Growth 
In addition to inducing repair mechanisms, the E. coli SOS response is also 
known to include cell division inhibitors such as MinC and SulA (Justice, et al., 
2000). Indeed, when Msm was exposed to MMC for prolonged periods of time, 
a cell filamentation phenotype was observed (Figure 3-14 and Figure 3-15). 
After 4 h of exposure to MMC, approximately 50 % of Msm bacilli exhibited cell 
lengths greater than 98 % of cells grown in standard 7H9 liquid broth. 
Similarly, after 24 hours, 79 % of cells exhibited inhibited cell division with a 
population mean length of 19.5 'm. This indicated that, although cell division 
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was inhibited during MMC-exposure, cell growth continued uninterrupted at 
a linear rate of approximately 2.4 'm per generation time. Additionally, this 
growth appeared to be accompanied by completion of genome replication – as 
suggested by the formation of multiple ImuB-DnaN foci in single filamentous 
bacilli (Figure 3-16 and Figure 3-17) – potentially providing an opportunity for 
accelerated micro-evolution. Avenues exploring bacilli filamentation are well 
merited as Mtb has been observed to exhibit a filamentous phenotype during 
infection of macrophages (Chauhan, et al., 2006; Caire-Brändli, et al., 2014), 
indicating that this is an infection-relevant phenotype and that cell division-
inhibiting conditions do occur in vivo.  Future experiments may benefit from 
using membrane stains such as Nile Red (Strahl, et al., 2014), 4-N,N-
dimethylamino-1,8-naphthalimide-trehalose conjugates (Kamariza, et al., 
2017), or fluorescent D-alanine analogs (Botella, et al., 2017); these would prove 
very useful for discerning septa formation in elongated cells – providing the 
clarity to identify filamented cells by the absence of labelled septa. 
 
Genotoxic stress results in an increased number of mutations in Msm through 
the induction of the mycobacterial mutasome (Boshoff, et al., 2003; Warner, et 
al., 2010). In addition to this, MMC exposure resulted in the dysregulation of 
cell division, possibly leading to the presence of multiple, differentially-
mutated chromosomes within individual bacilli (Figure 3-17). This scenario 
may result in accelerated evolution through the recombination of genes and 
chromosomal regions, resulting in the duplication (or deletion) of DNA 
previously repaired by the error-prone mutasome (Figure 4-2). Notably, 
multiple chromosomes within filamentous bacilli will be differentially (and 
randomly) mutated, allowing for recombination events to result in unique 
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combinations of mutations. The possibility of such events occurring as a 





Figure 4-2 | The pathway to genotoxic stress-induced micro-evolution in bacteria  
The flow diagram on the left represents the series of events that may contribute to the micro-evolution 
of mycobacteria during prolonged genotoxic stress. The flow diagram on the right illulstrates the 
processes that occur during this time in mycobacterial bacilli as part of chromosome replication and cell 
division. The two primary contributors to genetic diversity are the introduction of SNPs as a funtion of 
the mutasome as well as the potential recombination of accumulated chromosomes as a function of cell 
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Filamentation may represent an important survival response in pathogenic 
bacteria (reviewed by Justice, et al., 2008, 2014). In this work, it is hypothesized 
that this phenotype has the potential to generate polyploidy, which is a 
commonly observed occurrence amongst bacteria (Soppa, 2017). The 
phenomenon of polyploidy is thought to facilitate evolution during cell 
division inhibition in bacteria (Van der Peer, et al., 2017) and has been observed 
to facilitate adaptation in yeast (Selmecki, et al., 2015). In addition to this, a 
recent study by Sun and colleagues has identified that in E. coli, multi-fork 
chromosome replication (which results in polyploidy) causes phenotypic delay 
whereby the presence of multiple different, mutant alleles of the same gene 
contribute to the success of the mutant phenotype by minimising the 
deleterious effect of the mutation – thereby reducing mutational load of the 
mutation in the short-term (Sun, et al., 2018). Notably, multi-fork replication 
has been recently observed in mycobacteria (Trojanowski, et al., 2017). 
Additionally, polyploidy may contribute to the survival of bacteria by acting 
as a phosphorus storage mechanism (Zerulla, et al., 2014). 
 
The exact contribution of polyploidy to the evolution of bacteria remains to be 
further elucidated; however, this phenomenon is likely able to contribute to the 
evolution of drug resistance (Bos, et al., 2015). Therefore, it remains an 
unanswered question as to whether the development of transient polyploidy 
during filamentation (and the resolution of multiple chromosomes) in Mtb 
contributes to evolution of the genome and development of drug resistance 
during infection. At a basic level, it is not known how filamentation affects 
viability of the resultant daughter cells, nor how effectively these daughter cells 
are resolved during division of the filamented mother cell. Furthermore, the 
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potential for polyploidy occurring highlights an important risk associated with 
chemotherapeutics that cause DNA damage, such as the fluoroquinolones 
(FLQs), whereby the rate of drug resistance development increases as a result 
of the mechanism of action (Malik, et al., 2012; Mo, et al., 2016) – likely as a result 
of the induction of the SOS response as seen in E. coli (Cirz, et al., 2005). 
Therefore, it is of great interest to investigate new anti-tuberculosis (TB) agents 
that are capable of restricting micro-evolution-promoting mechanisms during 
chemotherapy treatment (Reiche, et al., 2017). 
 
5. GRS-mediated Inhibition of DnaN Prevented Functional Interaction 
with ImuB 
The natural product compound GRS is reported to be bactericidal in Mtb 
(Kling, et al., 2015). In line with this observation, the compound was also found 
to be bactericidal in Msm, resulting in a 2-log10 reduction in culturable bacilli in 
48 h. GRS inhibits DNA replication by blocking the hydrophobic pocket located 
between DnaN subdomains II and III (Kling, et al., 2015) responsible for 
polymerase binding and recruitment (denoted “sub-site 1” by Burnouf, et al., 
2004, and “hydrophobic channel on the surface of the β-clamp,” by Bunting, et 
al., 2003). In particular, this hydrophobic cleft is noted as being important for 
the recruitment of TLS polymerases in E. coli, making GRS an attractive 
compound to investigate. Indeed, when ∆imuB::PSOS(imuA’)-egfp-imuB bacilli 
were exposed to GRS, it was notable that EGFP-ImuB did not form clearly 
defined foci as produced during MMC exposure (Figure 3-18), indicating that 
the protein was not recruited as previously observed. Importantly, the diffuse, 
cell-wide fluorescence observed in GRS-exposed ImuB-EGFP-expressing cells 
was indistinguishable from the phenotype of the mutant ∆imuB::PSOS(imuA’)-
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egfp-imuBAAAAG strain following MMC exposure (Figure 3-13). This suggested 
that chemical inhibition of the PPI between DnaN and ImuB had a similar effect 
on the recruitment of ImuB to the genetic disruption of the ImuB β clamp 
binding site. Given that the WT QLPLWG motif of ImuB was reported as 
essential for the function of the mutasome (Warner, et al., 2010), it can be 
reasoned that GRS-mediated inhibition of ImuB recruitment to DnaN will 
result in the similar abrogation of mutasome function and inducible 
mutagenesis in mycobacteria; although, similar results need to be reproduced 
in other species of mycobacteria – particularly Mtb. 
 
Although the mechanism of action that prevented ImuB recruitment to DnaN 
can only be postulated at this point, it is likely that this occurred as a result of 
competitive binding of GRS to the binding domain located on the surface of 
DnaN. This could potentially result in the steric occlusion of ImuB and 
interference of the mutasome-essential interaction. It seems very likely that this 
renders the mutasome unable to function and results in the absence of 
inducible mutagenesis in the presence of inhibitory concentrations of GRS; 
however, demonstrating this effect was extremely challenging. GRS is 
bactericidal (Figure 3-18a; and Kling, et al., 2015), therefore it proved 
problematic to determine whether a decrease in mutation frequency in the 
presence of the compound (as measured by the survival of rifampicin (RIF)-
resistant mutants following UV irradiation) was a result of mutasome 
inhibition or simply cell death caused by GRS. As a result of this complexity, 
GRS-mediated inhibition of mutasome function remains purely theoretical and 
requires further investigation to validate. It is important to highlight that, at 
sub-inhibitory concentrations, GRS did not prevent recruitment of EGFP-ImuB 
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in the presence of MMC but, conversely, on its own induced mutasome 
recruitment at 0.2× MIC. Therefore, it is possible that GRS may induce 
mutagenic DNA repair at non-inhibitory concentrations. Future investigations 
need to establish if low concentrations of GRS can cause mutagenesis in the 
presence or absence of other genotoxic agents. Furthermore, how GRS prevents 
ImuB recruitment is unknown and requires attention. This work demonstrates 
that high (inhibitory) concentrations of GRS prevented the functional 
association between DnaN and ImuB and resulted in the dissociation of ImuB 
from DnaN – either directly by sterically occluding ImuB by competitive 
binding to DnaN or indirectly through other, unknown mechanisms.  
 
This work further identified the utility of novel compounds that target the 
DNA replication and repair machinery and validated the continued study of 
GRS as an anti-TB therapeutic. With respect to the inhibition of the 
mycobacterial mutasome, the concept of “anti-evolution” adjuvants has been 
proposed and investigated before (reviewed by Culyba, et al., 2015; Mo, et al., 
2016); however, GRS has a subtle deviation from the standard concept. 
Although it is hypothesized here that GRS may be able to prevent the function 
of the mycobacterial mutasome, this is a secondary effect resulting from the 
inhibition of the essential function of the β clamp. This suggests that resistance 
mechanisms against the anti-evolution effect of GRS may be different to purely 
non-lethal adjuvant therapies. Therefore, this sets GRS apart from other 
proposed non-lethal anti-evolution drugs such as suramin (Nautiyal, et al., 
2014), iron(III) phthalocyanine-4,4’,4’’,4’’’-tetrasulfonic acid (Alam, et al., 2016), 
natural compounds (Bellio, et al., 2017), as well as others (Mo, et al., 2017; 
Yakimov, et al., 2017). In addition, these other anti-evolution adjuvants function 
Chapter IV 232 
predominantly by targeting the induction of the SOS response by inhibiting 
RecA; whereas GRS has the unique potential to specifically prevent mutagenic 
DNA repair – which also co-incidentally reduces the risk of off-target effects 
within the human host of Mtb. Regardless, the potential reduction of 
mutational frequency through the disruption of the ImuB-DnaN PPI during 
GRS treatment warrants further investigation. Specifically, it is imperative to 
showcase the effect GRS co-treatment has on the development of RIF-resistance 
in a mouse infection model of TB (as previously performed by Boshoff, et al., 
2003) in order to confirm the anti-evolution capacity of the compound. More 
specifically, genetic disruption of the mycobacterial mutasome was associated 
with a decrease in both virulence and the development of RIF-resistance in this 
mouse infection model (Boshoff, et al., 2003); therefore, given the similarities 
between the genetic disruption of the mutasome and the chemical inhibition of 
ImuB foci by GRS presented in this work, there is enticing evidence to indicate 
that GRS may result in a similar suppression of the development of drug 
resistance of Mtb during infection of mice.  
 
6. Conclusion 
DNA repair is an important survival mechanism in Mtb that may have 
contributed to the success of Mtb as one of the greatest pathogens in history 
(Hingley-Wilson, et al., 2003). However, the substantial reliance of Mtb on DNA 
repair, often seen as an advantageous self-sufficiency mechanism, may also 
present a vulnerability. In this vein, there is potential to exploit the non-
redundant DNA repair pathways such as the mycobacterial mutasome to 
prevent the micro-evolution of drug resistance and help maintain the efficacy 
of currently employed anti-TB chemotherapeutics. The possibility that the 
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novel antibiotic GRS is capable of restricting mutagenic DNA repair by 
preventing the assembly of the mutasome on the β clamp (by inhibition of the 
proven ImuB-DnaN PPI) illustrates vulnerability of the system and encourages 
further investigation into the inhibition of the mutasome and other DNA repair 
systems. Of additional interest is the impact of GRS on mutagenesis and short-
term evolution of mycobacteria. Moreover, evidence in this work suggests that 
SOS-mediated cell elongation may contribute to the adaptation of mycobacteria 
through the recombination of multiple chromosomes during conditions of 
genotoxic stress. Therefore, GRS presents the unique potential to inhibit a 
downstream SOS effector response – specifically DNA damage-inducible 
mutagenic DNA repair – with a bactericidal compound. Investigation into the 
potential anti-evolutionary capacity of GRS is critical in limiting the 
development of drug-resistant TB in the future and ensuring the prolonged 
efficacy of current treatment options. 
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